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Abstract  I 
Abstract 
Engineered cystine-knot miniproteins represent an auspicious alternative protein scaffold for 
therapeutic and diagnostic applications, allowing specific tailoring of several molecular properties in 
addition, to target affinity and specificity, in particular stability solubility and pharmacokinetic 
behavior of the binding protein. Furthermore, the simple architecture of those small peptidic 
molecules facilitates conventional chemical manufacturing and the construction of multi-functional 
fusion molecules. Cystine-knot miniproteins are characterized by a remarkable stability and an 
extraordinary tolerance to sequence variation enabling the construction of combinatorial libraries. 
The starting basis for this thesis was a previously established cystine-knot miniprotein technology 
platform that allows the development of new drug candidates for diagnostic and therapeutic 
applications. The platform comprised a randomized cystine-knot miniprotein phage library 
(MCopt 1.0) that was constructed on the basis of an open chain variant of the squash trypsin inhibitor 
MCoTI-II (Momordica cochinchinensis) and a phage display screening system for ligand selection 
against soluble target proteins.  
The first objective of this thesis was the establishment of an efficient cell-based phage panning 
protocol and the development of a robust procedure to identify cystine-knot miniproteins that bind 
to plasma membrane proteins in their native conformation. In a proof of concept experiment a 
previously identified model ligand (MC-FA-010), which binds to FAP-α was utilized. MC-FA-010 
phages were mixed at different ratios into the established MCopt 1.0 phage library and the mix was 
screened against FAP-α expressing eukaryotic cell line. Using an adapted screening protocol, MC-FA-
010 phages could be specifically enriched after one, two or three successive screening rounds, 
depending on the initially applied mixing ratio. Additionally, a novel cell-based hit identification 
procedure consisting of high-throughput compatible protein expression and purification of individual 
clones combined with target binding analysis based on flow cytometry was established. The 
applicability of the whole cell-based panning and downstream hit identification procedure was 
confirmed by successful identification of high-affinity binders upon screening of the naïve MCopt 1.0 
phage library against a FAP-α expressing eukaryotic cell line. The detection sensitivity was further 
enhanced with the development of a second expression system enabling biotin/streptavidin based 
tetramerization of proteins in order to gain higher binding strength as a result of the avidity effect.  
The second objective of this thesis was the design and construction of novel cystine-knot miniprotein 
phage libraries to increase the repertoire and size of the library. Three rationally designed sub-
libraries with scattered randomized positions in loop 1 (MCopt 2.0), loop 5 (MCopt 2.1) or both loops 
(MCopt 3.0) in the open chain sequence of MCoTI-II were successfully generated. Phage displaying of 
cystine-knot miniproteins through the minor coat protein pIII was obtained using a pJuFo phagemid 
system, comprising Fos-cystine-knot miniprotein and Jun-pIII´ gene fusions for independent protein 
folding. Library quality controls included the expression analysis on phage level via ELISA and western 
blotting indicating the functional surface presentation of cystine-knot miniproteins. MCopt 2.0 library 
clones showed good protein expression rates and overall proper folding capabilities, while MCopt 2.1 
and MCopt 3.0 library clones performed in a marginal inferior manner. This suggested a moderate 
tolerance of MCoTI-II scaffold towards sequence randomization in loop 5 or in both adjacent loops 1 
and 5. Moreover, also the phagemid backbone was optimized to circumvent an enrichment of 
deletion mutants (clones lacking the M13 coat protein and the cystine-knot miniprotein encoding 
sequence part). In the novel phagemid vector, pPDIII-1, repetitive sequence parts were completely 
eliminated and different genetic elements for tighter gene expression control were introduced. A 
 
 
Abstract  II 
model selection experiment showed a clearly improved genetic stability of the pPDIII-1-MCopt 2.0 
sub-library as compared to the original pJuFo vector. 
The third objective of this thesis focused on the development of engineered cystine-knot miniproteins 
for in vivo targeting of the tumor vasculature. To this end, MC-FN-010, a cystine-knot miniprotein 
identified by screening of MCopt 1.0 und MCopt 2.0 libraries that specifically binds to fibronectin 
extra domain B (EDB) was used. Detailed characterization of MC-FN-010 via alanine scanning 
mutagenesis revealed its target binding relevant amino acids and resulted in defining a second 
derivative candidate (MC-FN-016). Both cystine-knot miniproteins featured high EDB specificity but 
relatively low affinities. However, chemical oligomerization of the ligands and site-directed 
fluorescence dye conjugation increased the binding strength enormously, while retaining its high 
specificity. The resulting trimeric constructs were analyzed in vivo in a U-87 MG based xenograft 
glioblastoma mouse model. For both variants, a strong accumulation in the tumor and overall low 
background signals could be detected via in vivo and ex vivo fluorescence measurement. These 
findings together emphasize the high potential of cystine-knot miniproteins as molecular scaffolds 
for tumor imaging technologies.  
 
 
Abstract  III 
Zusammenfassung 
Cystin-Knoten Miniproteine stellen ein vielversprechendes alternatives Proteingerüst für 
therapeutische und diagnostische Anwendungen dar, welches neben der Target Affinität und 
Spezifität, eine spezifische Anpassung verschiedener molekularer Eigenschaften ermöglicht. 
Insbesondere die Stabilität, Löslichkeit und das pharmakokinetische Verhalten dieser Bindeproteine 
sind von großer Bedeutung. Die einfache Architektur dieser kleinen peptidischen Moleküle erleichtert 
zudem die konventionelle chemische Herstellung und die Konstruktion multifunktionaler 
Fusionsmoleküle. Cystin-Knoten Miniproteine zeichnen sich durch eine bemerkenswerte Stabilität 
und außergewöhnliche Toleranz gegenüber Sequenzvariationen aus, die den Aufbau von 
kombinatorischen Bibliotheken ermöglicht. Ausgangspunkt für diese Arbeit war eine zuvor etablierte 
Cystin-Knoten Miniprotein Technologie Plattform, die eine Entwicklung neuer Wirkstoffkandidaten 
für diagnostische und therapeutische Applikationen ermöglicht. Die Plattform umfasste eine 
randomisierte Cystin-Knoten Miniprotein Phagen-Bibliothek (MCopt 1.0), die auf einer offenkettigen 
Variante des Squash-Trypsin-Inhibitors MCoTI-II (Momordica cochinchinensis) und eines Phagen-
Display Screening Systems zur Liganden-Selektion gegen lösliche Zielproteine beruht. 
Das erste Ziel dieser Arbeit war die Etablierung eines effizienten, zellbasierten Phagen Panning 
Protokolls und die Entwicklung eines robusten Verfahrens zur Identifizierung von Cystine-Knoten 
Miniproteinen, die an Plasmamembranproteinen in ihrer nativen Konformation binden. In einem 
Proof of Concept Experiment wurde ein zuvor identifizierter Modellligand (MC-FA-010) verwendet, 
der an FAP-α bindet. MC-FA-010 Phagen wurden in verschiedenen Verhältnissen in die etablierte 
MCopt 1.0 Phagenbibliothek gemischt und die Mischung wurde gegen ein auf einer eukaryotischen 
Zelllinie exprimiertes FAP-α selektiert. Abhängig vom initialen Mischungsverhältnis´ konnten die MC-
FA-010 Phagen mit einem angepassten Screening Protokoll nach ein, zwei oder drei 
aufeinanderfolgenden Selektionsrunden spezifisch angereichert werden. Zusätzlich wurde ein 
neuartiger zellbasierter Hit Identifizierungsprozess bestehend aus einer hochdurchsatzfähigen 
Protein Expression und Reinigung von individuellen Klonen in Kombination mit einer 
durchflusszytometrischen Bindungsanalyse etabliert. Die Anwendbarkeit des gesamten zellbasierten 
Panning und des nachgeschalteten Hit Identifizierungsprozess´ wurde durch ein Screening der naiven 
MCopt 1.0 Phagen-Bibliothek gegen eine FAP-α exprimierenden eukaryotischen Zelllinie verifiziert. 
Zudem wurde die Detektionssensitivität mit der Entwicklung eines zweiten Expressionssystems 
verbessert, welches eine Biotin/Streptavidin basierte Tetramerisierung von Proteinen ermöglicht, um 
durch den Aviditätseffekt eine höhere Bindungsstärke zu erreichen.  
Das zweite Ziel dieser Arbeit war das Design und die Konstruktion von neuen Cystin-Knoten 
Miniprotein Phagen-Bibliotheken, um das Repertoire und die Größe der Bibliothek zu erweitern. Drei 
rational konzipierte Bibliotheken mit verstreuten, randomisierten Positionen in Loop 1 (MCopt 2.0), 
Loop 5 (MCopt 2.1) oder in beiden Loops (MCopt 3.0) in der offenkettigen Sequenz Variante von 
MCoTI-II wurden erfolgreich generiert. Die Phagen-Präsentation von Cystin-Knoten Miniproteinen 
über das kleine Hüllprotein pIII wurde mittels eines pJuFo Phagemid Systems bewerkstelligt, das aus 
Fos-Cystin-Knoten Miniprotein und Jun-pIII´ Genfusionen besteht und eine unabhängige 
Proteinfaltung ermöglicht. Die Qualitätskontrolle der Bibliotheken beinhaltete die 
Expressionsanalyse auf Phagenebene mittels ELISA und Western Blot und deutete auf die funktionale 
Oberflächenpräsentation von Cystin-Knoten Miniproteinen hin. MCopt 2.0-Bibliotheksklone zeigten 
gute Proteinexpressionsraten und Faltungseigenschaften, während MCopt 2.1- und MCopt 3.0-
Bibliotheksklone zu marginal schlechteren Ergebnisse führten. Dies wies auf eine moderate Toleranz 
 
 
Abstract  IV 
des MCoTI-II Gerüstes gegenüber Sequenz Randomisierung in Loop 5 oder in beiden benachbarten 
Loops 1 und 5 hin. Darüber hinaus wurde auch der Phagemid Vektor optimiert, um eine Anreicherung 
von Deletionsmutanten zu umgehen (Klone ohne M13 Hüllprotein und Cystin-Knoten Miniprotein 
Sequenzen). Im neuen Phagemid Vektor, pPDIII-1, wurden repetitive Sequenzeinheiten vollständig 
eliminiert und verschiedene genetische Elemente zur strengeren Kontrolle der Genexpression 
eingeführt. Ein Modell Selektionsexperiment zeigte eine deutlich verbesserte genetische Stabilität 
der pPDIII-1-MCopt 2.0 Bibliothek im Vergleich zum ursprünglichen pJuFo Vektor.  
Das dritte Ziel dieser Arbeit konzentrierte sich auf die Entwicklung von Cystin-Knoten Miniproteinen 
für die in vivo Targetierung von Tumorgefäßen. Zu diesem Zweck wurde MC-FN-010 verwendet, ein 
Cystin-Knoten Miniprotein, das durch das Screening von MCopt 1.0 und MCopt 2.0 Bibliotheken 
identifiziert wurde und das spezifisch an die Extra Domäne B von humanem Fibronektin (EDB) bindet. 
Eine detaillierte Charakterisierung von MC-FN-010 mittels Alaninscan Mutagenese deckte die 
bindungsrelevanten Aminosäuren auf und führte zur Bestimmung eines zweiten Derivatkandidaten 
(MC-FN-016). Beide Cystin-Knoten Miniproteine wiesen eine hohe EDB Spezifität, aber eine relativ 
geringe Affinität auf. Die chemische Oligomerisierung der Liganden und die gerichtete Konjugation 
eines Fluoreszenzfarbstoffs erhöhten wiederum die Bindungsstärke deutlich, wobei die hohe 
Spezifität konstant blieb. Die daraus resultierenden trimeren Konstrukte wurden in vivo in einem U-
87 MG basierten Xenograft Glioblastom Mausmodel analysiert. Für beide Varianten wurde eine 
starke Akkumulation im Tumor und insgesamt niedrige Hintergrundsignale mittels in vivo und ex vivo 
Fluoreszenzbestimmung detektiert. Diese Ergebnisse unterstreichen das hohe Potenzial der Cystin-
Knoten Miniproteine als molekulare Grundgerüste für tumorbildgebende Technologien. 
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Introduction  1 
1 Introduction 
1.1 The process of protein drug discovery and development 
The discovery and development of drugs represents an essential process to identify potential 
biopharmaceutical agents aiming for the treatment or diagnosis of diseases. Novel and improved 
medicines are constantly needed to provide best therapy options for affected patients, as existing 
medications may lose effectiveness due to probable alteration in disease progression1. In the last 
decades, many different drug molecules from chemical and biological classes have been developed 
and entered the market for cancer treatment2–4. But also successful approval of new molecular 
entities as imaging agents has been reported5. However, the route of drug development is an 
elaborate and long-term process, in which different successive steps take place as shown in 
Figure 1.1. These include disease-related target selection, screening and identification of drug 
molecules, preclinical in vivo studies, clinical trials and eventually regulatory approvals6. The 
preclinical procedure follows no ultimate guideline, hence the single steps and the experimental 
assays varies with dependency on pre-defined requirements and aims. This chapter introduces the 
general goals of each drug discovery phase and presents the target selection based on cancer as well 
as highlights representative experimental approaches suitable for the development of biological drug 
molecules. 
 
Figure 1.1  Overview of traditional protein drug discovery process. The drug discovery process typically 
begins with target identification and validation, followed by drug screening to select putative candidates. Those 
are further assessed within hit identification and optimized in the lead phase before starting in vivo studies. All 
these steps account to the preclinical phase. The most suitable drug candidates can be manufactured under 
good manufacturing practice (GMP) and enter clinical trials to receive regulatory approvals for entering the 
market. Adapted from 6. 
A complete understanding of molecular mechanisms in disease pathogenesis is essential for directed 
development of novel therapeutic applications. The identification of disease-associated targets and 
their functional classification plays a crucial role for the development of ideally suited drugs1. Drug 
targets cover enzymes, receptors, metabolites, substrates, ion channels, transport proteins, DNA, 
RNA and ribosomes. With this, diverse therapeutic targets can be addressed to interfere with tumor 
growth and progression7. So far, many tumor-associated molecules have been described, mostly 
being overexpressed or selectively or aberrantly expressed in tumor cells8. However, selected target 
proteins are not necessarily druggable and they need to be validated. The purpose of this validation 
is to confirm experimentally the disease-related role in advance and additionally to ensure 
therapeutic benefit by addressing the molecule. The validation process relies on multiple approaches 
that involve different in vitro and in vivo assays6. Target expression can be determined on genetic or 
protein level, e.g. based on whole transcriptome sequencing, in situ hybridization techniques, 
quantitative PCR methods or by immunohistochemistry analysis on patient samples9–11. The 
clarification of target functionalities includes cellular experiments with RNA and protein modulation 
approaches. Furthermore, animal models using knockout or transgenic mice represent an important 
tool to mimic pathogen conditions in a complex biological system9. 
After a suitable target protein has been chosen, in the following step potential drug candidates are 
selected using diverse screening campaigns6. The selection is done either using classical techniques 
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like hybridoma technologies for antibody discovery, rational design approaches e.g. based on known 
target-specific ligands or by applying screening systems that enable the identification of novel target 
interaction ligands12,13. These include phage, yeast or ribosomal display technologies, all conceptually 
similar as they rely on the physical linkage of the presented protein of interest (POI) and its 
corresponding genetic information. With state-of-the-art recombinant DNA technologies large 
combinatorial libraries of peptides or proteins can be generated with up to billions of individual 
variants that are screened against the target molecule in a high-throughput manner14–16. Ribosomal 
display library sizes can reach up to 1014 members, but panning against whole cells is challenging due 
to weak ribosome-protein-mRNA complex stability16. In contrast, yeast display is mostly limited to a 
rather smaller library size, while allowing a panning procedure combined with fluorescence-activated 
cell sorting (FACS) to directly select target binding clones15 that facilitate subsequent hit screening. 
Phage display represents a widely applied technology for drug discovery and enables target proteins 
to be used in soluble form or directly exposed on cell surfaces depending on their structural 
features17,18. A detailed overview of this system is described in chapter 1.2.  
The hit identification process, which is closely connected to the screening section, aims to identify 
and confirm putative target interacting ligands using a limited number of pre-selected candidates1,6. 
The assessment of binding ability or biological activity is commonly conducted using biochemical and 
cellular high-throughput assays19. Flow cytometry screening for instance represents a widely applied 
system to gain multiparametric data sets20. Furthermore, in some cases a functional assay has to be 
developed in advance that fulfills the intended outcome robustness6. However, in hit screening 
approaches a high chance of detecting false positive or false negative hits exits, which is generally 
difficult to prevent. A subsequent second screen and deeper analysis of individual drug candidates is 
therefore usually conducted to confirm putative hits19. Further analysis, such as dose-response-
curves, can be implemented as well6. Many drug molecules are being excluded in the course of the 
hit screening and identification, while the remaining candidates that passed all the testing enter the 
following drug discovery phase. 
The lead phase describes the process of refining and optimizing the most promising drug candidates. 
A deeper characterization of the drug molecule facilitates directed fine-tuning. Important parameters 
concern the biochemical properties and the pharmacological profile, such as solubility, stability and 
absorption, distribution, metabolism and excretion (ADME). Whereas revealing the structure-activity 
relationship (SAR) is required to determine target binding sites and potential regions accessible for 
modifications. Hereby, starting points for improvements can be identified towards drug potency once 
having e.g. adverse biochemical properties or pharmacological profiles6. 
The final goal of the preclinical drug discovery process is to deliver most suitable drug candidates for 
clinical trials. Drug testing with in vivo animal models provides a characterization of the 
pharmacokinetic and pharmacodynamic performance in a whole biological environment to consider 
ADME. Furthermore, the drug efficacy is studied in in vivo disease models in order to analyze 
pharmacological response6,21. Once the preclinical studies are completed and the drug candidate 
passes all desired requirements the clinical trial process can be initiated. 
Before entering the market the potential drug undergoes clinical testing. Clinical trials are separated 
into different stages aiming for an investigation of drug tolerability, dose, safety, side effects and 
efficacy in human cohorts. Furthermore, regulatory guidelines require preclinical data of in vivo and 
toxicology studies, manufacturing information as well as an outline of the clinical study protocol22. 
The first human study can be performed in phase 0, which was introduced to offer the opportunity 
of early drug testing with non-therapeutic purpose. This study is typically conducted with a small 
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cohort of healthy volunteers or patients and a very low single-dose application aiming to obtain first 
insights of drug performance23. In a phase I trial, 20 to 80 healthy volunteers are recruited for drug 
safety validation, including reporting of adverse effect, determination of dosing range and toxicity 
profile22. However, a phase I study is not necessarily performed with healthy volunteers, e.g. many 
anti-tumor drug molecules are directly tested in cancer patients24. The phase II study requires 100 to 
300 patients to analyze drug efficacy and gain more safety information. The last pre-approval step, 
the phase III trial, with 1.000 to 3.000 patients is conducted to achieve ultimate drug safety and 
efficacy results. After accomplishment of clinical trials, a new drug application with all drug 
information and clinical data can be filed for evaluation and approval by the United States (U.S.) Food 
and Drug Administration (FDA). Once the FDA grants the approval, the drug molecule is commercially 
available in the U.S. and additional clinical studies are subjected to phase IV trials22. The drug 
evaluation for the European market is regulated by the European Medicines Agency (EMA). While the 
clinical trials follow roughly similar guidelines as described, the drug approval relies on four different 
pathways based on the drug class and the preference of the manufacturer25. 
1.2 Phage display technology 
Since Smith introduced phage display by using filamentous bacteriophage fd for displaying peptides 
on the virion surface more than three decades ago26, this technique gained strong value for drug 
discovery and development17. In the early 1990s, this methodology has been also demonstrated to 
enable functional presentation of complex folded proteins on phage surface27–29. The powerful phage 
display technique allows selection of polypeptides from large combinatorial libraries based on the 
genetic manipulation of filamentous phage surface proteins. Most commonly, the gene coding for 
the POI is either fused to the gene coding for the minor coat protein (pIII) or major coat protein (pVIII). 
The physical linkage of genotype and phenotype results in a surface presentation of the POI, while 
the phage contains the corresponding genetic information26,30,31. Both presentation systems differ 
with respect to the display valency of the presented protein with one to five copies in the case of pIII 
or the truncated form pIII´ and up to 2700 in pVIII32,33. In addition, the usage of the other coat proteins 
pVI, pVII or pXI for POI displaying is possible as well34,35. Figure 1.2 presents the structure of Ff 
filamentous bacteriophage and its coat proteins.  
 
Figure 1.2  Structure of filamentous bacteriophage. An Ff bacteriophage consists of ssDNA encapsulated by 
major coat protein pVIII. The minor coat proteins pIII and pVI as well as pVII and pIX are located at each tip of 
the phage, respectively. Adapted from 36. 
The Ff filamentous phage particles (M13, f1 and fd) infect E. coli that harbors the F episome coding 
for the F-pilus37. Bacterial infection is mediated by pIII coat protein interaction, which consists of      
N1-, N2- and C-domain. The N2-domain of the pIII coat protein binds to the tip of the bacterial F-pilus, 
while the N1-domain interacts with the periplasmic domain of the TolA protein. The C-domain is 
 
 
Introduction  4 
involved in translocation of viral DNA into the cytoplasm of the E. coli cell. After translocation, the 
viral single-stranded DNA (ssDNA) is converted to double-stranded replicative form DNA (dsDNA) by 
the host replication machinery and serves as template to generate ssDNA through rolling circle 
replication and to express required phage proteins. Resulting ssDNA is covered by protein V dimer 
prior to packaging into coat proteins of phages and release from the cell through the bacterial 
membrane after assembly of the particle32,38, Figure 1.3. 
 
Figure 1.3  Life cycle of filamentous bacteriophage. Phage binds with pIII to tip of F-pilus on host cell and 
mediates transfer of viral ssDNA into cytoplasm. Host enzymes convert ssDNA to dsDNA for replication, protein 
expression and ssDNA synthesis. The single ssDNA is protected by dimers of protein V until phage assembling 
and export. Adapted from 39.  
Phagemids are very popular vectors for creating phage display libraries that contain M13 and plasmid 
elements. A phagemid typically carries two replication origins to enable dsDNA as well as ssDNA 
synthesis and a gene coding for the POI fused to gene III/III´ or gene VIII protein, but lacking phage 
packaging relevant genes. Consequently, host cells harboring the phagemid cannot produce 
recombinant phages on their own, but they rather require a superinfection with helper phage 
particles (typically VCS M13 or M13K07) to provide missing gene elements32,36. 
A modified phagemid system, called pJuFo, was initially engineered by Crameri et al. for the 
construction and screening of cDNA libraries40. In this system, gene products are displayed through 
indirect fusion to phage coat proteins based on attached leucine zipper heterodimerization domains 
jun and fos. The expression cassettes of a gene coding for the POI and fos gene as well as a gene 
coding for the respective coat protein and jun gene allow an independent processing of the POI and 
coat protein to ensure functional displaying. Both constructs are secreted to the oxidative 
environment of the periplasmic space, in which an assembly and folding of complex proteins  
occurs40–42. 
Phage display is a long and well established method for screening combinatorial libraries that present 
large diversity of peptides or proteins with various size and complexity43–45. Conceptual design of 
phage libraries follows different rational and experimental strategies. Especially the displaying of 
antibody fragments showed high success in development of target specific antibodies based on 
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immune, naïve, semi synthetic or fully synthetic libraries46–49. Numerous reports describe the isolation 
of high affinity antibody fragments from phage display libraries directed against many individual 
therapeutic targets. Those molecules became candidates for engineering to accomplish clinical 
relevant therapeutics50. In the last decades, also non-immunoglobulin proteins have been 
functionally displayed on phages, including Affibodies, Anticalins, DARPins and Fynomers. The 
authors showed the capability of phage technology to screen large libraries consisting of a variety of 
protein scaffolds51–54.  
The success of this technology relies on many synergistic factors, such as the protein scaffold of 
choice, efficient protein displaying and library size17. An effective panning process is also required for 
ligand selection from a large phage library. Figure 1.4 shows a standard panning procedure of a phage 
library. A panning cycle begins with an incubation of the phage library with the target molecule that 
can e.g. be coated on tubes or beads. Removal of non-binding phages is done via washing procedure 
and target-binding phages are eluted for amplification in E. coli. In general, several successive panning 
cycles are performed in order to enrich target interacting proteins32. Consequently, even rare 
presented variants can be selected from a large library. 
 
Figure 1.4  Schematic overview of a standard phage panning round. Phage library is incubated with target 
coated on beads or tubes. Non-binding phages are removed by washing, while target-interacting phages are 
eluted and amplified in E. coli. Adapted from 32. 
Different panning opportunities of phage libraries are possible depending on the target type. The 
most common methods are based on the usage of target proteins in a soluble form, but this strategy 
is limited to proteins that are amenable to recombinant soluble production. A direct selection against 
whole cells on the other hand enables addressing of proteins in their native cellular environment, 
which is especially preferable for complex and membrane-bound proteins. Also in vivo phage library 
selection approaches have been described representing a further possibility especially for addressing 
organ- or tissue-specific targets in their natural environment18,32. 
In summary, phage display is a very powerful technology for selection of novel peptide or protein 
ligands against any desired target molecule and a key methodology in early phase drug discovery. An 
efficient and fast identification of promising candidates facilitates the development of innovative 
therapeutics. 
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1.3 Protein-based applications 
The evolution of protein therapeutics highly accelerated with the first approval of a recombinant 
protein, which was human insulin for the treatment of diabetes mellitus in 198255. Since then, 
proteins have become an important drug class for a broad range of clinical indications with more than 
hundred approved proteins56. Protein therapeutics are derived from a large variety of biological 
molecule types, including natural cytokines, growth factors, enzymes, soluble receptors, coagulation 
factors, monoclonal antibodies (mAbs) or engineered variants of these proteins57. Furthermore, they 
can be assigned into different categories based on their pharmacological activities. The groups are 
divided into enzymatic or regulatory activity, special targeting activity, vaccine purposes and 
diagnostic approaches58. 
Protein-based drugs gained a valuable source for targeted cancer therapy. In contrast to conventional 
surgery, chemotherapy and irradiation treatment, the high specificity and selectivity are 
advantageous to minimize numerous adverse effects mainly caused by undirected addressing of 
normal tissue59. 
1.3.1 Antibody-based therapeutics 
mAbs represent a well-established and rapidly growing class of protein therapeutics8. By the end of 
2014, 47 mAbs were approved for the treatment of various diseases60, whereby the annual novel 
approvals increases constantly and numerous additional candidates are under clinical 
investigation61,62. Antibody-based therapeutics showed great success in clinical outcome of patients 
suffering from haematologic and solid cancers. Thereby, antibodies are engineered as anticancer and 
immunological drugs to specifically target tumor-associated molecules63. 
Antibodies, also termed as immunoglobulins, are naturally synthesized by B lymphocytes and as a 
part of the immune system, they play a major role in host defensing from bacterial or viral pathogens. 
The large ~150 kDa molecule consists of two identical heavy chains (HC) and light chains (LC) that are 
connected and stabilized via disulfide bonds. The complementarity-determining regions (CDRs) of the 
variable HC- and LC- domains form a highly specific antigen recognition site. While the constant 
fragment of an antibody mediates effector function, such as target neutralization or activation of cell-
killing mechanism64. 
The remarkably inherit antibody properties are exploited for therapeutic applications. These 
especially involve the high target selectivity and specificity that allows precise binding to the tumor 
cells or compartments within the tumor microenvironment. Thereby, a direct or immune-mediated 
tumor killing can be evoked by alteration and modulation of various mechanisms. In addition, an 
antibody can serve as vehicle system to deliver conjugated drug compounds directly to the tumor 
site8.  
The development of therapeutically relevant antibodies relies on a wide range of engineering 
technologies that evolved over the last decades65. The advent was basically the discovery of the 
hybridoma technique allowing a continuously production of mAbs66. Chimerization and humanization 
strategies of rodent-derived mAbs were applied to improve their drug safety profile in terms of 
immunogenicity and tolerability. In chimeric mAbs the constant region is exchanged with human 
sequence, while humanized mAbs undergo complete replacement except for the murine CDRs67. The 
introduction of transgenic animals and displaying technologies further facilitated the development of 
fully human antibodies68,69. 
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Despite the great success of mAb therapeutics, limitations emerged mainly related to their large 
molecular size and complex structural features. In general, the large size elicits poor penetration into 
solid tumors and therefore lowers the efficacy. The complex architecture and various post-
translational modifications hamper controlled manufacturing process and results in high production 
costs70,71. Furthermore, the long circulation time of full-length antibody is adverse for molecular 
imaging, as a high-quality contrast resolution requires fast blood clearance72. 
To overcome the given limitations of antibodies, designing of antibody fragments, including 
Diabodies, Fab fragments and single-chain Fv fragments, with lowered molecular size while 
maintaining characteristic antigen binding properties, has been made. Despite the clinical approval 
of some Fab fragments, antibody fragments generally are prone to aggregate as a consequence of 
protein instability that can lead to increased immunogenicity potential70,73. 
To counteract the issue of large sized molecules and putative immunogenicity, a new class of non-
immunoglobulin molecules emerged to fulfill the need. The next-generation binders evolved during 
the last decades with enhanced pharmacokinetic properties, efficacy and better safety profile over 
classical antibody74, while being mostly simple structured, small, monomeric, soluble and stable65. 
1.3.2 Non-immunoglobulin protein scaffolds 
Non-immunoglobulin protein scaffolds are a valuable alternative for the evolution of therapeutic and 
diagnostic agents, providing promising benefits apart from antibody-based therapeutics. These 
proteins are mainly divided into two categories, the domain-sized molecules and the constrained 
peptides. Affibodies, Affilins, Anticalins, DARPins, Fynomers, Kunitz domains with molecular weights 
between 6 and 20 kDa belong to the domain-sized category, while small-sized Avimers, bicyclic 
peptides and cystine-knot miniproteins are part of the constrained peptides category75. Figure 1.5 
shows structural features of representative non-immunoglobulin protein scaffolds. 
A B C D 
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Figure 1.5 Three-dimensional structures of representative non-immunoglobulin protein scaffolds. 
(A) Affibody (PDB 2KZI) (B) Affilin (PDB 2JDF) (C) Anticalin (PDB 4GH7) (D) Avimer (PDB 1AJJ) (E) Cystine-knot 
miniprotein (PDB 1HYK) (F) DARPin (PDB 1SVX) (G) Fynomer (PDB 4AFS) (H) Kunitz domain (PDB 4BQD). Domain 
or loop accessibility for amino acid substitutions are presented in red and disulfide bridges are highlight as 
yellow sticks. Adapted from 75. 
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Typical characteristics of alternative protein scaffolds are their small size and high stability, leading 
to altered pharmacokinetic properties and target preference compared to mAbs. The compact size 
offers the opportunity to achieve good tissue penetration in therapeutic approaches. The generally 
simple architecture of non-immunoglobulin scaffolds exhibits limited protein complexity compared 
to antibody molecules, which are usually highly post-translationally modified. Therefore, the protein 
scaffolds are accessible for recombinant expression in bacterial hosts and in case of the smaller ones 
also for conventional solid phase chemical synthesis. This consequently leads to facile, controlled and 
cost-efficient manufacturing74,76,77. 
Although the alternative protein scaffolds have some general characteristics in common, their 
differences in sequence length, sequence composition and structural shape arise in altered 
pharmacokinetic behavior, such as half-time life, stability, immunogenicity, tissue penetration and 
bioavailability. Therefore in principle, the choice of the protein scaffold itself depends on the 
intended application75,78. 
Over the last decades, substantial progress has been made to generate tailored binding proteins using 
domain or loop specific engineering. Thereby, sequence and length modifications in the respective 
protein framework are created without having impact on the intrinsic structural fold. The derived 
molecules reveal binding properties, including specificity and affinity, comparable to traditional 
antibody behavior. Platforms for display of large combinatorial libraries represent the most common 
way in de novo discovery of target interacting ligands. So far, a large number of engineered protein 
scaffolds for diverse medical indications are currently under preclinical and clinical investigations75,77. 
The plasma kallikrein inhibitor Ecallantide (DX-88) is an approved molecule administered for the 
treatment of hereditary angioedema and originally derived from a Kunitz domain79. The approval of 
Ecallantide together with two further cystine-knot miniprotein-based drug molecules laid in principle 
the foundation of alternative protein scaffolds in terms of their clinical relevance77. With this, the 
cystine-knot miniprotein family gained particular attention for evolution of in vivo imaging 
technologies and targeted drug delivery purposes due to its beneficial pharmacological properties 
(chapter 1.3.3).  
1.3.3 Cystine-knot miniproteins 
The structural cystine-knot miniprotein (knottins) family comprises three main sub-groups, the 
inhibitor cystine-knot miniproteins, the cyclotides and the growth factor cystine knot proteins. These 
molecules are small peptides with typically 30 – 50 amino acids in size and a characteristic tertiary 
structure, which consists of intramolecular disulfide bonds connecting the antiparallel β-strands. The 
disulfide bonds within inhibitor cystine-knot miniproteins and cyclotides are formed between the first 
and fourth and between the second and fifth cysteine residues resulting in a macrocycle, through 
that a third disulfide bond between third and sixth cysteine residues passes (Figure 1.6). In growth 
factor knottin members the positions of cysteine residues connectivity differs80. The rigid knot-like 
structure mediates an extraordinary thermal, proteolytic and chemical stability of this knottin 
family81. The cyclotides subclass entails a further feature of the N-terminal to C-terminal cyclized 
backbone82. 
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Figure 1.6 Schematic illustration of a cystine-knot miniprotein structure. Connective disulfide bonds are 
depicted in yellow. Dashed line in grey represents cyclization of C- and N-terminus present in the cyclotide 
family. Adapted from 83. 
Cystine-knot miniproteins are found in a variety of different species and have diverse biological 
activities, including inhibitory, antimicrobial, cytotoxic or antifungal functions80,83. The functional loop 
regions of the constrained fold are important for bioactivity and are flexible with respect to sequence 
and length among various cystine-knot miniprotein types84. A large group of cystine-knot 
miniproteins have ion channel blocking activity, naturally occurring e.g. in the venom of spiders or 
marine cone snails85. The squash inhibitors represent a further group with protease inhibitory 
activities and prominent family members, such as cyclic Momordica cochinchinensis trypsin 
inhibitor II (MCoTI-II) and Ecballium elaterium trypsin inhibitor II (EETI-II) from the seeds of 
Cucurbitaceae86,87. Both proteins mediate their functional activity by a single loop located between 
the first and the second cysteine residues88,89. Figure 1.7 represents the three-dimensional structure 
and amino acid sequence of prominent cystine-knot miniproteins. 
A B 
  
  
 
C D 
  
  
 
Figure 1.7 Three-dimensional structure and amino acid sequence of cystine-knot miniproteins. 
(A) Cholorotoxin (PDB 1CHL) (B) EETI-II (PDB 2IT7) (C) Kalata B1 (PDB 2LUR) (D) MCoTI-II (PDB 1HA9). Cystine-
knot miniproteins are shown in grey and disulfide bridges are presented as yellow sticks. Dashed line represents 
cyclization of C- and N-terminus. The structures were obtained from RCBS PDB and illustrated using PyMol. 
Adapted from 83. 
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In recent years, several cystine-knot miniprotein members, including MCoTI-II, EETI-II, Agouti-related 
protein (AgRP) and Spinacia oleracea trypsin inhibitor (SOTI), have been engineered to specifically 
bind a variety of target proteins. Mostly, combinatorial libraries were created on the basis of the 
protein scaffold for yeast displaying approaches90–93. Despite the small size and limited randomization 
space, the exposed surface loops of cystine-knot miniproteins well tolerate sequence and length 
modifications without losing the structural characteristics. 
The EETI-II framework underwent functional loop grafting in combination with directed evolution via 
yeast display to develop αvβ3/αvβ5 or αvβ3/αvβ5/α5β1 integrin binding variants. These integrins are 
highly tumor-associated receptors expressed on the surface of various cancer cells90. Ever since, the 
selected 2.5D and 2.5F knottins were intensively investigated for the path to tumor imaging 
approaches. Both molecules thereby served as targeted moiety and were functionalized with various 
radionuclides or fluorescence dyes. A tumor-specific targeting was demonstrated with different 
peptide variants in a human glioblastoma xenograft mouse model94–96. While a 64Cu-DOTA conjugated 
2.5F knottin variant specifically accumulated in lung nodules of a transgenic mouse model97. Another 
compound, chlorotoxin (CTX) from scorpion venom, was initially discovered to target glioma-specific 
chloride ion channel98. This molecule was the starting scaffold for designing imaging compounds with 
specific accumulation in different tumor models and great progress as tumor diagnostic tool99–101. But 
also AgRP-based imaging agents for visualization of glioblastoma xenograft tumors102 and an acyclic 
variant of MCoTI-II for A431 xenografts have been reported91. 
Apart from the intense preclinical development of many promising imaging candidates for the clinic, 
to date two knottin-derived drug molecules achieved regulatory approval77. Ziconotide, a ω-
conotoxin MVIIa from conus magnus snail venom, was the first approved knottin-based protein 
therapeutic for the treatment of neuropathic pain. This drug is administered intrathecal and interacts 
with presynaptic N-type calcium channels, which leads to an inhibition of neurotransmission103. 
Linaclotide represents a further knottin drug molecule to treat patients suffering from irritable bowel 
syndrome with constipation. Linaclotide shares homology with the hormones guanylin and 
uroguanylin and acts as agonist of the guanylate cyclase C receptor104. 
Taken together, cystine-knot miniproteins exhibit beneficial pharmacological properties for tumor 
diagnostic and therapeutic approaches. Their simple structure allows convenient chemical 
manufacturing and facilitates site-directed compound conjugation84. Based on the high proteolytic 
and thermal stability an oral drug administration may be feasible with the potential to simplify regular 
medications81. Furthermore, the fast clearance of knottin-like compounds is advantageous for 
imaging purposes in order to achieve high tumor to background contrast83. The excellent 
performance of this binding molecule class as molecular scaffolds in preclinical studies and the FDA 
approval of two knottin-based drugs encourage their further engineering for cancer and other 
diseases. 
1.4 Targeting fibronectin extra domain B 
The extracellular matrix (ECM) is a complex system composed of different macromolecules creating 
a dynamic and well-defined network in the pericellular space. The matrix components contribute to 
structural integrity and regulate multiple cellular functions105. Fibronectin (FN) represents an 
essential multidomain glycoprotein of the ECM with a critical role in distinct physiological processes, 
including cell adhesion, migration, differentiation and growth106. FN is a large, dimeric protein paired 
by nearly two identical subunits through C-terminal disulfide bonds. Each monomer consists of type I, 
type II and type III domains that arrange to form a linear array. Type I and type II modules possess 
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45 – 60 amino acids and intramolecular disulfide bonds, whereas type III modules are around 90 
amino acids in length without disulfide bonds107,108. FN typically contains 12 type I, 2 type II and 15-
17 type III modules109. Additionally, extra domain A (EDA), extra domain B (EDB) and type III 
connecting sequence (IIICS), all type III modules of FN, can be inserted upon alternative splicing110. As 
a multifunctional protein FN exhibits multiple binding sites for various cellular and matrix proteins 
such as fibrin, collagen and heparin111. Figure 1.8 shows a schematic representation of FN with the 
three types of repeating modules and its splice-in domains. 
 
Figure 1.8 Structure of fibronectin. Fibronectin consists of three different repeating modules, type I (blue), 
type II (green) and type III (red) as well as spliced-in domains (rose). Binding sites for various molecules and two 
disulfide bonds are depicted. Adapted from 111. 
FN naturally occurs in two distinct forms as plasma FN (pFN) and cellular FN (cFN)112. The pFN is 
expressed by hepatocytes and secreted as soluble protein into the blood113. pFN plays a role in 
hemostasis, in which it accumulates at the damaged tissue and incorporates in fibrin clots114. In pFN 
the splice-in domains EDA and EDB are completely absent, while the IIICS domain exists in one 
subunit110,115. In contrast, the insoluble cFN is produced by fibroblasts, endothelial cells and other cell 
types109, and found in the ECM assembled to a fibrillar network116. FN is expressed as multiple 
alternatively spliced variants derived from a primary transcript117,118. The splice-in domains are 
inserted at three distinct positions of FN with EDB being located between type III domains 7 and 8, 
EDA between type III domains 11 and 12 and variable regions of IIICS between type III domains 14 
and 15119. The oncofetal EDA and EDB domains arise from a single exon and can be included in the FN 
mRNA upon exon skipping110,120. 
The highly conserved EDB region consists of 91 amino acids and occurs with 100 % sequence identity 
among different species, including mice, rats, rabbits, dogs and humans121. EDB is usually absent in 
normal adult tissues, but involved in tissue remodeling and angiogenesis121,122. In addition, EDB has 
been found in many different cancer types with abundant expression pattern in the neovasculature 
of several aggressive solid human tumors such as head and neck, breast and glioma cancer121,123–125. 
Being a selective tumor marker EDB has been investigated as a target for cancer imaging and therapy 
in research and development as well as in several early clinical studies126. The most advanced EDB 
ligand has been isolated from an antibody phage display library in the lab of Dario Neri127. This L19 
antibody exhibits specific tumor targeting properties and has been extensively investigated as vehicle 
for many diagnostic and therapeutic applications128–131. Despite the high clinical impact of the L19 
antibody, several non-antibody ligands have been developed to specifically target EDB. These include 
binding ligands based on Fynomers, peptides, Anticalins and an ubiquitin-derived protein, which were 
all selected from combinatorial phage libraries with nanomolar or micromolar affinities54,132–135. The 
EDB binding Anticalins were used as diagnostic tracer to detect human gliomas136. Apart from protein-
based molecules, two EDB recognizing peptides were generated and conjugated with fluorescence 
dyes for preclinical in vivo imaging studies. One report demonstrates the effective visualization of 
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human prostate tumor xenografts with a cyclic nonapeptide ZD2132. In another study, artificial high-
affinity peptides (so called aptides) have been shown to specifically target human glioblastoma tumor 
xenografts135. The development of many EDB-specific molecules emphasizes this tumor-associated 
protein to be an ideal model for the generation of further non-antibody ligands126. 
1.5 Purpose of the thesis 
In the last decades non-immunoglobulin protein scaffolds emerged as a promising alternative to 
complement antibodies and antibody derivatives for therapeutic and diagnostic applications. 
Engineered cystine-knot miniproteins represent an alternative protein scaffold with drug-like 
properties such as high target affinity and specificity, extraordinary stability, solubility and favorable 
pharmacokinetic characteristics. Additionally, these small peptidic molecules with a simple 
architecture facilitate a straight-forward chemical production and the construction of multi-
functional fusion molecules. Thus far, our internal cystine-knot miniprotein technology platform 
consists of one combinatorial MCopt 1.0 phage library, which was constructed with sequence 
variation in the open chain variant of the squash trypsin inhibitor MCoTI-II originally found in gac fruit. 
The discovery of novel candidates is based on phage display screenings within the soluble screening 
pipeline using recombinant target proteins. But standard phage display protocols are not readily 
applicable for certain proteins, especially those with complex structural features. 
Therefore, one aim of this thesis was the development of a cell-based screening approach for 
addressing target membrane proteins or other proteins that are not amenable to recombinant 
production in a soluble form. The phage screening procedure using target overexpressing cell lines 
should be efficient for cystine-knot miniprotein selection. Whereas the downstream hit identification 
process should be reliable in analysis of individual clones with respect to their target binding activity 
and specificity. Additionally, the library repertoire should be extended by the construction of novel 
cystine-knot miniprotein phage libraries based on sophisticated rational design strategy. The libraries 
should reveal good quality and functionality, including high clonal diversity and proper phage 
displaying of cystine-knot miniproteins. Another part of this work is focusing on the advancement of 
a cystine-knot miniprotein for targeting of EDB expressing tumors. The ligand should be further 
characterized and engineered to develop an EDB specific imaging probe, which should be finally 
evaluated in significant murine tumor model systems. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Cell lines 
CHO-K1 ATCC 
Flp-In™-CHO Thermo Fisher Scientific 
U-87 MG ATCC 
2.1.2 Cell culture media  
Dulbecco’s Modified Eagle Medium (DMEM)/-
F12 + GlutaMAX™ 
Gibco 
Eagle's Minimum Essential Medium (EMEM) ATCC 
Ham's F-12 Nutrient Mix Thermo Fisher Scientific 
 
Cell line Cell culture media Supplements 
CHO-K1 DMEM/-F12 + GlutaMAX™ 10 % FBS (v/v) 
CHO-K1-DSG-3, CHO-K1-
dsRed-Mock, CHO-K1-FAP-α, 
CHO-K1-Mock 
DMEM/-F12 + GlutaMAX™ 
10 % FBS (v/v), 200 µg/mL 
hygromycin-B 
U-87 MG EMEM 10 % FBS (v/v) 
Flp-InTM wt Ham's F-12 Nutrient Mix 
10 % FBS, 2 mM L-glutamine, 
100 µg/mL zeocin 
Flp-InTM-CHO-FAP-α Ham's F-12 Nutrient Mix 
10 % FBS (v/v), 2 mM L-
glutamine, 200 µg/mL 
hygromycin-B 
2.1.3 Microorganisms 
E. coli strain Genotype Purpose Manufacturer 
SHuffle® T7 
Express 
fhuA2 lacZ::T7 gene1 [lon] ompT ahpC 
gal λatt::pNEB3-r1-cDsbC (SpecR, lacIq) 
ΔtrxB sulA11 R(mcr-73::miniTn10--
TetS)2 [dcm] R(zgb-210::Tn10 --TetS) 
endA1 Δgor ∆(mcrC-mrr)114::IS10 
Expression of 
cystine-knot 
miniproteins 
New England 
BioLabs 
SS320 
(MC1061F\') 
[F\'proAB+lacIqlacZΔM15 Tn10 (tetr)] 
hsdR mcrB araD139 Δ(araABC-
leu)7679ΔlacX74 galUgalK rpsL thi 
MCopt 2.0/2.1/3.0 
phage library 
construction 
Lucigen 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIqZΔM15 
Tn10 (Tetr)]) 
Phagemid 
preparation, 
phage sub-library 
construction 
Stratagene 
2.1.4 Bacterial growth media 
LB-agar was prepared by adding of 1.5 % agar-agar powder to LB-medium. LB-agar and cultivation 
medium was autoclaved at 121 °C at 1 bar for 20 min. Sterile filtered antibiotics and glucose were 
added to LB-agar after cooling below 60 °C. LB and SOC-medium were stored at 4 °C and supplements 
were added before usage.  
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LB-medium 
1 % (w/v) bacto-tryptone, 0.5 % (w/v) yeast-
extract, 0.5 % (w/v) NaCl in 1 L H2O 
LBCarbGlu-medium 
LB-medium + 100 μg/mL carbenicillin + 0.4 % 
(w/v) glucose 
LBCarbKanaIPTG-medium 
LB-medium + 100 μg/mL carbenicillin + 
25 μg/mL kanamycin + 1 mM IPTG 
LBTetKana-medium 
LB-medium + 12.5 μg/mL tetracycline 
hydrochloride + 25 μg/mL kanamycin 
LBTet-medium 
LB-medium + 12.5 μg/mL tetracycline 
hydrochloride 
LBCarbChlora-medium 
LB-medium + 100 μg/mL carbenicillin + 
10 µg/mL chloramphenicol + 0.4 % (w/v) 
glucose 
SOC-medium 
0.5 % (w/v) yeast extract, 2 % (w/v) tryptone, 
0.05 % (w/v) NaCl, 2.5 mM KCl, 10 mM MgSO4 
in 1 L H2O; upon usage, add 20 mM glucose 
2.1.5 Viral strain 
VCSM13 bacteriophage Stratagene 
2.1.6 Vectors 
Vector name Purpose Manufacturer/origin 
pBirAcm 
Generation of E. coli SHuffle® T7 Express 
pBirAcm cells 
Avidity 
pJuFoIII 
Generation of MCopt 2.0/2.1/3.0 phage 
library 
Prof. Mark Suter, SIAF, 
Davos, Switzerland 
pPDIII-1 Generation of MCopt 2.0 phage sub-library Derivative of pJuFoIII 
pET32-LibEx 
Expression of MCopt 1.0 cystine-knot 
miniprotein fusions 
Derivative of pET-32a, 
Novagen 
pET32-LibEx_GS 
Expression of MCopt 2.0/2.1/3.0 cystine-knot 
miniprotein fusions 
Derivative of pET-32a, 
Novagen 
pET-32-AX 
Expression of biotinylated cystine-knot 
miniprotein fusions 
Derivative of pET-32a, 
Novagen 
Piggy Bac transposase Generation of stable cell line Sanger institute 
pPB transposon 
Generation of stable CHO-K1-DSG-3 cell line 
and CHO-K1-dsRed-Mock cell line 
Sanger institute 
 
The pPB transposon vector was used to construct pPB transposon_DSG-3 and pPB transposon_dsRed 
vectors. The pPB transposon_DSG-3 carries gene segments coding for human Desmoglein-3 (DSG-3, 
Uniprot ID P32926, amino acids M1-I999) and green fluorescent protein (GFP). The pPB 
transposon_dsRed carries the coding gene for Discosoma red fluorescent protein (dsRed). 
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A B 
  
Figure 2.1 Phagemid vector maps. Genetic elements: colE1 ori: E. coli origin of replication; f1 ori: phage origin 
of replication; pelBss: pelB periplasmic leader sequence; ompA: ompA periplasmic leader sequence, bla: beta-
lactamase; lacO: lac operator; -10/-35: lac promotor/operator region; fos/jun: leucine zipper domains; 
pIII´: gene encoding for a truncated recombinant minor coat protein of M13; RBS: ribosomal binding site; tHP 
term: tHP terminator sequence; T7 term: T7 terminator sequence. Arrows are shown in direction of 
transcription. DNA fragments encoding for MCopt 2.0/2.1/3.0 sequences were cloned using unique BamHI and 
KpnI restriction sites in frame with a pelBss and fos. (A) pJuFoIII phagemid vector. (B) pPDIII-1 phagemid vector. 
A B 
  
Figure 2.2 Expression vector maps. Genetic elements: f1 ori: phage origin of replication; bla: beta-lactamase; 
T7 prom: regulatory T7 promotor; lacO: lac operator; Trx: gene encoding for E. coli thioredoxin-A; H6: 
hexahistidine-tag; S: S-tag, peptide derived from RNase A, Thrombin: cleavage site for thrombin protease; avi-
tag: specific peptide for biotinylation137; Xa: cleavage site for factor Xa protease; T7 term: T7 terminator 
sequence. Arrows are presented in direction of transcription. DNA fragments encoding for 
MCopt 1.0/2.0/2.1/3.0 sequences were cloned using unique BamHI and KpnI restriction sites. (A) pET-32-LibEx 
and pET-32-LibEx_GS vector. The pET-32-LibEx_GS vector carries six additional nucleotides encoding for the 
amino acids glycine and serine downstream of the thrombin cleavage site. (B) pET-32-AX2 vector. 
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A B 
  
Figure 2.3 Schematic representation of the cystine-knot miniprotein fusion elements. (A) Protein expression 
via pET-32-LibEx or pET-32-LibEX_GS resulted in cystine-knot miniprotein fusion with thioredoxin-A (for 
efficient disulfide bond formation in the cytoplasm), His-tag (for rapid purification or detection by an antibody), 
S-tag (for detection by an antibody), thrombin cleavage site (for removal of fusion tag) and cystine-knot 
miniprotein in successive order. (B) Protein expression using pET-32-AX2 resulted in the similar cystine-knot 
miniprotein fusion as described before, but with an additional avi-tag sequence (for site-specific biotinylation 
using BirA biotin ligase) and a factor Xa protease cleavage site.  
2.1.7 Antibodies and streptavidin conjugates 
Alexa Fluor® 647 rat anti-mouse CD31, clone 
390 
BioLegend 
APC mouse anti-his-tag, clone AD1.1.10 R&D Systems 
APC streptavidin eBioscience 
Cy3 streptavidin Rockland Immunochemicals 
Cy5 goat anti-mouse IgG, 115-175-146 Dianova 
HRP goat anti-mouse IgG, 554002 BD Bioscience 
HRP goat anti-rabbit IgG, A6154-1ML Sigma-Aldrich 
HRP goat anti-S-tag, ab19324 Abcam 
HRP rabbit anti-S-tag antibody, ab18589 Abcam 
HRP streptavidin Thermo Fisher Scientific 
Mouse anti-human DSG-3, clone MM0245-
4W25 
Abcam 
Mouse anti-human EDB+Fn, clone BC-1 Abcam 
Mouse anti-human FAP-α, clone 1E5 Abnova 
Rabbit anti-c-Fos, HPA018531 Sigma-Aldrich 
Rabbit anti-M13, 27-9420-01 Sigma-Aldrich 
2.1.8 Enzymes 
Accutase® Sigma-Aldrich 
Alkaline Phosphatase (rSAP) New England BioLabs 
ApaI New England BioLabs 
BamHI New England BioLabs 
Benzonase® Merck Millipore 
BglII New England BioLabs 
FastDigest ApaI Thermo Fisher Scientific 
FastDigest BamHI Thermo Fisher Scientific 
FastDigest KpnI Thermo Fisher Scientific 
KpnI New England BioLabs 
Lysozyme Merck Millipore 
T4 DNA ligase New England BioLabs 
T4 DNA ligase Thermo Fisher Scientific 
Taq DNA polymerase Thermo Fisher Scientific 
Thrombin from human plasma Sigma-Aldrich 
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Restriction enzymes and ligase for phage library generation as well as for vector preparation was used 
from New England BioLabs. All other cloning works were performed with enzymes obtained from 
Thermo Fishier Scientific. Enzymes were applied according to manufacturer´s instruction. 
2.1.9 Recombinant proteins 
Name Protein description Purpose 
FN-B Single Fibronectin EDB domain Target protein 
FN-6789 Fibronectin type III domains 6 – 9  Off-target protein 
FN-67B89 
Fibronectin EDB domain, flanked by 
surrounding type III domains 
Target protein 
Trx-MC-Myc-010 
Cystine-knot miniprotein with grafted 
c-myc epitope in loop 1 
Negative control 
 
In this work, all recombinant proteins were produced in E. coli and purified in-house. Recombinant 
human fibronectin EDB either as a single domain (FN-B, Uniprot ID P02751, isoform 7, amino acid 
E1265-T1355) or flanked by its surrounding type III domains (FN-67B89) served as target proteins, 
while domains 6 – 9 without EDB (FN-6789) was used as control. All variants were expressed with a 
C-terminal hexahistidine (H6) tag and stored in aliquots in PBS supplemented with 5 % mannitol and 
5 % trehalose at −20 °C. Biotinylated proteins were obtained via primary NH2-groups using EZ-Link 
Sulfo-NHS-LC-Biotin according to manufacturer’s instructions. Trx-MC-Myc-010 protein, an oMCoTI-
II scaffold with grafted c-myc epitope in loop 1, was stored in PBS at −20 °C. 
2.1.10 Synthetic DNA fragments 
Gene fragments encoding for MCopt 2.0 or MCopt 2.1 library sequences were directly assembled by 
GeneArt™ (Thermo Fisher Scientific) using trinucleotide mixtures encoding for nineteen amino acids 
excluding cysteine at the variable positions. The MCopt 2.0 and MCopt 2.1 DNA fragments were 
amplified by the manufacturer and used for library construction or as a template for fragment 
amplification. 
For generation of alanine scanning MC-FN-010 derivatives mutations were either introduced via PCR 
or the whole coding sequence was assembled via direct synthesis of GeneArt™ Strings™ fragments 
(Thermo Fisher Scientific). 
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2.1.11 Oligonucleotides 
Name Oligonucleotides sequence (5´-3´) Purpose 
BamHI-Lip-up GCAGATCTGGGGGTGGTTCGGCCGGATCCGC 
MCopt 1.0 insert 
amplification 
Bsp120I-MC-lo GCGCGGGCCCTCATTAACCGCAGTAACCGTTACCA 
MCopt 1.0 insert 
amplification 
M13 fwd long TTGTAAAACGACGGCCAGTGAGC 
MCopt 2.0 DNA fragment 
or  
MCopt 3.0 DNA fragment 
amplification 
M13 rev long GGAAACAGCTATGACCATGTTAATGCAGC 
MCopt 2.1 DNA fragment 
or 
MCopt 3.0 DNA fragment 
amplification 
M13 uni (-43) 
lo 
AGGGTTTTCCCAGTCACGACGTT Colony PCR 
MC-FA-010-up GGAAAGTGTCCTTATTCGAACTGG Colony PCR 
MCopt 2.0 rev AATACATGCACCCGGGCAATCGCTATCGCGAC 
MCopt 2.0 DNA fragment 
amplification 
MCopt 2.1 fwd GATAGCGATTGCCCGGGTGCATGT 
MCopt 2.1 DNA fragment 
amplification 
2.1.12 Kits 
EZ-Link Sulfo-NHS-LC-Biotin Thermo Fisher Scientific 
High Pure PCR Product Purification Kit Roche 
High Pure Plasmid Isolation Kit Roche 
Plasmid DNA purification kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
Wizard® Plus SV Minipreps DNA Purification 
System 
Promega Corporation 
Wizard® SV Gel and PCR Clean-up System Promega Corporation 
2.1.13 Reagents and chemicals 
10x Blocking solution, B6429-500ML Sigma Aldrich 
10x Fermentas fast digest buffer Thermo Fisher Scientific 
10x Taq buffer (NH4+) Thermo Fisher Scientific 
2-methylbutane Carl Roth 
50x Tris/Acetic Acid/EDTA (TAE)Puffer Bio-Rad Laboratories 
6x DNA loading dye Thermo Fisher Scientific 
Acetic acid, 100 % Carl Roth 
Acetonitrile Carl Roth 
Active cole Carl Roth 
Agarose low melting Bio-Rad Laboratories 
BactoTM Trypton AppliChem 
BactoTM Yeast extract BD Biosciences 
Betaine solution, 5 M, PCR reagent Sigma Aldrich 
Beta-Mercaptoethanol Gibco 
Bromophenol blue sodium salt AppliChem 
Carbenicillin disodium salt Carl Roth 
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Chloramphenicol Carl Roth 
Complete EDTA free protease inhibitor 
cocktail 
Roche 
Coomassie Brilliant blue R-250 AppliChem 
D(+)-glucose monohydrate Merck Miilipore 
D-biotin Carl Roth 
DifcoTM Agar BD Biosciences 
Dimethyl sulfoxide (DMSO) AppliChem 
Disodium hydrogen phosphate Carl Roth 
Dithiotreitol (DTT) Carl Roth 
dNTP set (100 mM, each A,C,G,T) Thermo Fisher Scientific 
DPBS Gibco 
eFluor 450™ eBioscience 
E-PAGE™ loading dye, 4x Life Technologies 
Ethanol >96 % (EtOH) Carl Roth 
Ethylenediaminetetraacetic acid (EDTA) AppliChem 
GelRed™ Nucleic Acid Gel Stain Biotium 
Glycerol Carl Roth 
Glycine Carl Roth 
Hoechst 33342 Thermo Fisher Scientific 
Hydrochloric acid, 37 % Carl Roth 
Hydrochloric acid, 5 M AppliChem 
Imidazole Carl Roth 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) AppliChem 
Kanamycin sulfate Carl Roth 
Magnesium chloride hexahydrate AppliChem 
Magnesium sulfate heptahydrate AppliChem 
Mannitol Carl Roth 
Methanol, > 99.7 % (MeOH) Carl Roth 
MgCl2 (25 mM) Thermo Fisher Scientific 
Milk powder Carl Roth 
Nuclease free, sterile water Carl Roth 
NuPAGE® MES SDS Running Buffer (20x) Life Technologies 
Polyethylene glycol (PEG) AppliChem 
Polyethylenimine (PEI) Sigma-Aldrich 
Potassium chloride AppliChem 
Sodium carbonate AppliChem 
Sodium chloride (NaCl) Carl Roth 
Sodium dodecyl sulfate (SDS), ultra-pure Carl Roth 
Tetracycline hydrochloride Carl Roth 
TMB substrate (3,3’,5,5’-
Tetramethylbenzidine) 
Sigma-Aldrich 
Trehalose AppliChem 
Triethylamine (TEA) Sigma-Aldrich 
Trifluoracetic acid (TFA) AppliChem 
Tris ultrapure AppliChem 
2.1.14 Standard DNA and protein marker 
Gene Ruler™ 1 kbp DNA ladder Thermo Fisher Scientific 
Gene Ruler™ 50 bp DNA ladder Thermo Fisher Scientific 
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Precision Plus Protein™ Dual Color Standard Bio-Rad Laboratories 
Precision Plus Protein™ Dual Xtra Prestained 
Standard 
Bio-Rad Laboratories 
2.1.15 Buffer 
4x non-reducing SDS-loading buffer 
250 mM Tris, 34 % (w/v) glycerol, 8.2 % (w/v) 
SDS, spatula bromophenol blue, pH 6.8 
4x reducing SDS-loading buffer 
250 mM Tris, 34 % (w/v) glycerol, 8.2 (w/v) % 
SDS, 5 % (w/v) β-Mercaptoethanol, spatula 
bromophenol blue, pH 6.8 
Coating buffer 50 mM Na2CO3 pH 9.4 
Coomassie destain solution 45 % (w/v) MeOH, 10 % (w/v) acetic acid 
Coomassie stain solution 
0.25 % (w/v) coomassie, 40 % (w/v) EtOH, 
10 % (w/v) acetic acid 
FACS buffer DPBS, 5 mM EDTA, 5 % FBS, pH 7.5 
Freezing buffer FBS, 10 % DMSO 
IMAC A buffer 
20 mM Tris-HCl pH 8.0, 10 % glycerol, 500 mM 
NaCl, 10 mM imidazole 
IMAC B buffer 
20 mM Tris-HCl pH 8.0, 10 % glycerol, 500 mM 
NaCl, 500 mM imidazole 
Lysis buffer 
20 mM Tris pH 8.0, 2 mM MgCl2, 20 mM NaCl, 
0.1 mg/mL Lysozym, 15 U/mL Benzonase 
PBS 
14 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4, pH 7.5 
PBS-T 
14 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4, 0.1 % (w/v) Tween® 20pH 7.5 
PEG/NaCl solution 25 % (w/v) polyethylene glycol, 2.6 M NaCl 
TAE buffer 40 mM Tris, 20 mM acetic acid, 1 mM EDTA 
TBS-T 
50 mM Tris, 150 mM NaCl, 0.1 % (w/v) 
Tween® 20, pH 7.4 
Thrombin cleavage buffer 
20 mM Tris, 150 mM NaCl, 1.5 mM CaCl2 and 
5 % (w/v) glycerol, pH 8.45 
Western Blot transfer buffer 
25 mM Tris, 192 mM glycine, 20 % (w/v) 
MeOH 
2.1.16 Consumables  
24-deepwell plates, 10 mL Thermo Fisher Scientific 
48-well PCR plates Thermo Fisher Scientific 
6-well plates, 12-well plates, 24-well plates, 
96-well plates 
Thermo Fisher Scientific 
96-deepwell plates, 2 mL Carl Roth 
96-well plates polystyrene and MaxiSorpTM Thermo Fisher Scientific 
96-well round-bottom plates Thermo Fisher Scientific 
Adhesive PCR film Thermo Fisher Scientific 
Adhesive seals Thermo Fisher Scientific 
Amicon® Ultra-4 and -15 Centrifugal Filter 
Units (3 kDa NMWL, 10 kDa NMWL) 
Merck Millipore 
AMPure XP Beads Beckman Coulter 
Aspiration pipette 2 mL Greiner bio-one 
CASY cup OLS OMNI Life Science 
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CASYton solution OLS OMNI Life Science 
Cell culture flask 175 cm2, 75 cm2, 25 cm2 Greiner bio-one 
Cell culture triple flask Thermo Fisher Scientific 
Cell scraper Heathrow Scientific 
Cell strainer 70 μm Greiner bio-one 
Combitip 25 mL, 50 mL Eppendorf 
Cover slip 75x25 mm Carl Roth 
Cryo tubes 1.8 mL Sigma-Aldrich 
Cuvette BRAND 
Dialysis hose (exclusion size, 10 kDa) Carl Roth 
Dialysis tubes Carl Roth 
Durapore membrane filter (0.22 μm) Merck Millipore 
Dynabeads® M-280 Streptavidin Life Technologies 
Electroporation cuvette 0.1 cm Bio-Rad Laboratories 
E-PAGE™ 96-well gels (6 %) Life Technologies 
FACS tubes, polystyrene BD Biosciences 
Filter Tips 10 μL, 20 µL, 100 μL, 200 µL, 300 μL, 
1000 μL 
Eppendorf 
FluoroTrans® polyvinylidene difluoride 
transfer membrane(PVDF) 
Pall Life Sciences 
High Sensitivity DNA chip Agilent Technologies 
High speed falcon tubes 50 mL Carl Roth 
HisPur™ Ni-NTA spin columns Thermo Fisher Scientific 
HisTrap column 1 mL GE Healthcare Life Science 
Immunotube Thermo Fisher Scientific 
Lumi-Light Western Blotting Substrate Sigma-Aldrich 
MagicMedia™ (autoinduction medium) Invitrogen 
Microscope slides 76x26 mm Carl Roth 
Mounting medium Dako 
Nitrocellulose membrane (0.1 µm pore size) GE Healthcare Life Science 
NuPAGE® Novex 12 % Bis-Tris gels, 1.00 mm 
(10, 12 and 15 well) 
Invitrogen 
NuPAGE® Novex 4-12 % Bis-Tris gels, 1.00 mm 
(10, 12 and 15 well) 
Invitrogen 
PCR reaction tubes 0.2 mL, 8-tube-strip Molecular BioProducts 
Petri dish square, 245x245 mm Sigma-Aldrich 
Petri dishes 100x15 mm, 140x20 mm Greiner bio-one 
Pipette tips 10 μL, 200 μL, 1000 μL Eppendorf 
Reaction tubes 5 mL, 2 mL, 1.5 mL, 0.5 mL Eppendorf 
Reaction tubes 5 mL, 2 mL, 1.5 mL, 0.5 mL, 
protein LoBind 
Eppendorf 
Reagent reservoir 25 mL, 50 mL Roth 
Rod pipette 5 mL, 10 mL, 25 mL, 50 mL Greiner bio-one 
Serological pipettes 2 mL, 5 mL, 10 mL, 25 mL, 
50 mL 
Greiner bio-one 
SOC medium New England BioLabs 
Streptividin sensor chip GE Healthcare Life Science 
SuperSignal™ West Dura Extended Duration 
Substrate 
Thermo Fisher Scientific 
Syringe 30 mL BD Biosciences 
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Syringe filter 0.45 μm, sterile Sartorius 
Syringes 5 mL, 1 mL, 0.5 mL BD Biosciences 
Syringes, fixed needle, 0.3 mL, 0.5 mL, 1 mL BD Biosciences 
Tubes 15 mL, 50 mL Greiner bio-one 
Whatman paper Carl Roth 
2.1.17 Laboratory equipment 
Agarose gel comb Bio-Rad Laboratories 
Agarose gel tray Bio-Rad Laboratories 
Agilent 1260 Infinity Quarternary LC system Agilent Technologies 
ÄKTA Pure GE Healthcare Life Science 
ÄKTAprime plus GE Healthcare Life Science 
Autoclave SHP Steriltechnik AG 
BD FACSCanto II BD Biosciences 
Biacore T-100 device GE Healthcare Life Science 
Bioanalyzer 2100 Agilent Technologies 
Blotting Roller Invitrogen 
Branson Digital Sonifier 250 Branson 
CASY TCC OLS OMNI Life Science GmbH 
Centrifugal flasks 1 L Thermo Fisher Scientific 
Centrifuge 4K15 Sigma 
Centrifuge 5810R Eppendorf 
Centrifuge, SorvallTM LYNXTM Superspeed, 
Multitron pro 
Thermo Fisher Scientific 
ChemiDocMP Bio-Rad Laboratories 
CO2 incubators HERAcell 150 Heraeus 
Conical flask 250 mL Duran 
DynaMag™-2 Invitrogen 
ELGA PURELAB Chorus 1 ELGA Veolia 
E-PAGE™ System Life Technologies 
FACS Aria™ BD Biosciences 
Impulse sealer Typ300 GEHO Pack Services 
Incubation shaker Multitron Pro INFORS HT 
IVIS Spectrum System PerkinElmer 
Laminar flow bench HERAsafe 2020 Heraeus 
LCMS Single Quad G6130B System Heraeus 
Microplate Reader Infinite M200 PRO Tecan 
MicroPulser Electroporation device Bio-Rad Laboratories 
Multichannel pipette Eppendorf 
Multistep pipette Eppendorf 
PCR thermocycler (3 blocks, 48-well 
microplates) 
Biometra 
peqSTAR 96X Universal (gradient PCR 
thermocycler) 
Peqlab Brand 
Pipette 10 μL, 200 μL, 1000 μL VWR Eppendorf 
Reciprocal shaker CAT RM5-80L CAT 
Reciprocal shaker MaxQ 2508 Modell 4363 Thermo Fisher Scientific 
Resource RPC column 3 mL GE Healthcare Life Science 
Rotational vacuum concentrator, RVC 2-18-CD 
Plus 
Christ 
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Sample loop, 5 mL GE Healthcare 
Scale Mettler Toledo 
Spectral photometer Ultrospec 2100 GE Healthcare 
Spectrophotometer, Nanodrop2000c Thermo Fisher Scientific 
Superloop 10 mL GE Healthcare 
Table top centrifuge Fresco 21 Heraeus 
Thermomixer 0.5 mL, 1.5 mL, 2 mL Eppendorf 
Trans-Blot® Turbo™ Blotting System Bio-Rad Laboratories 
TSKgelG3000SWXL Tosoh Bioscience 
UV transilluminator NIPPON Genetics Europe 
Vi-Cell XR Beckman Coulter, Inc. Brea 
Vortex-Genie Scientific Industries 
Water bath JULABO TW 8 JULABO 
XCell SureLock Mini-Cell Electrophoresis 
chamber 
Invitrogen 
Zeiss Apotome microscope Carl Zeiss 
2.1.18 Software and database 
Biacore T-100 Evaluation Software GE Healthcare Life Science 
ChemStation Software Agilent Technologies 
E-Editor 2.0 Thermo Fisher Scientific 
FlowJo X TreeStar 
GraphPad Prism GraphPad Software Inc. 
ImageQuant™ TL 8.1 GE Healthcare 
Living Image® software PerkinElmer 
PrimeView Evaluation Program GE Healthcare Life Science 
ProtParam Bioinformatics Resource Portal 
PyMol Schrödinger 
ZEN software Carl Zeiss 
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2.2 Methods 
2.2.1 Cell biological methods 
2.2.1.1 Cell culture 
Cell lines were handled under sterile conditions inside a laminar flow bench. All cell lines 
(chapter 2.1.1) were cultured under aseptic conditions in an incubator at 37 °C with 5 % CO2 and 
>80 % humidity. 
A tube containing cryopreserved cell bank was placed in a 37 °C bath to thaw cells until a small piece 
of ice was left. Cells were immediately transferred to 10 mL pre-warmed cell culture medium and 
centrifuged at 300 x g for 5 min. The supernatant was discarded and the cell pellet was re-suspended 
in the respective cell culture medium. Cell number and viability were determined as described in 
chapter 2.2.1.2 and seeded in a 75 cm2 flask for cultivation. 
For subcultivation of adherent cell lines medium was removed by aspiration, cells were washed with 
1x Dulbecco´s phosphate-buffered saline (DPBS) and detached with 3 mL Accutase® solution for 
3 – 5 min at 37 °C. Enzymatic reaction was stopped by adding 10 mL of cultivation medium and cell 
clusters were separated by pipetting up and down. Subsequently, cells were counted as described in 
chapter 2.2.1.2 and seeded with desired cell density (Table 2.1) into a new culture 175 cm2 flask with 
respective amount of culture medium for further cultivation (chapter 2.1.2). 
Table 2.1 Cultivation conditions of cell lines. 
Parameters CHO-K1 
CHO-K1 
transfectant 
Flp-In™ wt 
Flp-In™-CHO-
FAP-α 
U-87 MG 
Cell type adherent adherent adherent adherent adherent 
Seeding density 
(subcultivation) 
1x104 
cells/cm2 
1x104 
cells/cm2 
1x104 
cells/cm2 
1x104 
cells/cm2 
2x104 
cells/cm2 
Subcultivation 
frequency 
every 3rd day every 3rd day every 3rd day every 3rd day every 4th day 
2.2.1.2 Cell counting 
Cell number and viability were measured with automated cell counters Vi-Cell XR or CASY TCC.  
The Vi-Cell XR cell optical counting system determines cell density and viability according to size, 
morphology, contrast via bright field and a trypan blue staining. For cell counting cell suspension was 
diluted 1:2 or 1:10 with DPBS in a total volume of 1 mL.  
The CASY TCC automated cell counting device is based on electrical current exclusion and pulse area 
analysis. Cells travel in an electrolyte solution through a measuring pore into a capillary and are 
exposed to an electric field. Thereby, living cells generate greater pulse height compared to dead cells 
as they have intact membranes. For counting purposes, 10 µL cell suspensions was added to 10 mL 
CASYton solution in a CASY cup, which was then placed under the capillary for analysis.  
2.2.1.3 Generation of stable cell lines 
In this work stable cell lines were generated using the PiggyBac transposon system138. After cell 
harvesting (chapter 2.2.1.1), 2.4 x 105 CHO-K1 cells were seeded into a 6-well plate and grown 
overnight. A mixture of 8.4 µg PEI, 0.8 µg Piggy Bac transposase vector and 2 µg pPB transposon 
vector (pPB transposon_DSG-3 or pPB transposon_dsRed vector) was incubated at RT for 30 min and 
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added dropwise to the cells in transfection medium (DMEM/F12 + GlutaMAX™). Cells were then 
rested for around 8 h at 37 °C before changing transfection medium to growth medium. After three 
days of cultivation the medium was removed and replaced with fresh growth medium supplemented 
with 200 µg/mL hygromycin-B to induce the selection of successfully transfected cells. 
A monoclonal cell from the pool of transfected cells was selected by FACS using the FACS Aria™ 
device. Single cells showing a high expression of dsRed were sorted into a 96-well, flat bottom plate. 
To generate a stable cell line expressing DSG-3, prior to sorting, cells were stained with an anti-DSG-
3 antibody and anti-mouse IgG (chapter 2.1.7). Hereby, single cells with strong co-expression of GFP 
and DSG-3 were selected. After sorting, the plate was centrifuged at 300 x g for 5 min at RT to 
sediment the single cells. The plate was then incubated at 37 °C with 5 % CO2 for cell outgrowth. 
For cryopreservation, 1x107 cells were re-suspended in 1 mL freezing buffer in a cryo tube and stored 
in an isopentane filled cryo freezing container at −80 °C overnight. Afterwards, the cryo tube was 
transferred to a liquid nitrogen tank (−196 °C) for long-term storage. 
2.2.2 Molecular biological methods 
2.2.2.1 DNA preparation 
Isolation of plasmid DNA was performed according to manufacturer´s instruction using Wizard® Plus 
SV Minipreps DNA Purification System or plasmid DNA purification kit. 
2.2.2.2 Restriction of vectors and DNA fragments 
Vectors were digested with ApaI, BamHI or KpnI. Enzymes were applied with 10 U per 1 µg DNA and 
enzymatic reaction was conducted at 37 °C for 2 h. pET-32-LibEx vector was digested with ApaI and 
BamHI. pET-32-LibEx_GS, pET-32-AX, pJuFoIII and pPDIII-1 vectors were restricted with BamHI and 
KpnI. Digested vectors were separated by gel electrophoresis (chapter 2.2.2.3) and DNA was 
subsequently purified via gel extraction (chapter 2.2.2.4). The 5´-ends of digested and purified vector 
backbone were then dephosphorylated with 1 U rSAP per 1 µg DNA at 37 °C for 1 h and 5 min at 65 °C 
for enzyme inactivation. As a final step, DNA was purified with the Wizard® SV Gel and PCR Clean-up 
system and eluted in an appropriate volume of H2O. Prepared vectors were stored at −20 °C. 
DNA fragments were restricted with FastDigest ApaI, FastDigest BamHI or FastDigest KpnI with 10 U 
per 1 µg DNA fragment. Incubation was performed at 37 °C for 1 h. 
2.2.2.3 Agarose gel electrophoresis 
DNA was separated according to its molecular size in an electric field within an agarose gel. For long 
DNA fragments gels with 1 % (w/v) agarose in TAE buffer were prepared and for short DNA fragments 
2 % agarose gels were used. To this end, an appropriate amount of solid agarose was dissolved in TAE 
buffer by heating up inside a microwave at ~600 Watt. For detection of DNA fragments the agarose 
solution was supplemented with GelRed™ (Biotium, diluted 1:10000) and poured into a gel tray with 
a suitable well comb. 6x DNA loading dye was added to the DNA samples (final concentration 1x) and 
transferred together with an appropriate DNA ladder (50 bp DNA ladder or 1 kb DNA ladder) into the 
pockets of the gel. Depending on the gel size an optimal constant voltage of 100 V was adjusted and 
run for 40 – 90 min. Separated DNA bands were visualized with UV-light and documented with 
ChemiDoc MP. For preparative purposes, respective DNA bands were cut out of the gels on an UV 
transilluminator (chapter 2.2.2.4). 
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2.2.2.4 DNA purification from agarose gels 
A piece of agarose gel containing the desired DNA fragment was cut with a sterile scalpel under UV 
light on a UV transilluminator. Isolation of DNA fragments out of an agarose gel was performed 
according to manufacturer´s protocol using QIAquick Gel Extraction Kit or Wizard® SV Gel and PCR 
Clean-up System. 
2.2.2.5 Ligation of DNA fragments 
DNA fragments were ligated enzymatically to the vector backbone using T4 DNA ligase. Ligation 
reactions were composed of 100 ng vector DNA and a fivefold molar excess of DNA fragments in a 
total volume of 20 µL, unless other described elsewhere. Enzymatic reactions were conducted at RT 
for 2 h, followed by a transformation of E. coli cells (chapter 2.2.2.6). 
2.2.2.6 Transformation of E. coli SHuffle® T7 Express and E. coli SHuffle® T7 Express pBirAcm cells 
The transformation was performed with competent E. coli SHuffle® T7 Express cells or E. coli SHuffle® 
T7 Express pBirAcm cells. The ligation sample was added to the bacterial cells and placed on ice for 
30 min. The cells were then heat-shocked at 42 °C for 30 sec and incubated on ice for 5 min. For 
expansion of cells 950 µL pre-warmed SOC medium was added and the mixture was incubated at 
37 °C for 1 h before plating them on a selective agar plate. 
2.2.2.7 Generation of chemical competent E. coli SHuffle® T7 Express pBirAcm cells 
E. coli SHuffle® T7 Express cells were transformed with pBirAcm plasmid according to the protocol as 
described in chapter 2.2.2.6. A single clone was grown in 5 mL LBCarbChlora-medium culture at 37 °C and 
200 rpm overnight. At the following day, a 50 mL culture containing LB-medium was inoculated with 
500 µL of bacterial preculture. The culture was incubated at 37 °C at 150 rpm until an OD600 of 0.5 
was reached. The cells were harvested by centrifugation at 4 °C and 4000 rpm for 10 min. Cell pellet 
was carefully taken up in 25 mL ice-cold 100 mM CaCl2 and centrifuged (4 °C, 4000 rpm for 10 min). 
The supernatant was discarded, cell pellet re-suspended in 20 mL ice-cold 100 mM CaCl2 and 
centrifuged again. As a final step of generating chemical competent cells, pellet was taken up again 
in 2 mL ice-cold 100 mM CaCl2 and incubated for 30 min on ice. For long term storage at −80 °C, 
300 µL glycerol was added to cell suspensions and aliquots of 200 µL were prepared. 
2.2.2.8 Photometric determination of DNA concentration 
DNA concentration and purity was determined by spectroscopic measurement at 260 nm absorption 
using NanoDrop2000c UV-Vis spectrophotometer. The spectrophotometer was blanked with 1.5 µL 
of the respective buffer and 1.5 µL of DNA solution was applied for quantification. 
2.2.2.9 Sequencing 
DNA sequencing was performed by a commercial provider (Eurofins Genomics, GATC or 
Microsynth AG). Plasmid DNA was prepared as described in chapter 2.2.2.1 and adjusted to a final 
concentration of 50 – 100 ng/µL in a volume of 15 µL. For sequencing, 2 µL of forward or reverse 
primer (10 pmol/µL) were added to purified plasmid DNA, respectively and send to Eurofins 
Genomics in a 1.5 mL reaction tube. 
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For high-throughput sequencing in 96-well plates, single E. coli clones were placed in 150 µL LBCarbGlu-
medium and incubated at 37 °C for 4 h. The plate together with a tube containing 200 µL of primer 
(10 pmol/µL) was shipped to Microsynth AG. 
For high-throughput sequencing at GATC, a provided 96-well agar plate containing ampicillin was 
inoculated with 5 µL E. coli preculture from a 96-deepwell plate. The primer (10 pmol/µL) in a total 
volume of 100 µL was provided in a separate tube. 
2.2.2.10 Colony polymerase chain reaction 
Polymerase chain reaction (PCR) is a sensitive method to amplify DNA sequences with heat-stable 
polymerase enzyme and specific oligonucleotide primers. The reaction starts with a separation of 
dsDNA into two strands by a heat denaturation step. During the annealing step primers are able to 
bind their complementary DNA strand. This step is followed by the synthesis of the complementary 
DNA strand in 5´-3´direction via polymerase within the elongation step. 
Colony PCR was performed with E. coli XL1-Blue cells to analyze enrichment of MC-FA-010 in spike-in 
selection experiments. E. coli cells were obtained from dilution plating of a cell-based panning round 
(chapter 2.2.5.1). Single clones were picked from selective agar plates with a sterile tip and dipped 
into a well of a 48-well PCR plate that contained 25 µL of PCR reaction mix (Table 2.2). 
Table 2.2 Reagents and volumes for colony PCR. 
Reagent Volume (µL) 
10x Taq buffer (NH4+) 2.5 
MgCl2 (25 mM) 1.5 
dNTPs (10 mM) 0.5 
MC-FA-010-up (10 μM) 0.5 
M13 uni (-43) lo (10 μM) 0.5 
Taq polymerase (1 U/μL) 0.25 
H2O ad 25 
 
A pJuFoVIII vector with a gene coding for MC-FA-010 was used as positive control, while pJuFoVIII 
vector and H20 served as negative controls. PCR reaction program was performed as stated in 
Table 2.3 in a PCR thermocycler. 
Table 2.3 PCR reaction program for colony PCR. 
Duration Temperature Step  
2 min 94 °C First denaturation  
30 sec 94 °C Denaturation 
30x 30 sec 53 °C Annealing 
1 min 72 °C Synthesis 
2 min 72 °C Final elongation  
∞ 4 °C Hold  
 
After PCR reaction, 4 µL of 6x loading dye was added to each well. To analyze PCR products 10 µL of 
each reaction sample was electrophoretically separated on a 2 % agarose gel (chapter 2.2.2.3). 
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2.2.2.11 Gradient PCR 
The optimal PCR condition for amplification of MCopt 2.0, MCopt 2.1 and MCopt 3.0 DNA fragments 
was assessed using gradient PCR and with addition of different supplements. The general composition 
of a PCR reaction is shown in Table 2.4 with addition of either 2.5 %, 5 %, 7.5 % or 10 % DMSO or 
0.4 M, 0.8 M, 1.2 M or 1.6 M betaine. PCR reactions were performed in a gradient PCR cycler 
according to Table 2.5 with an annealing temperature gradient ranging from 53 °C to 64 °C.  
Table 2.4 Reagents and volumes for gradient PCR. DMSO was added to a final concentration of 2.5 %, 5 %, 
7.5 % or 10 % and betaine to 0.4 M, 0.8 M, 1.2 M or 1.6 M. Primer sets for amplification of MCopt 2.0, 
MCopt 2.1 and MCopt 3.0 DNA fragment pools are given in chapter 2.1.11. 
Reagent Volume (µL) 
10x Taq buffer (NH4+) 2 
MgCl2 (25 mM) 1.2 
dNTPs (10 mM) 0.4 
Forward primer (10 μM) 0.4 
Reverse primer (10 μM) 0.4 
Taq polymerase (1 U/μL) 0.5 
Supplement DMSO or betaine 
Template 50 ng DNA fragments 
H2O ad 20 
 
Table 2.5 PCR reaction program for gradient PCR. In a gradient PCR, annealing temperatures of 53 °C, 
54.6 °C, 56.1 °C, 57.7 °C, 59.3 °C, 60.9 °C, 62.4 °C or 64 °C were applied. 
Duration Temperature Step  
5 min 95 °C First denaturation  
30 sec 95 °C Denaturation 
30x 30 sec 53 °C – 64 °C Annealing (gradient) 
1 min 72 °C Synthesis 
5 min 72 °C Final elongation  
∞ 4 °C Hold  
 
For analysis of amplified PCR products, samples were mixed with 4 µL 6x loading dye and separated 
on a 2 % agarose gel (chapter 2.2.2.3). Based on the visual evaluation, single PCR samples were 
chosen for a control of fragment size and quality. Therefore, PCR products were purified via AMPure 
XP Beads according to manufacturer´s instruction and inspected on a High Sensitivity DNA chip using 
a Bioanalyzer 2100 chip-based capillary electrophoresis device, which was performed by colleagues 
from the Medical Genomics-NGS unit at TRON gGmbH. 
2.2.2.12 Splicing by overlap extension PCR 
The MCopt 3.0 DNA fragment pool for phage library construction was generated using splicing by 
overlap extension (SOE) PCR as depicted in Figure 2.4. Here, the MCopt 2.0 and MCopt 2.1 DNA 
fragments assemble through their complementary overlapping regions. By means of a PCR with a 
primer pair, which binds on each DNA fragment, both parts were genetically combined. This resulted 
in a novel amplified DNA fragment pool.  
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Figure 2.4 Experimental outline of MCopt 3.0 DNA fragment amplification via SOE PCR.  
In a first PCR, fully synthetic MCopt 2.0 DNA fragments were amplified using M13 fwd long and 
MCopt 2.0 rev primers, while for synthetic MCopt 2.1 DNA fragments MCopt 2.1 fwd and M13 rev 
long primers were applied (chapter 2.1.11). The reaction mix as well as the applied PCR program is 
shown in Table 2.6 and Table 2.7. After fragment amplification in a PCR thermocycler, PCR products 
were gel-electrophoretically separated and respective amplicons were purified (chapter 2.2.2.3, 
chapter 2.2.2.4). 
In the second PCR, the purified MCopt 2.0 and MCopt 2.1 DNA fragments served as templates for the 
construction of MCopt 3.0 DNA fragments with the primer pair M13 fwd long and M13 rev long 
(chapter 2.1.11). Resulting PCR products were again separated vial gel-electrophoresis and purified 
(chapter 2.2.2.3, chapter 2.2.2.4). Obtained MCopt 3.0 DNA fragments were used for phage library 
generation as described in chapter 2.2.2.14.  
Table 2.6 PCR reagents and volumes for MCopt 2.0, MCopt 2.1 and MCopt 3.0 DNA fragment amplification. 
 Volume (µL) 
Reagent MCopt 2.0 fragment MCopt 2.1 fragment MCopt 3.0 fragment 
10x Taq buffer (NH4+) 20 20 20 
MgCl2 (25 mM) 12 12 12 
dNTPs (10 mM) 4 4 4 
Forward primer (10 μM) 4 4 4 
Reverse primer (10 μM) 4 4 4 
Taq polymerase (1 U/μL) 5 5 5 
Betaine (0.8 M) 0 32 0 
DMSO (5 %) 0 0 10 
DMSO (10 %) 20 0 0 
Template 50 ng 50 ng 
42 ng of each 
template 
H2O ad 200 ad 200 ad 200 
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Table 2.7 PCR reaction program for MCopt 2.0, MCopt 2.1 and MCopt 3.0 DNA fragment amplification. 
Duration Temperature Step  
5 min 95 °C First denaturation  
30 sec 95 °C Denaturation 
30x 30 sec 53 °C * Annealing 
1 min 72 °C Synthesis 
5 min 72 °C Final elongation  
∞ 4 °C Hold  
* 64 °C annealing temperature for MCopt 2.1 and MCopt 3.0 DNA fragment amplification. 
2.2.2.13 Cloning of cystine-knot miniprotein sequence into expression vector 
Plasmids of pJuFo-VIII-MCopt 1.0, pJuFoIII-MCopt 2.0/2.1/3.0 were prepared from 5 mL overnight 
E. coli culture (chapter 2.2.2.1). For cloning of MCopt 1.0 inserts into pET-32-LibEx vector, a BamHI 
restriction site was introduced via PCR using BamHI-Lib-up primer, whereas Bsp120I-MC-lo served as 
reverse primer (chapter 2.1.11). A standard reaction mix is shown in Table 2.6 (similar to MCopt 2.1 
DNA fragment pool amplification), but with 100 ng template DNA. The applied program is presented 
in Table 2.3. After amplification, PCR products were separated via gel electrophoresis 
(chapter 2.2.2.3), purified and eluted in 60 µL H2O (chapter 2.2.2.4). Amplified MCopt 1.0 inserts were 
digested with ApaI and BamHI in a volume of 200 µL at 37 °C for 1 h. Restricted MCopt 1.0 inserts 
were purified via Wizard® SV Gel and PCR Clean-up System for following ligation into prepared pET-
32-LibEx vector (chapter 2.2.2.5). 
For MCopt 2.0/2.1/3.0 insert cloning, 5 µg plasmid were directly digested with BamHI and KpnI in a 
total volume of 200 µL at 37 °C for 2.5 h (chapter 2.2.2.2). Inserts were purified after gel 
electrophoretic separation (chapter 2.2.2.3, chapter 2.2.2.4) and used for ligation into pET-32-
LibEx_GS or pET-32-AX2 vector (chapter 2.2.2.5). Cloned expression vectors were introduced into 
E. coli SHuffle® T7 Express cells as described in chapter 2.2.2.6. 
2.2.2.14 Generation of cystine-knot miniprotein phage libraries  
Combinatorial phage libraries were constructed based on an open chain variant of the trypsin 
inhibitor II from Momordica cochinchinensis (oMCoTI-II). Three libraries differed with respect to the 
randomization scheme. MCopt 2.0 was randomized in loop 1, MCopt 2.1 in loop 5 and MCopt 3.0 in 
both loops with ten amino acids. 
DNA fragments encoding for MCopt 2.0 or MCopt 2.1 sequences were directly used after 
manufacturing by GeneArt™ (chapter 2.1.10), while MCopt 3.0 DNA fragments were obtained using 
SOE-PCR (chapter 2.2.2.12). 
In the first step, 5 µg of each DNA fragment pool were digested with BglI in a total volume of 200 µL 
for 4 h at 37 °C, gel-electrophoretically separated (chapter 2.2.2.3), purified (chapter 2.2.2.4), 
followed by a second digestion of remaining DNA with BamHI and KpnI in a total volume of 150 µL 
for 4 h at 37 °C and subsequent purification using Wizard® SV Gel and PCR Clean-up System. For 
ligation, 7200 ng pJuFoIII vector backbone was combined with a five-fold molar excess of purified PCR 
fragments and 30 µL T4 DNA ligase (40 U/µL) in a total volume of 480 µL and incubated at 16 °C 
overnight. Ligation product was purified using DNA purification kit and eluted in 60 µL H2O. 
Subsequently, ligation product was introduced into electrocompetent E. coli SS320 cells. In total 12 
electroporation reactions were performed with 5 µL ligation products and 50 µL E. coli cells 
respectively in a 0.1 cm cuvette using the program Ec1 with 1.8 kV of MicroPulser electroporation 
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device. Immediately after the electroporation pulse, 1 mL of pre-warmed SOC medium was added 
and the cuvette was rinsed three times with 1 mL SOC medium. Cell suspensions were combined and 
incubated at 37 °C for 1 h at 150 rpm. In order to calculate the library size a serial dilution with 4.8 µL 
of the pooled cell suspension was made and plated on small agar plates containing 100 µg/mL 
carbenicillin and 0.4 % (w/v) glucose. Remaining 4795.2 µL suspension was plated on large square 
agar selective plates. All plates were incubated overnight at 30 °C. At the following day, colonies were 
scrapped off the large plates by adding 4 mL LB-medium to each plate and stored in the presence of 
10 % DMSO at −80 °C. Library size and diversity was calculated based on colony forming cells from 
the dilution plates and sequencing of individual clones.  
In order to eliminate double transformed E. coli SS320 cells, infection of E. coli XL1-Blue cells with 
library phages was performed with a multiplicity of infection (MOI) of 0.1. To this end, an E. coli XL1-
Blue culture (2.1 L) at an optical density (OD) of 0.5 was infected with 5 x 1010 produced MCopt 2.0, 
MCopt 2.1 or MCopt 3.0 library phages (chapter 2.2.5.4). Cells were rested for 30 min at 37 °C and 
agitated for 30 min at 37 °C with 120 rpm. Afterwards, cell suspensions were harvested by 
centrifugation at 4500 x g for 10 min. The pellet was taken up in 1.25 L LBCarbGlu-medium for incubation 
at 37 °C with 120 rpm overnight. Bacterial cells were harvested by centrifugation (4500 x g for 10 min) 
and stored with 10 % DMSO in small aliquots at −80 °C for further analysis and phage production. 
Library size was calculated by plating serial dilution of bacterial suspension on respective agar plates. 
2.2.2.15 Generation of MCopt 2.0 phage sub-library 
A MCopt 2.0 phage sub-library was constructed in a second phagemid vector (pPDIII-1). Library 
generation was performed essentially as described in chapter 2.2.2.14, but in a smaller scale. After 
synthetic MCopt 2.0 DNA fragment pool restriction, ligation of 60 ng MCopt 2.0 DNA fragments and 
400 ng restricted pPDIII-1 vector was conducted with 6 µL T4 DNA ligase in a total volume of 80 µL 
and incubated overnight at 16 °C. Thereafter, ligation product was purified via Wizard® SV Gel and 
PCR Clean-up system and eluted in 30 µL H2O. Three electroporation reactions were performed each 
with 10 µL ligation product and 100 µL electrocompetent E. coli XL1-Blue competent cells in a 0.1 cm 
cuvette using MicroPulser electroporation device. Cells were re-suspended in 1 mL of pre-warmed 
SOC medium right after electrical pulse and the cuvette was rinsed three further times with 1 mL SOC 
medium. Cell suspension (12 mL) was rested at 37 °C for 1 h at 150 rpm, 1.2 µL was taken for dilution 
plating and remaining suspension was plated on agar plates containing 100 µg/mL carbenicillin and 
0.4 % (w/v) glucose. After overnight incubation at 30 °C, colonies were scrapped off by dispensing 
4 mL LB-medium to each plate and stored in the presence of 10 % DMSO at −80 °C. Colonies from the 
dilution plates were counted and individual clones were sequenced for library size as well as quality 
determination. 
2.2.3 Microbiological methods 
2.2.3.1 High-throughput production of cystine-knot miniprotein fusions 
Recombinant protein production was carried out using E. coli SHuffle® T7 Express cells carrying either 
pET-32-LibEx or pET-32-LibEx_GS vector encoding for the respective cystine-knot miniprotein 
sequence. For a 96-well production of cystine-knot miniprotein fusions, single E. coli clones were 
expanded overnight at 37 °C in 1 mL LBCarbGlu-medium in a 96-deepwell plate. The following day, 1 mL 
of MagicMedia™ (autoinduction medium) supplemented with 100 µL/mL carbenicillin were 
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inoculated with 10 µL of the respective bacterial preculture and incubated at 30 °C for 18 – 24 h at 
200 rpm. 
Cells were harvested by centrifugation at 4000 rpm for 30 min. Cell pellets were re-suspended in 
250 µL lysis buffer and frozen at −80 °C for 1 h. The suspension was thawed and purified by heat-
incubation at 80 °C for 10 min. After a final centrifugation for the removal of cell debris, the bacterial 
supernatants containing the cystine-knot miniprotein fusions were transferred to a fresh plate and 
stored at 4 °C until use. 
2.2.3.2 In vivo biotinylation of cystine-knot miniprotein fusions in E. coli 
In vivo biotinylation of cystine-knot miniprotein fusion was performed using chemically competent 
E. coli SHuffle® T7 Express pBirAcm cells bearing pET-32-AX2 vectors encoding for the respective 
cystine-knot miniprotein sequence. Single clones were grown in 1 mL LBCarbChlora-medium overnight at 
37 °C and 180 rpm in a 96-deepwell plate. At the next day, 10 µL of the bacterial suspension was 
transferred to a fresh 96-deepwell plate containing 1 mL MagicMedia™ (autoinduction medium with 
100 µL/mL carbenicillin and 50 µM D-biotin) per well and incubated at 30 °C for 18 – 24 h at 200 rpm. 
Further processing was done as described in chapter 2.2.3.1. 
2.2.3.3 Large-scale production of cystine-knot miniprotein fusion 
Recombinant protein production was done using E. coli SHuffle® T7 Express cells carrying pET-32-
LibEx or pET-32-LibEx_GS vectors encoding for respective cystine knot miniprotein sequence. For this, 
a 50 mL LBCarbGlu-medium preculture was inoculated with a single clone from a selective agar plate 
and incubated at 37 °C overnight with 180 rpm. The day after, the main culture with 750 mL LBCarbGlu-
medium was inoculated to an OD600 of 0.01. The culture was incubated at 30 °C with 120 rpm until an 
OD600 of approximately 0.7 was reached. Protein production was then induced by adding 1 mM IPTG 
and the culture was incubated further at 25 °C with 120 rpm overnight. E. coli cells were harvested, 
re-suspended in 10 mL IMAC A buffer, lysed by sonification and heated to 80 °C for 10 min. After 
centrifugation of cell debris (15000 x g for 30 min, 4 °C), the supernatant was purified by immobilized 
metal affinity chromatography (IMAC) (chapter 2.2.4.1). The cystine-knot miniprotein fusion 
containing fractions were collected and dialyzed against thrombin cleavage buffer as described in 
chapter 2.2.4.2. 
Cystine-knot miniprotein fusions were either directly used for enzyme-linked immunosorbent assay 
(ELISA) or flow cytometry assays or processed further in case that the untagged miniprotein was 
required, e.g. for surface plasmon resonance (SPR) spectroscopy. For this purpose cystine-knot 
miniprotein fusions were cleaved with thrombin protease (chapter 2.2.4.3). 
Separation of cleaved protein fragments was performed by reverse phase chromatography (RPC) as 
described in chapter 2.2.4.4. Respective fractions containing cystine-knot miniprotein were 
lyophilized in a rotational vacuum concentrator as a final step. Amount of cystine-knot miniprotein 
was determined by weighing and the proteins were stored in lyophilized form at −20 °C. Proteins 
were resolved in H2O or DPBS depending on the subsequent application. Cystine-knot miniprotein 
identity was verified by mass spectrometry with a LCMS Single Quad G6130B system using a standard 
electrospray ionization protocol and performed by colleagues from the Serodiscovery/Peptide unit 
at TRON gGmbH. 
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2.2.3.4 E. coli growth curves 
A 50 mL LB-medium culture (supplemented with 100 µg/mL carbenicillin) was inoculated to an OD600 
of 0.01 with E. coli preculture carrying respective vector and incubated at 37 °C and 180 rpm. To 
analyze bacterial density over time, the OD was determined every 30 min via absorption 
measurement at 600 nm (chapter 2.2.3.5). After the culture reached an OD600 of 0.5, induction of 
protein production was initiated by adding 50 µL 1 M IPTG. Bacterial growth was further observed 
every 30 min. 
2.2.3.5 Determination of bacterial cell density  
OD of bacterial culture was determined by absorption measurement at 600 nm using NanoDrop2000c 
UV-Vis spectrophotometer. An OD600 of 1 represents a concentration of 8 x 108 cells/mL. The 
spectrophotometer was blanked with 1 mL of respective bacterial growth medium in a cuvette and 
then 1 mL bacterial suspension was measured pure or diluted with medium. 
2.2.4 Biochemical methods 
2.2.4.1 Immobilized metal affinity chromatography 
IMAC was used to purify cystine-knot miniprotein fusions from a heterogeneous protein solution. 
This method is based on the binding of His-tagged proteins to Ni2+-NTA loaded column resin, whereas 
other proteins straight pass through. Retained proteins can subsequently be eluted upon increasing 
imidazole concentration. 
Protein solution was filled into a 50 mL super loop and connected to the injection valve of an 
ÄKTAprime™ plus system. 1 mL HisTrap column was used and the program “His Tag Purification His 
Trap” was applied with a constant flow rate of 1 mL/min. The program started with a system 
equilibration with IMAC A as running buffer and followed by sample injection with a flow rate of 
1 mL/min. Subsequently, the column was washed with 20-fold column volumes. Protein elution was 
done using a gradient from 0 − 100 % IMAC B buffer in 20-fold column volumes. Eluted proteins were 
collected in 1 mL fraction size and chromatograms were evaluated in PrimeView Evaluation Program. 
Protein containing fractions were analyzed on SDS-PAGE and pooled for further assays. 
2.2.4.2 Dialysis 
Protein solutions were filled into semipermeable dialysis tubes with an exclusion limit of 
approximately 14 kDa. Depending on the solution volumes, a ~1000-fold higher volume of thrombin 
cleavage buffer or PBS was used for dialysis at 4 °C overnight. 
2.2.4.3 Thrombin cleavage of cystine-knot miniprotein fusion 
Separation of cystine-knot miniproteins from its fusion protein was achieved using thrombin protease 
cleavage. Per 1 mg protein 0.5 U of thrombin was added to the purified cystine-knot miniprotein 
fusion solution and enzymatic reaction was incubated at 37 °C overnight. 
2.2.4.4 Reverse phase chromatography  
RPC was the method of choice to separate fusion protein from cystine-knot miniproteins after 
thrombin cleavage. For this chromatography technique, amino acid residues interact varyingly strong 
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with the hydrophobic column material, which usually contains alkyl chains covalently coupled to silica 
gel. 
Agilent 1260 Infinity Quarternary LC system and a 3 mL Resource RPC column were used to isolate 
monomeric cystine-knot miniproteins. As running buffer 2 % acetonitrile in H2O supplemented with 
0.05 % TFA and as elution buffer 80 % acetonitrile in H2O containing 0.05 % TFA was applied. The 
chromatography system was washed with H2O and equilibrated with running buffer. Protein solution 
was injected in a 500 µL of 5 mL sample loop and a constant flow rate of 1 mL/min was set. Running 
buffer was substituted by running a gradient to 100 % elution buffer. Protein solution in a constant 
flow system passes absorption measurement at 220 nm and 280 nm, prior to collection of 250 µL 
fractions in a 96-deepwell plate. Fractions containing the protein of interests were identified in the 
chromatogram using ChemStation software. 
2.2.4.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Proteins were separated according to their electrophoretic mobility and molecular mass by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Protein samples were loaded with 
4x reducing SDS-loading buffer or 4x non-reducing SDS-loading buffer after denaturating via heating 
at 98 °C for 10 min. Depending on the protein size, protein samples and 5 μL protein standard 
(Precision Plus Protein™ Dual Color Standard or Precision Plus Protein™ Dual Xtra Prestained 
Standard) were transferred into pockets of NuPAGE Novex Bis-Tris 4-12 % 1 mm gels or NuPAGE 
Novex Bis-Tris 12 % 1 mm gels. Gels were run for 45 min with a constant voltage of 200 V. 
Subsequently, gels were stained in coomassie stain solution until the whole gel turned dark blue. 
Afterwards, gels were destained in coomassie destain solution to remove background signals and 
photographically documented with a ChemiDoc MP. 
2.2.4.6 E-PAGE™ high-throughput gel system 
The E-PAGE™ high-throughput gel system allows the analysis of 96 protein samples in parallel 
according to the classical SDS-PAGE principle. Protein samples were supplemented with 5 µL E-
PAGE™ loading buffer and 2 µL DTT and heated at 70 °C for 10 min. The pockets of an E-PAGE™ 96-
well gel (6 %) were loaded with 10 µL H2O before adding 13.5 µL of prepared protein sample. As a 
protein reference Trx-MC-Myc-010 with an amount of 3 µg, 10 µg and 20 µg was additionally applied. 
At the end of each row 3 µL of a protein standard (Precision Plus Protein™ Dual Color Standard) was 
loaded. The gel was placed into the E-Holder™ platform and run for 16 min with a voltage according 
to manufacturer´s instruction. Proteins were visualized by coomassie staining as described in 
chapter 2.2.4.5. E-PAGE™ was documented photographically with a ChemiDoc MP and lanes sorted 
using the E-Editor program. The protein bands were densitometrically quantified using the 
ImageQuant™ TL 8.1 software and the concentration was determined by using a calibration standard 
resulting from known amount of Trx-MC-Myc-010. 
2.2.4.7 Photometric determination of protein concentration 
Spectrophotometric determination of protein concentration relies on the distinct absorbance of 
proteins at 280 nm. This is mainly mediated by the aromatic amino acids tyrosine and tryptophan as 
well as the disulfide bonds of the protein, which results in a molar absorption coefficient of the 
protein. The protein concentration can be calculated based on the molar absorption coefficient and 
according to Lambert-Beer law139: 
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𝐴 = 𝜀 × 𝑑 × 𝑐 
A = absorbance; ε = molar absorption coefficient (protein specific; L/mol x cm); d = utilized cuvette 
thickness (cm); c = protein concentration (mol/L) 
Protein concentration and purity were determined by spectroscopic measurement at 280 nm and 
260 nm using NanoDrop2000c UV-Vis spectrophotometer. The spectrophotometer was blanked with 
1.5 µL of respective protein buffer and 1.5 µL of protein solution was applied. 
2.2.4.8 Alanine scanning mutagenesis of selected MC-FN-010 
In order to identify the residues within MC-FN-010 that contribute to EDB-binding an alanine scanning 
mutagenesis was performed. This method includes a systemic substitution of amino acids against 
alanine at defined sequence positions and subsequent binding analysis of the generated mutants. For 
generation of alanine scanning MC-FN-010 derivatives, respective DNA fragments (chapter 2.1.10) 
were cloned into pET-32-LibEx expression vector using unique BamHI and KpnI restriction sites and 
introduced into E. coli SHuffle®T7 Express competent cells (chapter 2.2.2.2, chapter 2.2.2.5, 
chapter 2.2.2.6). All mutations were verified by DNA sequencing (chapter 2.2.2.9). The alanine scan 
mutagenesis variants were expressed in 24-deepwell plates using 5 mL of selective autoinduction 
medium. Cystine-knot miniprotein fusion production and purification was performed as described in 
chapter 2.2.3.1 for the 96-well format, but included a further purification step of the supernatant 
using HisPur™ Ni-NTA spin columns. Binding ability and specificity of cystine-knot miniprotein fusions 
to target and off-target protein was carried out with an antibody-based ELISA assay as described in 
chapter 2.2.6.2. 
2.2.4.9 Surface plasmon resonance spectroscopy  
Binding kinetics of monomeric and trimeric cystine-knot miniprotein ligands to its target protein was 
determined using SPR in a Biacore T-100 device. For this, PBS-T was used as running buffer and the 
biotinylated FN-67B89 protein (200 – 300 µg/mL) was captured by binding to a flow cell of a SA sensor 
chip. To analyze monomeric ligands an immobilized target density of maximum 750 response units 
(RU) was applied and for trimeric variants a RU of maximum 400 was aimed for. Binding analysis of 
monomeric ligands was performed using a multi-cycle kinetic method with concentrations ranging 
from 50 – 4000 nM. A cycle started with an association period of 90 sec, followed by a dissociation 
period of 420 sec and a final regeneration step. Kinetic measurement was conducted applying a flow 
rate of 20 µL/min. Trimeric variants were analyzed under the same association and dissociation 
conditions, but using the single-cycle kinetic measurement mode in a constant flow of 30 µL/mL. In 
this case the analyte concentration was between 1.25 – 10 nM. Binding kinetics and steady state 
analysis were calculated using a global kinetic fit model (1:1 Langmuir, Biacore T-100 Evaluation 
Software). 
2.2.5 Phage experimental methods 
2.2.5.1 Cell-based panning 
CHO-K1-Mock (negative cell line), CHO-K1-DSG-3 and CHO-K1-FAP-α (target expressing cell lines) cells 
were prepared as described in chapter 2.2.1.1. Phage library particles were diluted to 1 x 1013 or 
2.4 x 1013 (first round) and 1 x 1012 or 2.4 x 1012 (second and third round) phages in 2 mL 2 % milk 
powder in PBS and 2 µL of phage suspension was removed for phage input titration (chapter 2.2.5.3). 
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For a panning round 1 x 107 CHO-K1-Mock cells were incubated with the actual phage suspension of 
1998 µL for 2 h at 4 °C for negative selection of phages. Cells were discarded after centrifugation at 
1500 x g for 1 min and remaining 1996 µL supernatant (2 µL removed for phage titration) was added 
to 1 x 107 CHO-K1-FAP-α or CHO-K1-DSG-3 cells for 2 h at 4 °C. Subsequently, unbound phages were 
washed off by rinsing five times with TBS-T and centrifugation at 1500 x g for 1 min. In order to elute 
bound phages, a pH-shift elution was performed by adding 200 μL 100 mM glycine (pH 2) to the 
washed cells. The suspension was incubated for 10 min at 300 rpm, centrifuged at 1500 x g for 1 min 
and the supernatant was transferred to a fresh tube containing 37.5 μL 1 M Tris/HCl (pH 9) for 
neutralization. 2.37 µL of elution solution was removed for phage titration (chapter 2.2.5.3). 
Exponentially growing E. coli XL1-Blue cells at an OD600 of 0.5 (1762.5 µL) were infected with eluted 
phages. Therefore, E. coli cells were incubated with the phages for 30 min at 37 °C without agitation 
and further 30 min with agitation at 150 rpm. Afterwards, infected cells were plated onto two large 
agar plates (supplemented with 100 µg/mL carbenicillin and 0.4 % (w/v) glucose) and incubated at 
37 °C overnight. At the following day, cells were scraped from the plates by dispensing 4 mL LB-
medium. Resulting cell suspension was used for phage production as described in chapter 2.2.5.4. 
Produced phage particles were applied for subsequent panning round according to the same 
experimental procedure as described. 
2.2.5.2 Panning against soluble target proteins 
Panning against soluble FN-B protein was used as model system to compare screening outcome of 
pJuFoIII-MCopt 2.0 library and pPDIII-1-MCopt 2.0 sub-library. Both libraries were screened in three 
successive panning rounds, starting with a tube-based panning and two successive panning rounds 
with streptavidin-coated (SA) magnetic beads. 
For the first round of tube-based panning, 1.2 mL 2 % milk powder in Na2CO3 (pH 9.4) were added in 
one immunotube (negative selection) and 1.2 mL Na2CO3 (pH 9.4) with 100 µg FN-B was added to a 
second immunotube for an incubation overnight at 4 °C and 30 rpm. Afterwards, the solutions were 
discarded and both immunotubes were blocked with 1.2 mL 2 % milk powder in TBS for 2 h at RT and 
30 rpm. The uncoated immunotube was washed twice with TBS-T at 500 rpm for 3 min respectively 
and then 1 x 1013 phages in 1.2 mL 2 % milk powder in TBS was added to the tube. Incubation was 
conducted for 30 min at RT, while target coated immunotube was blocked for additional 30 min and 
washed twice with TBS-T. The phage solution from the negative selection was transferred to the 
target coated immunotube (1 µL removed for phage titration (chapter 2.2.5.3) and incubated for 1 h 
at RT and 30 rpm. Afterwards, the target coated immunotube was washed six times with TBS-T and 
two times with TBS for 3 min at 80 rpm, respectively. For phage elution, 950 µL 100 mM triethylamine 
(TEA) was added to the tube for 6 min at 80 rpm and afterwards transferred to a fresh tube containing 
950 µL 1 M Tris/HCl (pH 7) for neutralization. A second elution was performed with 950 µL 100 mM 
glycine (pH 2) for 10 min at RT and 80 rpm. Subsequently, the supernatant was added to the first 
elution solution (2850 µL) and 2.85 µL was removed for phage titration (chapter 2.2.5.3). The elution 
solution was used to infect exponentially growing E. coli XL1-Blue cells (27.2 mL culture). The culture 
was incubated for 30 min at 37 °C without agitation and further 30 min with agitation at 150 rpm. 
Afterwards, infected cells were plated onto two large agar plates containing 100 µg/mL carbenicillin 
and 0.4 % (w/v) glucose and incubated at 37 °C overnight. At the next day, cells were scraped off the 
plates by adding 4 mL LB-medium. The cell suspension was then used for phage particle production 
(chapter 2.2.5.4) and served as input phage pool for the next panning round. 
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For the second or third panning round 2 x 50 μL Dynabeads® M-280 SA were transferred to a 2 mL 
tube each and washed with 1 mL TBS-T. To the first tube 100 μg biotinylated FN-B in 200 μL TBS was 
added, whereas 200 μL TBS without target (for negative selection of phages) was added to the second 
tube and beads were incubated on the rolling mixer for 20 min at 30 rpm. Tubes were placed into a 
DynaMag™-2 to recover beads and the beads were washed twice with TBS-T. For blocking, beads 
were taken up in 2 % milk powder in TBS for 1 h at 4 °C and 30 rpm. Target coated SA beads remained 
meanwhile in blocking solution, whereas 1 x 1013 (second and third round) phages were added to 
uncoated SA beads in 1 mL 2 % milk powder in TBS and incubated for 30 min at RT, 30 rpm (negative 
selection). Afterwards, blocking solution of target coated SA beads was removed, the beads were 
washed twice with TBS-T and re-suspended in phage supernatant (1 µL removed for phage titration 
chapter 2.2.5.3) resulting from the negative selection. After incubation for 1 h at RT and 30 rpm, 
unbound phages were removed by washing the beads six times with TBS-T and twice with TBS. Bound 
phages were eluted by adding 50 μL 100 mM TEA to the beads for 6 min at 2000 rpm and neutralized 
by transferring the supernatant to a fresh tube with 100 μL 1 M Tris/HCl (pH 7). A further elution was 
performed with 50 μL 100 mM glycine (pH 2) for 10 min at 2000 rpm. Both eluted phage solutions 
(200 µL) were combined and 2 µL of the solution were removed for phage titration (chapter 2.2.5.3), 
while remaining solution was used for infection of 1.8 mL E. coli XL1-Blue cell culture. Plating and 
phage rescue was done as described above. 
2.2.5.3 Phage titration 
Phage titration was performed to monitor phage titer within a panning round using dilution plating. 
During a cell-based panning phage suspension was removed for dilution plating before and after 
negative selection against CHO-K1-Mock cells as well as from the elution solution, which was referred 
to input, post-input and output (chapter 2.2.5.1). Within a panning against soluble target protein, 
phage suspension after negative selection in immunotube or on magnetic beads was used for input 
titration and suspensions of eluted phage solution for output titration (chapter 2.2.5.2). Serial 
dilution of phage suspension was performed with LB-medium. For infection, 10 µL of each phage 
dilution was added to 90 µL exponentially growing E. coli XL1-Blue cells. Cells were incubated at 37 °C 
for 30 min without agitation and thereafter 30 min with agitation at 150 rpm. Subsequently, cell 
suspensions were plated on agar plates containing 100 µg/mL carbenicillin and 0.4 % (w/v) glucose 
and incubated at 37 °C overnight. At the following day, colony forming units (CFU) were counted to 
determine the number of infectious phages. 
2.2.5.4 Production of recombinant phages 
For production of recombinant phages, 50 mL LBCarbGlu-medium was inoculated with the respective 
E. coli suspension to an OD600 of 0.2 and incubated at 37 °C with 250 rpm until an OD600 of 0.5 was 
reached. Then 5 x 1011 VCSM13 helper phages were added for phage production from the phagemid 
vector and incubated at 37 °C for 30 min without agitation, followed by 30 min with agitation at 
150 rpm. Cell suspensions were harvested by centrifugation at 4500 x g for 10 min at RT and 
supernatant was discarded. Cell pellet was re-suspended in 50 mL LBCarbKanaIPTG-medium for induction 
of protein production and incubated at 30 °C overnight with 250 rpm. 
The following day, cells were centrifuged at 4500 x g for 15 min, 4 °C. Phages were precipitated by 
adding 10 mL PEG/NaCl solution to 40 mL supernatant and incubation on ice for 30 min. After a 
centrifugation at 15000 x g for 20 min at 4 °C, the supernatant was removed and precipitated phages 
were dissolved in 800 μL 10 mM Tris/HCl (pH 8.0) for a following centrifugation at 15000 x g for 
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10 min at 4 °C. The solution was transferred to a fresh tube containing 400 μL PEG/NaCl for a second 
precipitation on ice for 20 min, followed by a further centrifugation (15000 x g for 10 min at 4 °C). 
Phage pellet was taken up in 800 µL 10 mM Tris/HCl (pH 8.0), heated at 65 °C for 15 min as a last 
purification step and finally centrifuged (15000 x g for 10 min at RT). The phage particle concentration 
of the supernatant was determined photometrically using the dual wavelength modus A269-A320 on a 
spectral photometer. The concentration was calculated based on the nucleotide content and molar 
extinction coefficient of M13 phages30. 
Phage particle/mL =
(𝐴269 − 𝐴320) 𝑥 (6𝑥10
16)
6407 (𝑛𝑢𝑐𝑙𝑒𝑜𝑡𝑑𝑒 𝑜𝑓 𝑀13 𝑔𝑒𝑛𝑜𝑚𝑒)
 
Phage particle suspension was diluted 1/10 volume of 75% glycerol for storage at −80 °C. 
2.2.6 Immunological methods 
2.2.6.1 Whole-cell enzyme-linked immunosorbent assay  
Functional display of MC-FA-010 on phage particles was determined with a whole-cell ELISA. CHO-
K1-FAP-α and CHO-K1-Mock cells were harvested as described in chapter 2.2.1.1 and diluted to 
5 x 105 cells/mL in cultivation medium. A volume of 200 µL was added to the wells of a 96-well plate 
and cultivated overnight under aseptic conditions. At the following day, the supernatant was gently 
removed and blocking of cells was performed with 300 µL 5 % milk powder in PBS for 1 h at RT. 
Subsequently the plate was washed three times with PBS-T and 1 x 1011 phage particles diluted in 
100 µL PBS were added to each well. After incubation for 1 h at 4 °C the plate was washed again three 
times with PBS-T and horseradish peroxidase (HRP)-conjugated M13 antibody was applied diluted 
1:1000 in PBS-T for 1 h at 4 °C. The plate was washed three times with PBS before adding TMB as a 
chromogenic substrate (100 µl per well). Color development was stopped with 50 µL of 0.2 M HCl per 
well after approximately 5 min and absorbance was measured at 450 nm using an Infinite M200 PRO 
microplate reader. 
2.2.6.2 Specificity analysis of MC-FN-010 variants and quality control of recombinant FN-67B89 
protein via ELISA 
Binding ability and specificity of cystine-knot miniprotein fusion to target and off-target proteins was 
analyzed with an antibody-based detection method. Cavities of 96-well microtiter plates (MaxiSorp™) 
were coated with 1 µg FN-B, FN-67B89 or FN-6789 in a total volume of 100 µL coating buffer 
overnight at 4 °C. The cavities were washed three times with PBS-T, blocked with 1x casein diluted in 
PBS for 2 h at RT and washed again three times with PBS-T. Different concentrations of cystine-knot 
miniprotein fusion variants diluted in 100 µL PBS were applied to each well and incubated for 1 h at 
4 °C. After a washing step (three times) with PBS-T, binding of respective cystine-knot miniprotein 
fusion was detected with an HRP-conjugated anti-S-tag antibody. Enzymatic reaction was detected 
with TMB used as a chromogenic substrate and was stopped with 0.2 M HCl after approximately 
5 min. The measurement of absorbance at 450 nm was performed using an Infinite M200 PRO 
microplate reader. 
To determine the quality of expressed and purified FN-67B89 protein, ELISA was used as technique 
to analyze protein-protein interactions in a 96-well format. The procedure was similar as described 
above, but using 100 μL of BC-1 antibody diluted 1:1000 in PBS-T as primary antibody and an HRP-
conjugated anti-mouse antibody diluted 1:5000 in PBS as detection antibody. 
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2.2.6.3 Western blot analysis 
Detection of biotin in cystine-knot miniprotein fusion was performed using western blot analysis. 
Protein samples were separated using gel electrophoresis (chapter 2.2.4.5). For blotting, gels were 
placed on a nitrocellulose membrane and covered with transfer buffer and Whatman paper stacks 
(equilibrated in transfer buffer) at each site. Protein transfer was performed in a Trans-Blot® Turbo™ 
Blotting System at constant 0.3 A and up to 25 V for 60 min. After blotting the membrane was blocked 
in 5 % milk powder in PBS-T for 1 h at RT on an orbital shaker. Membrane wash was performed with 
TBS-T for 5 min before placing the membrane in a HRP-conjugated SA solution, 1:5000 diluted in TBS-
T, and incubated at 4 °C overnight. Subsequently, the membrane was washed twice quickly with TBS-
T and once with TBS. For chemiluminescent detection of HRP reaction, SuperSignal™ West Dura 
Extended Duration Substrate with a 1:1 mixing ratio of Luminol/Enhancer Solution and Stable 
Peroxide Solution was distributed on the membrane. Protein signals were analyzed with a defined 
exposure time on ChemiDoc MP and documented photographically. 
2.2.6.4 Analysis of Fos presentation on phages via ELISA and western blot 
As a part of the phage library quality control, surface presentation of Fos-cystine-knot miniprotein 
complex was analyzed by ELISA. Plates were coated with 1 µg anti-M13 antibody per well in a total 
volume of 100 µL coating buffer and incubated at 37 °C for 2 h. Blocking of cavities was conducted 
with 300 µL of 1x casein in TBS at 4 °C overnight. Afterwards, washing with TBS was performed and 
1 x 1012 phages diluted in 100 µL coating buffer were applied and incubated for 1 h at 37 °C. An anti-
c-Fos antibody, diluted 1:1000 with 1x casein in TBS, was used as primary antibody and incubated for 
1 h at RT. After two washing steps with TBS-T and another one with TBS, binding of primary antibody 
was detected with a HRP-conjugated anti-rabbit IgG antibody 1:5000 diluted with 1x casein in TBS. 
After washing twice with TBS-T and twice with TBS, assay was detected and completed as described 
in chapter 2.2.6.2. 
The second quality control was a western blot analysis. For this purpose, 5 x 1011 phages were boiled 
in 15 µL 1x reducing SDS-loading buffer at 98 °C for 15 min and subjected to an SDS-PAGE according 
to chapter 2.2.4.5. After electrophoresis, gels were placed on a PVDF transfer membrane and further 
experimental process was performed essentially as described in chapter 2.2.6.3. Anti-c-Fos antibody 
was diluted 1:100 in 1 % milk powder in PBS and secondary HRP-conjugated anti-rabbit IgG antibody 
was diluted 1:5000. PBS-T was applied as washing solution and final washing was conducted with PBS. 
Lumi-Light western blotting substrate was applied as detection substrate. 
2.2.6.5 Flow cytometry  
Flow cytometry is a laser based technique to analyze intracellular proteins and extracellular surface 
proteins of single cells. Single cells pass different laser beams within a fluid stream system to allow 
the analysis of multiple physical parameters. Scattered and reflected light, detected by forward (FSC) 
and side scatter (SSC), correspond to cell size and granularity. Protein expression of cells can be 
detected directly or indirectly with fluorescence labeled antibodies, which emit light on their 
respective wavelength. 
Flow cytometry was used to analyze binding ability of cystine-knot miniprotein fusions as a part of 
the hit identification procedure with roughly purified proteins in bacterial supernatant or purified 
proteins. Furthermore, this method was conducted to assess cell surface presentation of target 
proteins. 
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Binding analysis of cystine-knot miniprotein fusions was performed with bacterial supernatant 
(chapter 2.2.3.1) or fully purified proteins (chapter 2.2.3.3). Mammalian cells were harvested 
(chapter 2.2.1.1) by centrifugation at 300 x g for 5 min and washed with 300 µL FACS buffer. After 
centrifugation (300 x g for 5 min), cells were re-suspended in 10 µL bacterial supernatant diluted with 
90 µL DPBS or in 100 µL purified cystine-knot miniprotein fusion diluted in DPBS and incubated at 4 °C 
for 1 h. The cells were washed three times with 300 µL FACS buffer, centrifuged again (300 x g for 
5 min) and eventually taken up in 100 µL allophycocyanin (APC) conjugated anti-His-Tag antibody 
1:100 diluted in DPBS for staining at 4 °C for 30 min. Subsequently, cells were washed twice with FACS 
buffer and once with DPBS. For staining of dead cells, 100 µL fixable dye eFluor 450™ 1:7500 diluted 
in DPBS was added, incubated at 4 °C for 20 min followed by two washing steps with FACS buffer. For 
flow cytometry analysis, cells were re-suspended in 200 µL FACS buffer. The measurement was 
performed on BD FACSCanto II and data was analyzed using FlowJo X. 
Experimental procedure for binding analysis of biotinylated cystine-knot miniprotein fusion differed 
and is described as followed. For this purpose, biotinylated cystine-knot miniprotein was incubated 
with a five-fold molar excess of SA-APC in 100 µL DPBS protected from light at RT for 30 min. The 
mixture was added to the cells and placed at 4 °C for 1 h. After washing with FACS buffer and DPBS, 
staining of dead cells was performed as described above. 
Analysis of surface presentation of human FAP-α and human DSG-3, was analyzed with anti-FAP-α 
antibody diluted 1:50 and anti-DSG-3 antibody diluted 1:100, respectively. Cy5-conjugated anti-
mouse IgG diluted 1:100 was applied as detection antibody. 
2.2.6.6 Immunofluorescence staining 
Immunofluorescence (IF) staining is an imaging method to visualize biomolecule distribution on cells 
or tissue sections using antigen specific fluorescence labeled probes. 
For IF staining cryopreserved tumor or brain pieces were cut in six micron thick sections, fixed in ice 
cold acetone for 5 min and air-dried. Slides were then blocked in PBS with 3 % BSA at RT for 5 min. 
For staining of EDB, 1 µg of the respective biotinylated cystine-knot miniprotein was incubated with 
2.9 µg SA-Cy3 conjugate at RT for 30 min. The preformed complex was then added to the tumor 
sections and incubated for 30 min at 37 °C. Afterwards, the slides were washed three times with PBS 
containing 1 % BSA. CD31 staining was performed with an Alexa Fluor® 647 rat anti-mouse CD31 
antibody diluted 1:100 in PBS with 1 % BSA for 30 min at 37 °C. After three washing steps in PBS, cell 
nuclei were stained with Hoechst 33342 diluted 1:5000 in PBS for 30 min at RT. Slides were washed 
again as described above and covered with coverslips in a thin layer of mounting medium. Images 
were captured with a Zeiss Apotome microscope and analyzed with ZEN software. 
2.2.7 Peptide synthesis 
Trimeric Alexa Fluor 680 (AF680) conjugated ligands as well as N-terminally biotinylated miniproteins 
were purchased from Pepscan. The obtained peptidic constructs, listed in Table 2.8, were stored in 
100 µg aliquots at −20 °C. For the performed experiments all peptides were dissolved in 100 µL DPBS 
resulting in a concentration of 1 µg/µL. Their identities were verified by electrospray ionisation mass 
spectrometry (Pepscan). Purity was analyzed by analytical RPC by Pepscan. Additionally, trimeric 
ligands were analyzed via SDS-PAGE (chapter 2.2.4.5) and SPR (chapter 2.2.4.9) in order to 
characterize purity, target binding properties (binding to FN-67B89) and specificity (binding to FN-
6789). 
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Table 2.8 Synthetic peptides with molecular weight and purity. 
Peptidic construct Molecular weight Purity 
AF680-(MC-FN-010)
3
 13681.9 Da 90.5 % 
AF680-(MC-FN-016)
3
 13510.6 Da 90.5 % 
AF680-(MC-FN-0115)
3
 13129.0 Da 90.1 % 
MC-FN-010-bio 4171.9 Da 95.5 % 
MC-FN-0115-bio 4168.7 Da 94.9 % 
2.2.8 Animal experimental methods 
2.2.8.1 Tumor models 
Mice were housed in the animal facility at BioNTech AG and all animal protocols were approved by 
the German Tierschutzkommision des Landesuntersuchungsamts Rheinland-Pfalz. Four weeks old 
Fox n1/nu mice ranging in weights between approximately 25 and 28 g were purchased from Janvier 
Labs. For xenograft mouse studies, 7 x 106 human U-87 MG glioblastoma cells were subcutaneously 
(s.c.) injected into the right flank of Fox n1/nu mice. Tumors were allowed to grow for approximately 
five weeks. Subcutaneous tumor size was determined using ellipsoid formula (
𝑤𝑖𝑑𝑡ℎ 𝑥 𝑙𝑒𝑛𝑔𝑡ℎ2
2
). All 
animals with tumor volumes between 100 – 1200 mm3 were included in the studies and mice were 
randomly assigned to experimental cohorts. 
2.2.8.2 In vivo and ex vivo imaging 
Mice carrying a desired tumor size were included for analysis of biodistribution and tumor targeting 
of trimeric constructs. All trimeric constructs were injected intravenously (i.v.) via the retrobulbar 
venous plexus in a final volume of 100 µL DPBS buffer (3.34 nmol/mice). Mice groups (n=3 for each 
construct) were imaged in an IVIS Spectrum system using excitation range of 615 – 665 nm and 
monitoring emission signals at 695 – 770 nm. Imaging process was performed 1 h, 2 h or 6 h post-
injection. At the end of the experiment, after euthanization of the mice, the tumor and specific organs 
were excised, imaged, weighed and cryo-conserved in a 2-methyl butane containing tubes, which 
were placed in liquid nitrogen. Fluorescence intensity of regions of interest was quantified using 
Living Image® software. Statistically significance was calculated based on triplicate data sets using 
two-way ANOVA analysis with corrected p values (Dunnett´s method) for comparison of different 
time and organ signals in GraphPad Prism 6. * p<0.05, ** p<0.01, *** p<0.001, n.s. = not significant. 
All data are presented as mean ± SD. 
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3 Results 
3.1 Development of customized cell-based drug discovery platform 
The efficient discovery of lead compounds plays a crucial role for the further development of effective 
diagnostic and therapeutic products. As described in chapter 1.1, the screening of combinatorial 
molecular libraries represents a major pillar within the lead discovery field. Many selection strategies 
using surface display of molecules have been developed, which facilitate the de novo discovery of 
target interacting ligands. The phage display technology is the most widely applied method using 
target proteins either captured on beads, coated on immunotubes or exposed on the cell surface32. 
However, the usage of recombinant soluble proteins is partially limited due to poor expression, 
solubility or complex structure, which holds true especially for membrane proteins with multiple 
membrane spanning regions and small extracellular domains. Targeting whole cells could overcome 
these limitations and allow addressing surface proteins in their native conformation140,141. Even 
though many standard experimental protocols for phage panning have been described, they are not 
inevitably amenable for all combinatorial phage libraries. The panning as well as the following hit 
identification protocols rather needs to be verified and customized to the individual drug discovery 
platforms. 
To this end, the following sections are focusing on the establishment of a cell-based panning protocol 
applicable for cystine-knot miniprotein phage libraries. Furthermore, an efficient high-throughput 
system has been developed for the analysis of selected ligands in conjugation with flow cytometry 
analysis. In addition, the hit identification process was optimized to allow simultaneous detection of 
target and off-target binding as well as to increase binding sensitivity. In order to proof the feasibility 
of binder identification by applying the established cell-based panning protocol and the downstream 
hit identification process, a naïve library was screened against a target overexpressing cell line. 
3.1.1 Establishment of a cell-based phage panning protocol with a model system 
The aim of this work package was the establishment of an efficient cell-based panning protocol 
suitable for cystine-knot miniprotein based phage selections. In a proof of concept experiment the 
enrichment of a known tumor specific cystine-knot miniprotein (MC-FA-010), presented through the 
major coat protein on phages, within a panning against FAP-α overexpressing eukaryotic cell line 
(CHO-K1-FAP-α) was analyzed. Therefore, different amounts of MC-FA-010 displaying phages were 
spiked into the naïve MCopt 1.0 phage library and screened against CHO-K1-FAP-α cells. Phage titer 
and MC-FA-010 enrichment was monitored by colony PCR before and after each panning round. This 
model system mimics real selection conditions and demonstrates the general applicability for 
panning of naïve complex phage libraries. 
At first, as a part of a quality control of the materials needed for the selection experiment, target 
expression on CHO-K1-FAP-α cells was analyzed by flow cytometry (Figure 3.1 A) and western blot 
(Figure 3.1 B). Both assays showed a clear target expression in CHO-K1-FAP-α cells. A surface 
presentation of FAP-α was also observed, while the average of bulk population revealed a receptor 
density of less than 106 FAP-α molecules per cell. The amount was estimated based on the known 
receptor density of monoclonal CHO-K1-FAP-α cells. 
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Figure 3.1 Quality control of CHO-K1-FAP-α cells and MC-FA-010 displaying phages. (A) FAP-α expression on 
CHO-K1-FAP-α and CHO-K1-Mock cells. Expression of FAP-α was determined by flow cytometry using an anti-
human-FAP-α antibody and detected by a Cy5-conjugated anti-mouse antibody (green histograms). Grey 
histograms represent staining only with Cy5-conjugated anti-mouse antibody. Representative histograms are 
shown. (B) Analysis of FAP-α expression in CHO-K1-FAP-α and CHO-K1-Mock cells monitored by western blot. 
Target expression was analyzed with an anti-human-FAP-α antibody. Comparative loading amounts were 
measured using an anti-β-actin antibody. HRP-conjugated anti-mouse antibody was applied to detect primary 
antibody binding. (C) Binding analysis of MC-FA-010 presenting phages to CHO-K1-FAP-α via whole-cell ELISA. 
1 x 1011 of each phage particles were applied to adherent CHO-K1-FAP-α or CHO-K1-Mock cells. A HRP-
conjugated anti-M13 antibody was used to analyze binding. ELISA was performed in triplicates ± SD with MC-
Myc-010 presenting phages and M13 phages serving as negative controls. 
Additionally, the presentation of MC-FA-010 on phages was analyzed using whole-cell ELISA 
(Figure 3.1 C). MC-FA-010 presenting phages exhibited about three-fold higher binding signals to 
CHO-K1-FAP-α in comparison to CHO-K1-Mock cells. In contrast, the signals generated by the negative 
controls MC-Myc-010 presenting phages and M13 phages towards both cell lines were overall low. 
The described quality control experiments clearly indicated correct surface presentation of MC-FA-
010 on phages and a considerably high expression of the target protein FAP-α on the surface of the 
generated cell line, both being a prerequisite for the intended cell-based panning protocol validation. 
For the selection experiments, MC-FA-010 presenting phages were spiked into the MCopt 1.0 phage 
library in three different dilutions (1:103, 1:106, 1:109). The phage pools were screened separately 
against CHO-K1-FAP-α cells after depletion with CHO-K1-Mock cells according to the experimental 
outline as depicted in Figure 3.2. Panning was performed with 1 x 1012 phage particles at each round. 
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Figure 3.2 Experimental overview of a standard cell-based phage display panning procedure. MC-FA-010 
presenting phages were spiked into the MCopt 1.0 library in different ratios. The pools were then incubated 
with the negative cell line to eliminate unspecific binding phages. After removal of cells, the remaining 
supernatants were added to target expressing cells. Subsequently, unbound phages were removed by washing 
steps, cell-bound phages were eluted via pH shift and amplified for the following panning round. Presence of 
MC-FA-010 presenting phages was analyzed by colony PCR with respective oligonucleotides. 
Infectious phage input, post-input (after negative selection) and output titer was monitored within 
every panning round by counting CFU of infected E. coli XL1-Blue cells. The ratio of post-input to 
output generally decreased with increasing selection rounds, typically indicating an enrichment of a 
phage population (Figure 3.3 A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results  45 
A       
 Dilution Panning round Input Post-input Output Post-input/output ratio 
 1:103 1 4.80 x 10
11
 2.35 x 10
11
 3.43 x 10
5
 6.85 x 10
5
 
 
1:106 
1 3.35 x 10
11
 1.75 x 10
11
 1.05 x 10
6
 1.67 x 10
5
 
 2 7.95 x 10
10
 5.36 x 10
10
 1.90 x 10
6
 2.82 x 10
4
 
 
1:109 
1 1.70 x 10
11
 3.53 x 10
11
 3.43  x 10
5
 1.03 x 10
6
 
 2 5.85 x 10
10
 4.42 x 10
10
 1.69 x 10
5
 2.62 x 10
5
 
 3 1.40 x 10
11
 1.43 x 10
11
 5.95 x 10
6
 2.40 x 10
4
 
       
B       
 
Figure 3.3 Phage titers and enrichment of spike-in experiment against CHO-K1-FAP-α cells. (A) Titers of 
phage populations throughout the successive panning rounds against CHO-K1-FAP-α cells. Titers were 
determined by counting CFU. (B) Enrichment of MC-FA-010 presenting phages through cell-based selection 
against CHO-K1-FAP-α cells. Three different amounts of MC-FA-010 presenting phages were spiked into the 
MCopt 1.0 phage library. Clones were analyzed after the respective selection round by colony PCR with MC-FA-
010 specific oligonucleotides. Enrichment was calculated based on the ratio of MC-FA-010 carrying clones and 
the analyzed clones in total. Round 0 represents the starting pool before the selection process. 
The experimental evaluation of successful MC-FA-010 enrichment was assayed by colony PCR analysis 
with 47 recovered clones after each panning round as shown in Figure 3.3 B. With the highest amount 
of MC-FA-010 presenting phages mixed into the library, 93.6 % of the analyzed clones were PCR-
positive already after one panning round. In the experiment with the initial dilution factor of 1:106, 
MC-FA-010 enrichment could be observed after second panning round with a proportion of 97.9 %. 
With the last example of 1:109 phage dilution the specific enrichment could be detected after the 
second panning round with 14.9 % positive clones and reached 83 % in the third round. Taken 
together, depending on the initial dilution ratio, MC-FA-010 presenting phages could be enriched 
specifically after one, two or three successive panning rounds. At least for this particular model 
system this outcome thus demonstrates the high efficiency of the cell-based panning protocol for 
ligand selections based on our phage library. 
In a control experiment, the two highest amounts of MC-FA-010 presenting phages were again added 
into the MCopt 1.0 library (1:103, 1:106). However, this time the screening was performed only against 
CHO-K1-Mock cells and consequently no negative depletion was done in this experiment. The input 
to output ratio increased over consecutive panning rounds and suggesting no certain phage 
enrichment (Figure 3.4 A). The resulting clones after each phage panning cycle were again used for 
colony PCR in order to assay for MC-FA-010 existence. As expected, none of those analyzed clones 
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carried the MC-FA-010 insert, so that the calculated enrichment rate was 0 % in all cases 
(Figure 3.4 B). With this control experiment growth advantages of MC-FA-010 presenting phages 
could be excluded. 
A      
 Dilution Panning round Input Output Input/output ratio 
 
1:103 
1 1.26 x 1011 8.40 x 104 1.50 x 106 
 2 1.04 x 1011 2.80 x 104 3.71 x 106 
 
1:106 
1 2.24 x 1011 8.60 x 104 2.60 x 106 
 2 4.71 x 1011 1.60 x 104 2.94 x 107 
      
B      
 
Figure 3.4 Phage titers and enrichment of a spike-in experiment against CHO-K1-Mock cells. (A) Phage titers 
throughout panning rounds of control experiment against CHO-K1-MOCK cells. Counting CFU was performed 
for titer determination. (B) Analysis of growth advantages of MC-FA-010 presenting phages in a spike-in model 
by cell-based selection against CHO-K1-Mock cells. MC-FA-010 presenting phages were added with two 
different proportions into MCopt 1.0 phage library for panning. The presence of MC-FA-010 after each round 
was analyzed via colony PCR with corresponding oligonucleotides. 
3.1.2 Development of a flow cytometry-based hit identification process 
Having shown the efficiency of the cell-based panning protocol to specifically enrich MC-FA-010 
presenting phages, in the following a flow cytometry-based screening procedure has been developed 
to allow binding analysis of individual ligands in a high-throughput manner. The experimental 
overview of the whole hit identification procedure is depicted in Figure 3.5. For hit screening, selected 
cystine-knot miniproteins were expressed N-terminally fused to thioredoxin-A, a His-tag and an S-tag 
(Trx-cystine-knot miniprotein fusion) in a 96-well mini scale format. The expression rate of each clone 
was determined via E-PAGE™ analysis. The corresponding sequence was revealed and additionally 
binding of each variant to target and off-target protein was assayed via flow cytometry. Based on the 
derived signal-to-noise ratio of cellular binding and the expression value, a ranking value for each 
candidate was calculated as a measure for specific target interaction. 
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Figure 3.5 Experimental outline of downstream hit identification procedure. DNA sequences of selected 
cystine-knot miniproteins were cloned into an expression vector for 96-well production as Trx-cystine-knot 
miniprotein fusion. For each clone respective sequence, expression rate and flow cytometry-based target 
binding was determined. Cellular binding value [signal (target expressing cell)/signal (control cell)] was 
correlated to the expression rate resulting in a ranking value as a measure for specific target interaction. 
The phage pool of the second selection round (initial dilution ratio of 1:109) from the model selection 
against CHO-K1-FAP-α cells was used for establishment of the cellular binding analysis within the hit 
identification procedure. Enriched cystine-knot miniproteins were cloned as a pool into the pET-32-
LibEx expression vector and introduced into SHuffle® T7 Express competent E. coli cells. In order to 
analyze the sequence composition of the resulting repertoire, 92 single clones were randomly chosen 
for sequencing. As shown in Figure 3.6, different cystine-knot miniprotein sequences were presented 
at 55.4 % and peptide sequences at 10.9 %. Furthermore, a small portion of frameshift sequences, 
vector re-ligands and sequence errors were observed. But importantly, enriched MC-FA-010 
dominated the pool with a proportion of 23.9 %. 
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Figure 3.6 Sequence composition after cloning of the model screen pool into the pET-32-LibEx expression 
vector. In total 92 clones of the pool were randomly chosen for sequencing. 
In the course of the hit identification procedure, individual clones were expressed as Trx-cystine-knot 
miniprotein fusion in the cytoplasm of the host cell. A simple heat-purification step of cell lysates was 
performed to recover thermotolerant Trx-cystine-knot miniprotein fusions from endogenous 
proteins yielding in general a purity of approximately 70 – 99 % (supplementary Figure 5.1). The 
supernatant was directly used for cellular binding analysis towards CHO-K1-FAP-α cells and CHO-K1-
Mock cells in two separate 96-well plates, as both cell lines express intrinsic GFP. As presented in 
Figure 3.7, several constructs showed increased interaction with CHO-K1-FAP-α cells in comparison 
to CHO-K1-Mock cells. These included the known MC-FA-010 proteins, as depicted with asterisks. 
Importantly, no interaction of all analyzed constructs with CHO-K1-Mock cells could be observed 
allowing a specific discrimination of target and off-target binding. Furthermore, the low background 
signal indicated an efficient negative depletion during phage panning. 
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Figure 3.7 Cellular binding analysis of single variants on CHO-K1-FAP-α and CHO-K1-Mock cells. For flow cytometry measurements, 10 µL E. coli supernatant was applied 
to the cells and binding of Trx-cystine-knot miniprotein fusion was detected using an APC-conjugated anti-His antibody. The mean fluorescence intensity (MFI) of the APC 
signal was calculated for data evaluation. Trx-MC-FA-010 variants are marked with an asterisk. Purified Trx-MC-FA-10 (1 µM) served as positive control, while Trx-MC-Myc-
010 (1 µM) was used as negative control. 
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In order to take the potential differential expression of the candidates within binding analysis into 
account, the amount of each Trx-cystine-knot miniprotein fusion was determined using E-PAGE™ 
analysis calculated based on a protein standard with a defined protein concentration. The expression 
value was included for generation of ranking values, which consequently represent a point of 
reference for identifying promising candidates. The expression and cellular binding values of individual 
variants are shown in the supplementary (Table 5.1). The FAP-α binding cystine-knot miniprotein (MC-
FA-010) was observed 22 times in 92 analyzed variants. Remarkably, for all MC-FA-010 clones middle 
to high ranking values could be observed as summarized in Figure 3.8. In addition, two cystine-knot 
miniproteins (B01, D01) and two peptides (D10, F01) interacted with the CHO-K1 FAP-α cells and 
displayed high ranking values as well. But follow-up analysis of these clones was not performed. 
Altogether, these findings demonstrate the high efficiency of the downstream cell-based hit 
identification procedure to allow selection of target interacting cystine-knot miniproteins. 
 
Figure 3.8 Ranking values of clones after CHO-K1-FAP-α model selection and hit identification procedure. 
MC-FA-010 variants are depicted in green apart from other variants in black. Cellular binding, expression and 
ranking value as well as corresponding protein sequence of each variant is depicted in the supplementary 
Table 5.1. 
3.1.3 Panning and hit identification of naïve MCopt 1.0 library against CHO-K1-FAP-α cells 
Based on the described model system, a clear enrichment of MC-FA-010 displaying phages after 
panning and its identification within downstream hit screening could be achieved, providing evidence 
for a general feasibility of the established protocol. The aim of the following experiment was to apply 
a completely naïve MCopt 1.0 library for analyzing the whole process performance under real 
conditions. For this purpose, MCopt 1.0 library was screened in three successive panning rounds 
against CHO-K1-FAP-α cells according to the experimental outline in Figure 3.2. The first panning 
round started with 1 x 1013 MCopt 1.0 library phages in order to yield a high library coverage of ~10000 
fold. The two following rounds were conducted with 1 x 1012 amplified phage particles as input. The 
phage titers were again determined by CFU counting of infected E. coli XL1-Blue cells (Figure 3.9 A). 
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A      
 Panning round Input Post-input Output Post-input/output ratio 
 1 5.65 x 10
11
 3.53 x 10
11
 1.10 x 10
6
 3.21 x 10
5
 
 2 6.25 x 10
10
 6.01 x 10
10
 437 1.38 x 10
8
 
 2 9.50 x 10
10
 2.61 x 10
10
 2.74 x 10
3
 9.53 x 10
6
 
 3 2.68 x 10
11
 4.32 x 10
11
 6.40 x 10
4
 6.75 x 10
6
 
B      
 
Figure 3.9 Phage titers and sequence composition of the screening of the naïve MCopt 1.0 library against 
CHO-K1-FAP-α cells. (A) Titers of phage populations throughout panning rounds of MCopt 1.0 library screening 
against CHO-K1-FAP-α cells. Input, post-input and output was determined within every panning round by 
counting CFU. The second panning round was performed twice. (B) Sequence composition of the screen pool 
after the third panning round against CHO-K1-FAP-α cells. In total 96 clones were randomly selected and 
sequenced. 
At each selection round the input titers were much lower than intended, which indicated a portion of 
non-infectious phages in the pool. Nevertheless, in the first round an input of 5.65 x 1011 phages could 
be achieved yielding a 500-fold library coverage. The post-input titer was expected to be in general 
lower than the input upon negative depletion of phages, except in the third screening round. The 
second panning round was extracurricular performed twice, as the initial output with 437 clones was 
very low. Both obtained output phage pools were combined for the last panning round. The post-
input to output ratio as a measure of enrichment rate increased unexpectedly over panning rounds. 
However, the progress of post-input to output ratio only served as rough indications of binder 
enrichment. For detailed clarification, 96 clones were sequenced after panning completion. 
Figure 3.9 B shows the sequence distribution of clones derived after the third screening round. The 
proportion of cystine-knot miniproteins are arranged according to their amino acids length in loop 1 
and the proportion of peptide sequences and sequence failures are given. One peptide sequence 
(GKCGKVPSMDRTNQLPSRLRLPGNLYLPW) dominated the screen pool with 20.8 %, meaning that it has 
been strongly enriched during selection. Furthermore, many single cystine-knot miniprotein 
sequences with different lengths of randomized amino acids in loop 1 could be observed. Sequences 
containing a loop length of six amino acids occurred to 26 %, nine amino acids to 12.5 % and twelve 
amino acids to 18.8 %. Unexpectedly, also a sequence comprising ten amino acids in loop 1 appeared, 
even though this loop length was not included in the library design. 
In order to identify ligands specific for CHO-K1-FAP-α, a downstream hit identification procedure was 
performed as depicted in Figure 3.5. After cloning of the screen pool into the pET-32-LibEx expression 
vector for Trx-cystine-knot miniprotein production, single clones were sequenced again to monitor 
sequence distribution and to provide sequence information for hit identification.  
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A 
 
B 
 
Figure 3.10 Hit identification of MCopt 1.0 library panning against CHO-K1-FAP-α cells. (A) Sequence 
composition after cloning of the screen pool into the pET-32-LibEx expression vector. For sequencing 55 clones 
were randomly selected. (B) Ranking value of hit identification. For each clone the cellular binding value was 
divided by the expression rate to calculate its ranking value. Identical clones are highlighted with sequence 
information. Expression value, cellular binding value, ranking value and sequence of each clone are listed in the 
supplementary Table 5.2. 
Figure 3.10 A shows the sequence distribution of clones after cloning into the expression vector. 
Again, the sequences are arranged according to their amino acids length in loop 1 and the proportion 
of peptide sequences and sequence failures are depicted. As expected, the enriched peptide sequence 
(GKCGKVPSMDRTNQLPSRLRLPGNLYLPW) was highly represented after screen pool cloning with a 
proportion of 16.4 %, which is consistent to the findings on phage pool level (Figure 3.9 B). Apart from 
that, unique cystine-knot miniproteins with six and nine amino acids in loop 1, 32.7 % and 23.6 %, 
represented the highest proportion, followed by cystine-knot miniproteins carrying twelve amino 
acids (16.4 %) and ten amino acids in loop 1 (5.5 %) as well as a peptide sequence (1.8 %). 
Individual Trx-cystine-knot miniprotein fusions were then produced in a high-throughput compatible 
manner combined with subsequent expression and cellular binding analysis. Binding ability of the Trx-
cystine-knot miniprotein fusions was assayed via flow cytometry using the CHO-K1-FAP-α as well as 
the CHO-K1-Mock cells. As presented in Figure 3.10 B, the outcome of performed hit identification 
process resulted in ranking values, which were determined by dividing cellular binding value with the 
expression value for each clone. The enriched peptide sequence and furthermore a cystine-knot 
miniprotein showed strong FAP-α interaction, as the corresponding ranking value was relatively high 
(supplementary Table 5.2). Interestingly, the cystine-knot miniprotein sequence could be verified as 
MC-FA-010, the known FAP-α specific protein, which was previously identified via MCopt 1.0 
screening against soluble FAP-α. Even though on phage pool level MC-FA-010 sequence was not 
detected and consequently no specific enrichment could be observed, the downstream hit screening 
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allowed its selection. These findings underline the ability of the cell-based phage panning and 
subsequent hit identification to identify novel target binding cystine-knot miniproteins. 
3.1.4 Optimization and extension of hit identification process 
High-throughput hit screening represents a fundamental step for identifying target binding ligands 
after phage display selection. The capacity of analyzing large numbers in parallel would be highly 
beneficial for sufficient coverage of many clones. For the in-house drug discovery platform, an efficient 
high-throughput compatible expression and purification of individual clones combined with flow 
cytometry has been demonstrated. The cellular assay relied on distributing target positive and 
negative cell lines into two separate plates for binding analysis, as both cell lines endogenously 
overexpress GFP due to stable transfection. With the aim to further increase the throughput, a second 
negative cell line was generated that overexpresses another fluorescence dye (dsRed). Target 
expressing cells and red fluorescent control cells could then be merged for simultaneous detection of 
target and off-target binding in one well of a microtiter plate. 
For this purpose, stable CHO-K1 cells expressing dsRed were generated using the PiggyBac transposon 
system. A gene cassette carrying the dsRed expression gene as well as a hygromycin resistance gene 
for selection of transfected cells was integrated into the host cell genome. The transfection efficiency 
was monitored by flow cytometry and based on the percentage of dsRed positive CHO-K1 cells. As 
shown in Figure 3.11 A, five days after transfection 18.4 % of the cell population expressed dsRed. At 
day 18 dsRed positive cells reached 47.7 % expression and slightly increased to 55.3 % at day 29. This 
progress indicated a polyclonal cell population containing clones with different dsRed expression 
levels and an insufficient selection process. To isolate a monoclonal cell population, cells with strong 
dsRed expression were selected using FACS. Single cells were expanded for analysis of clonal diversity 
in terms of dsRed expression. Figure 3.11 B shows a flow cytometric analysis of monoclonal cells with 
high and homogeneous dsRed expression in comparison to the prior polyclonal population. The 
generated cells were termed CHO-K1-dsRed-Mock and represent a second negative cell line for the 
hit identification process. 
A B 
  
Figure 3.11 Generation of stable CHO-K1-dsRed-Mock cell line. (A) Transfection efficiency of dsRed expressing 
CHO-K1 cells determined by flow cytometry. Percentage of dsRed-expressing cells derived from total cell 
population and determined by referencing to CHO-K1 wild type cells. Day indicates analysis after transfection. 
(B) Representative density plot of polyclonal and monoclonal CHO-K1-dsRed-Mock population. Expression of 
dsRed was analyzed by flow cytometry before and after generation of monoclonal cell line via FACS. 
The applicability of a second negative cell line to be used for off-target binding analysis in the hit 
identification procedure was investigated in combination with CHO-K1-FAP-α cells and based on the 
known cystine-knot miniprotein MC-FA-010 again. For the validation of the flow cytometry assay 
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equal cell numbers of both cell lines were mixed prior to incubation with purified Trx-MC-FA-010 
miniprotein fusion or protein containing bacterial lysate. Bacterial lysate was applied in order to 
simulate cellular binding conditions like intended for downstream hit screening. Gating of the two cell 
lines was unproblematic due to the clear differentiation of GFP and dsRed fluorescence dyes 
(Figure 3.12 A). Both different presented versions of Trx-MC-FA-010 miniprotein fusion clearly 
interacted with CHO-K1-FAP-α cells, while no binding to CHO-K1-dsRed-Mock cells was observed 
(Figure 3.12 B). The proof of concept experiment demonstrates the ability to duplicate the throughput 
for hit screening as a result of combining CHO-K1-FAP-α and CHO-K1-dsRed-Mock cells allowing 
simultaneously target and off-target binding analysis of selected cystine-knot miniproteins within one 
96-well plate. 
   A 
 
   B 
 
Figure 3.12 Simultaneous analysis of cellular target and off-target binding using flow cytometry. 
(A) Representative density plot of mixed CHO-K1-dsRed-Mock and CHO-K1-FAP-α cell population presenting the 
dsRed and GFP signal. The histograms show the APC signal of gated CHO-K1-dsRed-Mock and CHO-K1-FAP-α 
cells that represents protein binding to the respective cells. (B) CHO-K1-dsRed-Mock and CHO-K1-FAP-α cells 
were equally mixed for binding analysis of 1 µM purified Trx-cystine-knot miniprotein fusion or 10 µL bacterial 
lysate. Protein binding was detected with an APC-conjugated anti-His-tag antibody. Graph represents the MFI 
of APC signals. Experiment was repeated three times with similar results. 
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The extension of the cellular hit identification repertoire also included an optimization of flow 
cytometry-based assay sensitivity to lower the possibility to miss putative binders due to low affinity. 
A previous report from Kim and co-workers described a remarkably increase of knottin-like peptides 
target affinity by dimerization as a result of exploiting the avidity effect142. Tetramerization was the 
strategy of choice to gain increased target binding strength of cystine-knot miniproteins via SA 
complexation. While keeping high-throughput suitable manner in sight, a system was developed to 
allow production of Trx-cystine-knot miniprotein fusion directly linked to a biotin molecule in a 96-
well scale. In vivo biotinylation in E. coli using the enzyme named biotin holoenzyme synthetase (BirA) 
has been shown to selectively attach biotin to lysine residue side chain within a specific recognition 
sequence termed AviTag™ (unique 15 amino acid peptide) attached to the protein of interest143. 
For this purpose, FAP-α binding cystine-knot miniprotein MC-FA-012, a derivative of parental MC-FA-
010, and Flp-In™-CHO-FAP-α cells were used as model system. Corresponding sequence encoding for 
cystine-knot miniprotein was genetically inserted to the pET-32-AX2 vector to conduct expression with 
an AviTag™. After cloning, vectors were introduced into E. coli SHuffle® T7 Express pBirAcm cells. 
Subsequent protein expression was done in a 96-well plate in autoinduction medium with or without 
the addition of D-biotin to the culture. Cystine-knot miniprotein fusions were subsequently roughly 
purified via heat incubation. Western blot analysis in Figure 3.13 A displays biotinylation success of 
Trx-MC-FA-012 miniprotein fusion with correct size, in case that D-biotin was present during 
production. For analysis of stronger binding, biotinylated Trx-MC-FA-012 miniprotein fusion of 
bacterial lysate was mixed with APC-conjugated SA to pre-assemble a tetramerized complex and 
compared to monomeric Trx-MC-FA-012 miniprotein fusion of bacterial lysate in a flow cytometry set 
up (Figure 3.13 B). Obviously, the tetramerized format of the Trx-cystine knot miniprotein led to an 
approximately 30-fold higher binding signal than the monomeric version. Therefore, it can be 
concluded that the tetramerization strategy indeed exploited avidity effect and resulted in stronger 
target binding as well as improved assay sensitivity for future hit screenings. Furthermore, the high-
throughput expression system for direct biotin conjugation to the proteins facilitates the 
implementation into the hit identification process. 
A B 
 
 
Figure 3.13 Analysis of biotinylated Trx-cystine-knot miniprotein fusions. (A) Successful in vivo biotinylation 
of Trx-cystine-knot miniprotein fusion. For western blot analysis 20 µL of protein containing bacterial lysate was 
applied and detected with a HRP-conjugated SA. The symbol “+” represents the presence and the symbol “–“ 
indicates the absence of D-biotin during production. (B) Increased binding strength of tetramerized Trx-MC-FA-
012 miniprotein fusion determined via flow cytometry. Tetramerization of protein was achieved by 
complexation with APC-conjugated SA. Monomeric and tetramerized Trx-MC-FA-012 fusion proteins were 
applied for binding analysis and binding was detected using APC-conjugated anti-His-tag antibody. The 
experiment was conducted with 4 µL bacterial lysate. Graph shows the MFI of APC signal. 
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The establishment of an efficient cell-based panning and downstream hit identification platform, 
which is suitable for selection of target-specific cystine-knot miniproteins, provides a novel 
opportunity to target membrane associated proteins in their natural conformation. A major progress 
of developing robust downstream methods has been made to enable high-throughput hit screening 
of selected cystine-knot miniproteins against target expressing cells and a control cell line. 
Furthermore, two different expression systems for cystine-knot miniprotein production in a 96-well 
scale allowed their application as monomeric or tetramerized protein directly from bacterial lysate for 
analysis of cellular binding capacity.  
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3.2 Novel cystine-knot miniprotein phage libraries 
The open chain sequence of MCoTI-II was the basis for combinatorial phage library construction144. 
An already existing phage library (MCopt 1.0) comprised sequences with randomized amino acids in 
loop 1, scattered positions in the third loop and two variable residues in front of the first cysteine. In 
this library cystine-knot miniproteins are presented via the pVIII on the surface of filamentous M13 
phages. This well characterized library represents the basis of our drug discovery platform for the 
development of novel cystine-knot miniprotein-based agents. In order to extent the internal library 
repertoire and to enhance ligand selection outcome, novel cystine-knot miniprotein phage libraries 
have been generated in this work applying an improved rational design strategy. 
This chapter describes the design, construction and characterization of three novel cystine-knot 
miniprotein phage libraries. As a part of quality evaluation, one phage library was additionally 
screened against a highly tumor-related target protein (DSG-3) recombinantly presented on 
mammalian cells for cell-based screening and ligand identification. However, panning experiments 
revealed an increased occurrence of deletion mutants lacking a large segment comprising Jun-pIII´ and 
Fos-cystine-knot miniprotein gene fusions. This genetic instability of the pJuFo vector has been 
mentioned in a published doctoral thesis145, but has besides not yet been described in the literature. 
At the end of this chapter a possible solution for this emerging issue is described that comprises a 
complete re-design of the phagemid vector and initial data showing feasibility of this new system. 
3.2.1 Cystine-knot miniprotein phage library design 
The generation of large and diverse libraries with correctly folded cystine-knot miniproteins as well as 
their phage surface presentation was based on the pJuFo phagemid vector42. Randomization of certain 
sequence positions of the oMCoTI-II scaffold was intended to gain high library diversity. The amino-
terminal loop in the wildtype miniprotein represents the active site of its trypsin inhibitory function 
and has been shown to well tolerate engineering for target binding88,91,92. Therefore, one library 
(MCopt 2.0) was developed with amino acid exchanges and sequence length extension in loop 1. In a 
previous report, the authors showed a general possibility to modify EETI-II protein in sequence 
diversity and length variation in two loop positions without losing conformational properties and 
trypsin-binding ability. Both loop positions are not directly involved in trypsin interaction, but located 
in proximity to the active loop site146. Although EETI-II and MCoTI-II have sequence differences, both 
share high structural similarity and belong to the same cystine-knot miniprotein family147. Loop 3 in 
the EETI-II scaffold seemed to slightly tolerate randomization better than loop 2146, which loop 
position is basically analog to loop 5 in MCoTI-II. Based on these observations, a second library 
(MCopt 2.1) was designed with loop 5 randomization and an additionally extended loop size in the 
oMCoTI-II scaffold. Furthermore, in another report an EETI-II protein was engineered with two 
separate integrin binding epitopes in the active loop and an adjacent loop 3 position. The mutated 
variants resulting from combinatorial yeast library selection showed proper folding to native 
functional knottin and high affinity binding capability to integrins148. Encouraged by their strategy, in 
the third library (MCopt 3.0) both adjacent loops 1 and 5 are randomized simultaneously in order to 
enlarge the potential binding surface of the oMCoTI-II protein and thus potentially increase its binding 
affinity and specificity. Figure 3.14 presents the three different library design strategies and the three-
dimensional structure of the oMCoTI-II protein149. All three libraries comprise a completely 
randomized sequence of ten amino acid residues in loop 1, loop 5 or both loops, including the whole 
range of canonical nineteen amino acids, except cysteine. Apart from the randomized region the 
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wildtype scaffold framework was maintained in all libraries with the exception of MCopt 2.1, which 
contained lysine substitutions to alanine, isoleucine and arginine in loop 1. Furthermore, the basic 
scaffold comprises three modified amino acids in front of the first cysteine due to cloning reasons. 
A B 
  
  
Figure 3.14 Library design strategy and three-dimensional structure of oMCoTI-II protein. (A) Schematic 
overview of the oMCoTI-II sequence framework and amino acid sequences of MCopt 2.0, MCopt 2.1 as well as 
MCopt 3.0 library. Bold letters represent amino acid cysteine and brackets indicate disulfide bonds between 
cysteines. Grey letters show randomized positions and X depicts a random amino acid, expect cysteine. 
(B) Three-dimensional structure of oMCoTI-II protein (PDB 2IT8)149. Surface exposed loop 1 is shown in red and 
loop 5 in green. Disulfide bonds are depicted as yellow sticks. The oMCoTI-II structure was obtained from 
RCBS PDB and illustrated using PyMol.  
Phage libraries were constructed using a pJuFo phage display system to present cystine-knot 
miniproteins through a recombinant pIII´ and thus maintain a low presentation valency. More 
precisely, cystine-knot miniprotein sequences were genetically fused to fos gene and pIII´ to jun gene, 
respectively42, allowing a simultaneous expression but autonomous folding of both fusions. After 
secretion of the fusions into the periplasmic space they assemble through the leucine zipper of 
heterodimeric Jun-Fos elements after individual processing. Subsequently, the recombinant coat 
protein fusions are incorporated into the phage envelope, leading to surface presentation of the 
encoded cystine-knot miniproteins. 
3.2.2 Generation and characterization of three novel cystine-knot miniprotein phage libraries 
For library generation, MCopt 2.0 and MCopt 2.1 DNA library fragments were directly synthesized 
with the intended randomized loop region. In contrast, MCopt 3.0 DNA library fragments were 
constructed based on the MCopt 2.0 and MCopt 2.1 DNA fragments using SOE PCR. As a start, the 
optimal conditions for amplifying MCopt 2.0 and MCopt 2.1 DNA fragments were analyzed to achieve 
high yields and likewise low amounts of side products. To this end, gradient PCR reactions were 
performed with annealing temperatures ranging from 53 °C to 64 °C in the presence of different 
betaine or DMSO concentrations. Figure 3.15 shows the analysis of yielded PCR products using 
agarose gel electrophoresis and two electropherograms of selected samples. 
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Figure 3.15 Determination of optimal PCR conditions for MCopt 2.0 and MCopt 2.1 DNA fragment pool 
amplification. Agarose gel electrophoretic analysis of MCopt 2.0 (A) and MCopt 2.1 (B) DNA fragment pools 
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amplified using different annealing temperatures. Synthetic MCopt 2.0 DNA fragment pool was amplified in the 
presence of 2.5 %, 5 %, 7.5 % or 10 % DMSO and synthetic MCopt 2.1 DNA fragment was amplified in the 
presence of 0.4 M, 0.8 M, 1.2 M or 1.6 M betaine at annealing temperatures of 53 °C, 54.6 °C, 56.1 °C, 57.7 °C, 
59.3 °C, 60.9 °C, 62.4 °C and 64 °C (from left to right). Intended MCopt 2.0 DNA fragment size was 176 bp, while 
MCopt 2.1 DNA fragment had a length of 183 bp (depicted with an arrow). Yellow boxes indicate PCR products 
selected for detailed fragment size analysis. Bioanalyzer electropherograms of amplified MCopt 2.0 (C) and 
MCopt 2.1 (D) DNA fragment pools. Size distribution of PCR amplicons are shown in the electropherograms (left) 
and in the gel image (right). The left peak represents the lower marker with 35 bp and the right peak the upper 
marker with 10380 bp. 
The addition of 2.5 % DMSO led to strong side products at all tested annealing temperatures during 
amplification of MCopt 2.0 DNA fragments, while the presence of 5 %, 7.5 % and 10 % DMSO resulted 
in less side products. The amplification of MCopt 2.1 DNA fragments with different concentrations of 
betaine showed in general a lower proportion of side products. Based on the visual appearance of 
separated PCR products on the agarose gel, a single sample of each library fragment pool was further 
assayed in size and quality via Bioanalyzer. The selected PCR condition for MCopt 2.0 DNA fragment 
amplification was 53 °C annealing temperature in the presence of 10 % DMSO and for MCopt 2.1 DNA 
fragment amplification with the addition of 0.8 M betaine and an annealing temperature of 64 °C. 
MCopt 2.0 and MCopt 2.1 DNA amplicons were used as template in the SOE PCR to generate 
MCopt 3.0 DNA fragments. Again, different DMSO concentrations were added to the PCR samples and 
the annealing temperatures was varied in the gradient PCR. All PCR products were assessed on an 
agarose gel and one sample was applied on a Bioanalyzer (Figure 3.16). 
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Figure 3.16 Determination of optimal PCR conditions for MCopt 3.0 DNA fragment pool amplification. 
(A) Agarose gel electrophoresis of MCopt 3.0 DNA fragments using SOE PCR. Amplified MCopt 2.0 and 
MCopt 2.1 DNA pool served as template to generate MCopt 3.0 DNA fragments. Gradient PCR was performed 
with annealing temperature of 53 °C, 54.6 °C, 56.1 °C, 57.7 °C, 59.3 °C, 60.9 °C, 62.4 °C and 64 °C (from left to 
right), in the presence of 2.5 %, 5 %, 7.5 % or 10 % DMSO. Yellow box indicates PCR sample chosen for detailed 
size analysis. (B) Bioanalyzer electropherogram of amplified MCopt 3.0 DNA fragments. PCR product was applied 
on a Bioanalyzer high sensitivity chip for analysis of size distribution. Results are depicted as electropherogram 
(left) and gel image format (right). The left peak shows the lower marker with 35 bp and the right peak the upper 
marker with 10380 bp. 
The gelelectrophoretic separation indicates, besides the expected PCR amplicon at 338 bp, also many 
side products with different size distribution. The Bioanalyzer results show several peaks in the 
electropherogram, which indicated the presence of side products too and marginally lowered the 
product quality. Nevertheless, the selected condition for SOE PCR was the addition of 5 % DMSO and 
an annealing temperature of 64 °C. 
After determining the optimal PCR conditions, a large amount of MCopt 3.0 DNA fragments was 
synthesized via SOE PCR. The synthetic MCopt 2.0 and MCopt 2.1 DNA fragments from GeneArt™ and 
the generated MCopt 3.0 DNA fragments were prepared for cloning. The restricted MCopt 2.0, 
MCopt 2.1 and MCopt 3.0 DNA fragments were cloned into the pJuFoIII phagemid vector and 
subsequently introduced into electrocompetent E. coli SS320 cells. Dilution plating of transformed 
cells was performed to count colony numbers and calculate the number of primary transformants 
(Figure 3.17 A). A primary library size of 1.06 x 109 cells for MCopt 2.0, 1.82 x 109 cells for MCopt 2.1 
and 2.16 x 109 cells for MCopt 3.0 could be achieved. 
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A   
 Library Number of primary transformants 
 MCopt 2.0 1.06 x 109 
 MCopt 2.1 1.82 x 109 
 MCopt 3.0 2.16 x 109 
   
B   
 
Figure 3.17 Primary MCopt 2.0, MCopt 2.1 and MCopt 3.0 library transformants and sequence composition 
after electroporation of E. coli SS320 cells. (A) Primary library size of MCopt 2.0, MCopt 2.1 and MCopt 3.0. 
E. coli SS320 colonies were counted after electroporation and dilution plating. (B) Sequence composition of the 
generated MCopt 2.0, MCopt 2.1 and MCopt 3.0 libraries. In total 96 clones were randomly selected for 
sequencing. 
The quality of each library was determined by sequencing of 96 randomly chosen clones and evaluated 
as percentage of sequence composition (Figure 3.17 B). In general, sequences were assigned to five 
categories. In the MCopt 2.0 library, the largest proportion represented correct cystine-knot 
miniproteins sequences with 72.9 %, while correct MCopt 2.1 library sequences and MCopt 3.0 library 
sequences were detected to only 37.5 and 44.8 %, respectively. In all libraries, a low frequency of 
clones was observed with longer or shorter randomized loop sizes than originally designed, but their 
presence is not expected to influence library quality. Furthermore, a proportion between 5.2 % and 
17.7 % of sequences contained frameshift mutations and < 2.1 % revealed sequence failure. 
Surprisingly, many clones showed non-assignable sequences in the randomized loop region, while the 
conserved scaffold framework was sequenced correctly. These clones were especially observed in 
MCopt 2.1 library at 40.6 % and in MCopt 3.0 at 35.4 %. Curiosity about their occurrence led to a 
deeper analysis of the respective clones, because a high frequency of incorrect clones decreases the 
library quality and might deteriorate ligand selection outcome. 
Non-assignable sequences could be a sign of poor sequencing quality, in which a clear assignment of 
one nucleotide within the analyzed DNA strand was missing. As a consequence, translation into amino 
acid level led to an X at the corresponding position. Interestingly, these events predominantly 
occurred in randomized loop positions (Figure 3.17 B). In order to exclude general sequencing failure, 
several clones were repeatedly sequenced. Table 3.1 shows representative amino acid sequences of 
MCopt 2.1 library clones. The data shows that the non-assignable residues mainly appeared in loop 5 
with comparative sequence pattern of the same clone. Such occurrence might be attributed to double 
or multiple transformed E. coli cells150, which would have a severe negative impact on the library 
quality, since this would impede the fundamental linkage of genotype and phenotype of the 
generated recombinant phages. 
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Table 3.1 Amino acid sequences of MCopt 2.1 library clones after electroporation of E. coli SS320 cells. 
Sequencing of the same clone was performed independently. X in bold letters counts for a non-assignable 
residue. 
Sequencing run Clone number Sequences 
1 
Clone 1 
GSVCPAILIRCRRDSDCPGACICXXXXXXXXRXCG 
2 GSVCPAILIRCRRDSDCPGACICXXXXXXXXXXCG 
1 
Clone 2 
GSVCPAILIRCRRDSDCPGACICXTWYXXXXXXCG 
2 GSVCPAILIRCRRDSDCPGACICXXXXXXXXTTCG 
1 
Clone 3 
GSVCPAILIRCRRDSDCPGACICWXXXXXXXXLCG 
2 GSVCPAILIRCRRDSDCPGACICWVESXXXDXXCG 
 
Sblattero and colleagues described a method to expand diversity of conventional antibody phage 
libraries. This involved recombination of VH and VL genes located on two separate phagemid vectors 
in a single bacteria after infection at a high MOI151. In contrast, an infection at a low MOI lead to 
entering of only one phagemid per cell. In order to reduce the strong occurrence of clones carrying 
more than one phagemid vector and restore the genotype-phenoptype linkage, phage particles of the 
primary MCopt 2.0, MCopt 2.1 and MCopt 3.0 libraries were produced and E. coli XL1-Blue cells were 
infected using a low MOI. Library titers after infection showed cell numbers between 1.54 x 109 and 
8.72 x 109 (Figure 3.18 A), which was nearly similar to electroporated E. coli SS320 and for MCopt 2.0 
even higher. Consequently, infection approach caused no significant changes in library size. 
A   
 Library Number of infected cells 
 MCopt 2.0 8.72 x 109 
 MCopt 2.1 1.54 x 109 
 MCopt 3.0 2.22 x 109 
   
B   
  
Figure 3.18 Properties of the final MCopt 2.0, MCopt 2.1 and MCopt 3.0 libraries after infection of E. coli XL1-
Blue cells. (A) Library titers of MCopt 2.0, MCopt 2.1 and MCopt 3.0 after infection of E. coli XL1-Blue cells. 
Colony numbers of dilution plating was counted. (B) Sequence composition of MCopt 2.0, MCopt 2.1 and 
MCopt 3.0 library after infection of E. coli XL1-Blue cells with a low MOI. Sequencing of 96 randomly chosen 
clones was performed. 
Sequencing of individual clones enabled the assessment of library status on molecular level. 
Figure 3.18 B presents the sequencing outcome of the final libraries after re-infection with a low MOI. 
A small proportion of sequences with prolonged or shortened loop length and frameshifts as well as 
clones with sequence failure still remained. But importantly, the frequency of correct cystine-knot 
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miniprotein sequences increased in all libraries and the non-assignable sequences in the loop 
positions likewise decreased dramatically. Particularly, for the MCopt 2.1 (86.5 %) and the MCopt 3.0 
library (77.1 %) the percentage of correct sequences were much higher compared to the primary 
E. coli SS320 library (Figure 3.17 B). The reduction of clones carrying more than one phagemid vector 
should result in enormously improved library qualities. 
Displaying of functional cystine-knot miniprotein on the phage surface represented another important 
quality control of the generated libraries. Based on our knowledge, no suitable antibody for the 
detection of oMCoTI-II exists but the fusion of the cystine-knot miniprotein to Fos enables an indirect 
detection using anti-Fos antibody. In a sandwich ELISA setting MCopt 2.0, MCopt 2.1 and MCopt 3.0 
library phage pools showed higher signals than negative control phages (Figure 3.19 A). Furthermore, 
individual phages of each library were randomly selected for analysis (Figure 3.19 B). The majority of 
single phages revealed strong signals, even though their strength varied. These findings clearly proved 
a Fos presentation on the phage envelope and thus indirectly indicated the display of the fused 
cystine-knot miniprotein as well. The expression of Fos on library phages was additionally determined 
in a western blot analysis as depicted in Figure 3.19 C. The Fos-cystine-knot miniprotein complex alone 
was not observed. But in all novel libraries a band was detected at around 37 kDa, whose size could 
be referred to assembled Fos-cystine-knot miniprotein and Jun-pIII´ complex. Furthermore, a distinct 
band above the protein complex at around 48 kDa occurred, which appearance could not be clearly 
assigned to proteins with expected molecular size. This band appeared in all three libraries and may 
result due to additional protein interaction of the Fos-cystine-knot miniprotein and Jun-pIII´ complex. 
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Figure 3.19 Analysis of Fos expression. Surface presentation of Fos-cystine-knot-miniproteins on library phage 
pools (A) and single phages (B). Phages of MCopt 2.0, MCopt 2.1 and MCopt 3.0 library were applied at 1 x 1012 
particles for ELISA. Binding of anti-Fos antibody to phages was detected using HRP-conjugated anti-rabbit 
antibody. ELISA was performed in triplicates ± SD. (C) Western Blot analysis of Fos expression on MCopt 2.0, 
MCopt 2.1 and MCopt 3.0 library phages. Western blot was performed with 5 x 1011 phage particles for binding 
analysis of anti-Fos antibody and detection with HRP-conjugated anti-rabbit antibody. For all analysis MCopt 1.0 
library phages served as positive control and M13 wildtype phages as negative control (performed by Tanja Ziß). 
3.2.3 Characterization of cystine-knot miniproteins on protein level 
To determine whether loop randomization and length extension has an impact on the biophysical 
properties of cystine-knot miniproteins, a producibility and folding analysis was performed. For the 
producibility study a 96-well mini-scale format was applied, as this method is also part of the hit 
identification procedure within the in-house drug discovery platform. Furthermore, single cystine-
knot miniproteins were expressed via large-scale production as well and purified to analyze their 
protein mass as a measure of proper folding. 
The overall producibility of Trx-cystine-knot miniprotein fusions resulting from MCopt 2.0, MCopt 2.1, 
and MCopt 3.0 library was analyzed in a 96-well production for yield determination. For this purpose, 
cystine-knot miniprotein sequences of library pools were cloned into pET-32-LibEx_GS expression 
vector and subsequently introduced into SHuffle® T7 Express competent E. coli cells. Single clones of 
each library were randomly picked for expression in 1 mL volume. Bacterial supernatant after heat-
treatment, containing roughly purified Trx-cystine-knot miniprotein fusions, was applied on an E-
PAGE™ high-throughput gel system (supplementary Figure 5.2). The concentration of each clone was 
calculated based on known protein references. For evaluation the proportional distribution of yielded 
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concentrations were assigned into three categories of < 1 mg/mL, 1 – 1.49 mg/mL and > 1.5 mg/mL 
(Figure 3.20). MCopt 1.0 library clones were considered as reference and their protein expression 
mainly resulted in concentrations between  1 – 1.49 mg/mL with a proportion of 74.2 %. Trx-cystine-
knot miniprotein fusions below 1 mg/mL and above 1.5 mg/mL were represented at 9.7 % and 16.1 %, 
respectively. The distribution of MCopt 2.0, MCopt 2.1, and MCopt 3.0 library clones differed. A high 
frequency between 49.5 % and 68.8 % had concentrations below 1 mg/mL, whereas nearly no or a 
very small number of clones showed yields above 1.5 mg/mL. In the range between 1 – 1.49 mg/mL 
were library clones at 31.2 % to 49.5 %. Especially the average yield of MCopt 2.1 and MCopt 3.0 
library clones were weaker in comparison to MCopt 2.0 library clones. 
 
Figure 3.20 Proportional distribution of yielded Trx-cystine-knot miniprotein fusion concentrations after 
expression in 96-well format. Protein concentrations of MCopt 2.0, MCopt 2.1 and MCopt 3.0 library clones 
were determined densitometrically based on a protein reference (supplementary Figure 5.2). The data set of 93 
analyzed clones was categorized in concentrations of < 1 mg/mL, 1 – 1.49 mg/mL and > 1.5 mg/mL. 
In order to evaluate correct folding of the cystine-knot miniproteins derived from MCopt 1.0, 
MCopt 2.0, MCopt 2.1 and MCopt 3.0 libraries, individual clones were randomly picked for large-scale 
production. Expressed Trx-cystine-knot miniprotein fusions were purified via heat-treatment and 
IMAC. The fusion protein-tag was cleaved from the cystine-knot miniprotein part and separated using 
RPC. The purified cystine-knot miniprotein was analyzed in mass spectrometry. A detection of the 
expected cystine-knot miniprotein mass with all three disulfide bonds accounted as correctly folded 
protein (Table 3.2). All three analyzed MCopt 1.0 library clones revealed proper protein mass. 
Whereas in one out of five MCopt 2.0 library clones, one out of four MCopt 2.1 library clones and one 
out of three MCopt 3.0 library clones the correct mass was not observed. 
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Table 3.2 Mass spectrometry based folding analysis of individual MCopt 1.0, MCopt 2.0, MCopt 2.1, and 
MCopt 3.0 library clones. Expected mass of two-, three- and four-fold charged cystine-knot miniprotein (2 H+, 
3 H+, 4 H+) and the actual detected mass resulting from mass spectrometry. Protein sequences of all analyzed 
library clones are listed in the supplementary Table 5.3. 
Library clone 
Molecular mass of 
cystine-knot miniprotein 
Expected cystine-knot 
miniprotein mass 
Detected cystine-knot 
miniprotein mass 
MCopt 1.0 clone 1 3270.51 Da 
1636.26 (2 H+) 
1091.18 (3 H+) 
818.63 (4 H+) 
1090.90 (3 H+) 
MCopt 1.0 clone 2 3771.13 Da 
1886.57 (2 H+) 
1258.05 (3 H+) 
943.79 (4 H+) 
1887.30 (2 H+) 
1257.90 (3 H+) 
943.70 (4 H+) 
MCopt 1.0 clone 3 4231.57 Da 
2116.79 (2 H+) 
1441.53 (3 H+) 
1058.90 (4 H+) 
2116.7 (2 H+) 
1411.2 (3 H+) 
 
MCopt 2.0 clone 1 3784.22 Da 
1893.12 (2 H+) 
1262.41 (3 H+) 
947.06 (4 H+) 
1893.10 (2 H+) 
1262.10 (3 H+) 
 
MCopt 2.0 clone 2 3866.28 Da 
1934.15 (2 H+) 
1289.77 (3 H+) 
967.58 (4 H+) 
1934.2 (2 H+) 
1289.40 (3 H+) 
 
MCopt 2.0 clone 3 3767.26 Da 
1884.61 (2 H+) 
1256.75 (3 H+) 
942.81 (4 H+) 
1884.6 (2 H+) 
1256.40 (3 H+) 
 
MCopt 2.0 clone 4 3822.19 Da 
1912.10 (2 H+) 
1275.07 (3 H+) 
956.56 (4 H+) 
- 
MCopt 2.0 clone 5 3585.96 Da 
1793.99 (2 H+) 
1196.33 (3 H+) 
897.50 (4 H+) 
1196.20 (3 H+) 
MCopt 2.1 clone 1 3885.54 Da 
1943.78 (2 H+) 
1296.19 (3 H+) 
972.39 (4 H+) 
- 
MCopt 2.1 clone 2 3962.54 Da 
1982.28 (2 H+) 
1321.86 (3 H+) 
991.64 (4 H+) 
1981.90 (2 H+) 
1321.60 (3 H+) 
991.50 (4 H+) 
MCopt 2.1 clone 3 3885.48 Da 
1943.75 (2 H+) 
1296.17 (3 H+) 
972.38 (4 H+) 
1943.20 (2 H+) 
1295.80 (3 H+) 
 
MCopt 2.1 clone 4 4008.53 Da 
2005.27 (2 H+) 
1337.18 (3 H+) 
1003.14 (4 H+) 
2005.6 (2 H+) 
1336.80 (3 H+) 
 
MCopt 3.0 clone 1 4428.98 Da 
2215.50 (2 H+) 
1447.34 (3 H+) 
1108.25 (4 H+) 
2215.40 (2 H+) 
1477.30 (3 H+) 
1108.00 (4 H+) 
MCopt 3.0 clone 2 4409.02 Da 
2205.52 (2 H+) 
1470.68 (3 H+) 
1103.26 (4 H+) 
- 
MCopt 3.0 clone 3 4568.12 Da 
2285.07 (2 H+) 
1523.71 (3 H+) 
1143.04 (4 H+) 
2284.70 (2 H+) 
1523.00 (3 H+) 
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The overall performance of MCopt 2.0, MCopt 2.1, and MCopt 3.0 library clones was slightly weaker 
in comparison to clones of the established MCopt 1.0 library. Nevertheless, the 96-well expression 
analysis showed producibility of all cystine-knot miniprotein fusions, but MCopt 2.0 library clones with 
general better expression yields of all new libraries. The rough analysis of correct cystine-knot 
miniprotein folding furthermore enabled insights into protein level with no major differences in all 
libraries. 
3.2.4 Panning of MCopt 2.0 library against a novel target-overexpressing cell line 
The functionality of the MCopt 2.0 phage library was in the following analyzed in a selection 
experiment using a tumor-associated antigen as a target. DSG-3, a transmembrane adhesion protein 
of desmosomes152, was defined as target protein for a cell-based panning approach. Initially, a stable 
CHO-K1 cell line that overexpresses DSG-3 was constructed with a PiggyBac transposon system. 
Transfected cells were selected through hygromycin resistance. FACS of transfected cells allowed an 
isolation of strong DSG-3 expressing clones to gain a monoclonal population, which was designated as 
CHO-K1-DSG-3. The expression of DSG-3 was determined by flow cytometry as shown in Figure 3.21. 
 
Figure 3.21 DSG-3 expression on CHO-K1-DSG-3 and CHO-K1-Mock cells. Analysis of DSG-3 expression was 
determined via flow cytometry with an anti-human-DSG-3 antibody and detected with a Cy5-conjugated anti-
mouse antibody (green histograms). Grey histograms indicate staining with Cy5-conjugated anti-mouse 
antibody. Representative histograms are shown. 
A Screening of the MCopt 2.0 library was performed in three successive rounds against CHO-K1-DSG-
3 cells based on the experimental outline given in Figure 3.2. In the first panning round 2.4 x 1013 
MCopt 2.0 library phages were applied and 2.4 x 1012 amplified phage particles in the second and third 
round. During each panning round phage titers were determined for input, post-input and output 
monitoring via CFU counting (Figure 3.22 A). 
 
 
 
 
 
 
 
 
 
Results  69 
A      
 Panning round Input Post-input Output Post-input/output ratio 
 1 2.78 x 10
12
 4.90 x 10
12
 4.40 x 10
4
 1.11 x 10
8
 
 2 2.59 x 10
12
 1.68 x 10
12
 4.90 x 10
5
 3.42 x 10
6
 
 3 8.85 x 10
11
 1.15 x 10
12
 4.99 x 10
6
 2.11 x 10
5
 
      
B      
 
C           
 
Figure 3.22 Phage titers and sequence compostion after MCopt 2.0 panning against CHO-K1-DSG-3 cells. 
(A) Phage titers of MCopt 2.0 library panning rounds against CHO-K1-DSG-3 cells. Input, post-input and output 
was determined based on CFU counting at each panning round. (B) Sequence composition resulting from the 
third panning round against CHO-K1-DSG-3 cells. Sequencing of 48 clones was performed. (C) Schematic 
overview of molecular gene elements in the observed deletion mutants. Grey area represents lacking gene 
segment of the deletion mutants. Genetic elements: colE1 ori: E. coli origin of replication; f1 ori: phage origin of 
replication; pelBss: pelB periplasmic leader sequence; bla: beta-lactamase; -10/-35: promotor elements; fos/jun: 
leucine zipper domains; pIII´: gene encoding for a truncated recombinant minor coat protein of M13. 
The input titer at every panning round was slightly lower as originally intended. The post-input was 
unexpectedly higher in the first and third round and a possible indication of insufficient negative 
depletion. However, the post-input to output ratio decreased over the successive panning rounds, 
which suggested an enrichment of a specific phage population. But to gain precise insights on a 
molecular level, 48 output clones of the third panning round were sequenced. 
Classification of sequence composition into three categories is depicted in Figure 3.22 B. Surprisingly, 
only 4.2 % of total clones revealed to be cystine-knot miniprotein sequences. A proportion of 18.7 % 
showed sequence failure for unknown reasons and a considerable high proportion of 77.1 % showed 
no cystine-knot miniprotein related sequences at all (deletion mutant). Sequence alignments of the 
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respective clones with the pJuFo phagemid vector revealed an absence of the complete Fos-cystine-
knot miniprotein and Jun-pIII´ gene cassettes as well as all segments in between, which is 
schematically presented in Figure 3.22 C.  
In order to gain an understanding of the reasons for this strong deletion mutant enrichment, the 
bacterial growth behavior of the E. coli XL1-Blue MCopt 2.0 library pool and the E. coli XL1-Blue 
deletion mutant clone (carrying the mutated pJuFo phagemid vector) was monitored over a period of 
300 min (Figure 3.23). The deletion mutant grew considerably faster compared to the MCopt 2.0 
library pool under the same cultivation conditions. The occurrence and enrichment of the deletion 
clones is highly problematic because selection of potential binders might be suppressed by the fast-
growing mutants. The dominant incidence of deletion mutants was also observed in several other 
screening experiments using diverse target proteins and under different selection conditions. 
 
Figure 3.23 Growth comparison of E. coli XL1-Blue MCopt 2.0 library pool and E. coli XL1-Blue deletion 
mutant. Cells were cultured in LB-medium supplemented with 100 µg/mL carbenicillin and 0.4 % (w/v) glucose 
at 37 °C. OD of bacterial culture was measured at different time points. Experiment was performed in duplicates 
± SD. 
3.2.5 Optimization of MCopt 2.0 phage library 
As shown in chapter 3.2.4, the dominant occurrence of deletion mutants negatively affected screening 
outcome and represented a major interference factor. Based on the experimental results an exact 
clarification of the deletion mutant origin remained to be challenging, since they could in principle 
either be already present in the MCopt 2.0 library repertoire from the start or might have developed 
via unknown recombination events during the panning procedure. 
The pJuFoIII phagemid vector contains tandem repeats in the promotor and the pelB leader sequences 
of Fos-cystine-knot miniprotein and Jun-pIII´ gene cassettes (Figure 3.24 A), which may be prone to 
homologous rearrangement events153. In order to proof this hypothesis and to overcome deletion 
mutant development an alternative phagemid vector (pPDIII-1) was designed and constructed. In the 
new vector design, the expression cassettes were genetically remodeled aiming to avoid repetitive 
sequences, while retaining the same molecular pathways and protein features. As schematically 
depicted in Figure 3.24 B, the new pPDIII-1 vector has, in contrast to pJuFo, a monocistronic structure 
where both gene fusions are driven by a single lac promotor sequence only separated by a shine 
dalgarno sequence in front of the second part. This feature and the exchange of one of the two pelB 
leader sequence to an ompA leader completely removed repetitive sequence parts from the 
phagemid. Additionally, new genetic elements were introduced (the lacI repressor gene, a CAP binding 
site and additional tHP terminator sequence 3´ and 5 ´of the operon) that should result in a tighter 
gene expression control of the recombinant fusions and thus should minimize potential growth 
difference of individual clones. 
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 B 
 
Figure 3.24 Schematic overview of expression cassettes. (A) Expression cassette of pJuFoIII phagemid vector. 
(B) Expression cassette of pPDIII-1 phagemid vector. pelB: pelB periplasmic leader sequence; ompA: ompA 
periplasmic leader sequence; fos/jun: leucine zipper domains; pIII´: recombinant minor coat protein; CAP: 
catabolite activator protein binding region; start and stop represent ATG and TAA codon, respectively. The 
complete vector maps of pJuFoIII phagemid vector and pPDIII-1 phagemid vector is shown in chapter 2.1.6. 
The benefit of the designed new phagemid vector in preventing deletion mutant appearance was 
analyzed by construction of a small MCopt 2.0 sub-library and a test panning against a soluble tumor-
associated antigen. The MCopt 2.0 sub-library was generated by cloning synthetic MCopt 2.0 DNA 
library fragments into the pPDIII-1 phagemid vector and a following electroporation of 
electrocompetent E. coli XL1-Blue cells. The number of transformed cells was determined using 
dilution plating and counting CFU (Figure 3.25 A).The primary size of the pPDIII-1-MCopt 2.0 sub-
library was 8.9 x 105 cells. 
A small number of 12 clones were sequenced to enable insights into molecular library composition 
(Figure 3.25 B). The pPDIII-1-MCopt 2.0 sub-library revealed 83.3 % with correct and unique cystine-
knot miniproteins sequences, while 16.7 % represented frameshift sequences. 
A   
 Sub-library Number of primary transformants 
 MCopt 2.0 8.9 x 105 
   
B              
 
Figure 3.25 pPDIII-1-MCopt 2.0 sub-library size and sequence composition. (A) pPDIII-1-MCopt 2.0 sub-library 
titer. Colonies of electroporated E. coli XL1-Blue forming units were counted after dilution plating. (B) pPDIII-1-
MCopt 2.0 sub-library sequences. Evaluation was based on 12 sequences. 
Surface display of cystine-knot miniproteins on pPDIII-1-MCopt 2.0 sub-library phages was indirectly 
evaluated with an anti-Fos antibody in an ELISA-based set up (Figure 3.26 A). The pPDIII-1-MCopt 2.0 
sub-library pool showed a stronger signal than the negative control, but a slightly weaker signal in 
comparison to the pJuFoIII-MCopt 2.0 library phages indicating a marginally lower surface density of 
the Fos-cystine-knot-miniprotein / Jun-pIII´ complex. 
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A previous experiment showed faster growth of the E. coli XL1-Blue deletion mutant in comparison to 
the E. coli XL1-Blue MCopt 2.0 library pool (Figure 3.23). Figure 3.26 B presents a similar experiment, 
in which no significant growth difference of E. coli pPDIII-1-MCopt 2.0 sub-library pool and E. coli XL1-
Blue deletion mutant was observed, especially in the early time frame. E. coli XL1-Blue pJuFoIII-
MCopt 2.0 library pool remained to have a delayed growth.  
A   B 
 
 
Figure 3.26 Phage surface presentation analysis and bacterial growth properties of the pPDIII-1-MCopt 2.0 
sub-library. (A) Phage surface display analysis of Fos-cystine-knot-miniprotein on pJuFoIII-MCopt 2.0 and pPDIII-
1-MCopt 2.0 sub-library pools. ELISA was performed with 1 x 1012 phage particles for binding analysis with anti-
Fos antibody and subsequent detection with HRP-conjugated anti-rabbit antibody. Assay was conducted in 
duplicates ± SD. (B) Bacterial growth curves of E. coli XL1-Blue pJuFoIII-MCopt 2.0 library, pPDIII-1-MCopt 2.0 
sub-library and the pJuFo derived deletion mutant. OD of bacterial culture were determined at different time 
points during cell cultivation in LB-medium supplemented with 100 µg/mL carbenicillin at 37 °C. 
The novel phagemid vector was constructed with the aim to prevent the occurrence and the 
enrichment of deletion mutants during phage selection experiments. To experimentally evaluate an 
advantage of the new system, a comparative panning of the pJuFoIII-MCopt 2.0 library and the pPDIII-
1-MCopt 2.0 sub-library against soluble FN-B target protein was performed for direct comparison of 
the screening outcome. Both libraries were screened in three successive panning rounds with 1 x 1013 
applied phages at each round. Infectious phage input and output titers were determined during every 
panning round using CFU counting (Figure 3.27 A). 
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A      
  Panning round Input Output Input/output ratio 
 
pJuFoIII-
MCopt 2.0 
library 
1 8.40 x 10
11
 2.97 x 10
7
 2.80 x 10
4
 
 2 6.55 x 10
11
 1.00 x 10
4
 6.55 x 10
7
 
 3 2.55 x10
11
 1.00 x 10
4
 2.55 x 10
7
 
 
pPDIII-1-
MCopt 2.0 sub-
library 
1 1.64 x 10
12
 1.17 x 10
7
 1.40 x 10
5
 
 2 8.35 x 10
11
 1.00 x 10
4
 8.35 x 10
7
 
 3 8.10 x 10
11
 1.00 x 10
4
 8.10 x 10
7
 
      
B      
        
Figure 3.27 Analysis of phage titers and sequence composition after a comparative selection experiment 
against FN-B target protein. (A) Phage titers of screen pools resulting from pJuFoIII-MCopt 2.0 library and pPDIII-
1-MCopt 2.0 sub-library panning against soluble FN-B target. Input and output was calculated within every 
panning round by determining CFU. (B) Composition of screen pool sequences after the third panning round of 
pJuFoIII-MCopt 2.0 library and pPDIII-1-MCopt 2.0 sub-library screening against soluble FN-B target. For 
sequence analysis 45 clones of each library screening approach were randomly chosen. 
Input titers were obviously lower than 1 x 1013 applied phages, indicating a proportion of non-
infectious phages. The output titer decreased throughout panning rounds in both library screenings. 
Sequencing of 45 clones after panning completion allowed monitoring of sequence compositions and 
particularly of the presence of deletion mutants (Figure 3.27 B). In both screening approaches 
different frequencies of correct cystine-knot miniprotein sequences, peptide sequences, frameshift 
sequences and clones with sequence failure were observed. The pJuFoIII-MCopt 2.0 library pool 
additionally revealed a small proportion of sequences with prolonged loop length. But importantly, 
deletion mutants were detected to a proportion of 15.6 % in the case of the pJuFoIII-MCopt 2.0 library 
screening, whereas no mutant was observed in the pPDIII-1-MCopt 2.0 sub-library pool at all.  
In summary, the usage of the novel vector system seems to prevent either the formation of the 
deletion mutants or its enrichment during selection. The described selection experiment thus provides 
strong evidence for the successful remodeling of the pJuFo phagemid vector. 
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3.3 Targeting of fibronectin extra domain B (EDB) 
This section describes the development of a cystine-knot miniprotein lead candidate targeting EDB for 
tumor imaging approaches. The target-specific cystine-knot miniprotein (MC-FN-010) was selected 
based on conventional phage display technology and initial in vitro target specificity was analyzed. The 
discovery of EDB binding cystine-knot miniproteins was performed by Nadja Salomon during her 
master thesis. Subsequently, in order to characterize MC-FN-010 more deeply, in vitro assays for 
revealing the target relevant binding site and affinity determination were applied. Furthermore, 
preclinical in vivo studies with two lead structures demonstrated their ability to detect EDB-positive 
tumors in a U-87 MG based xenograft glioblastoma mouse model. 
The MCopt 1.0 library and MCopt 2.0 library were screened separately for cystine-knot miniprotein 
identification against single domain FN-B. After three selection rounds of each library, six different 
cystine-knot miniprotein sequences could be enriched. Interestingly, five out of six amplified 
sequences comprise a common R-I/V-R-(L) motif at the C-terminal end of loop 1. Only those five 
cystine-knot miniproteins showed binding capability to EDB presented in different formats with low 
off-target (FN-6789) interaction as tested in ELISA-based set ups. Furthermore, binding ability of tag-
free proteins was determined by SPR analysis. Surprisingly, only one cystine-knot miniprotein (MC-
FN-010) revealed strong binding towards FN-67B89 target protein across all five candidates in the 
tested concentration range from 50 – 1000 nM. Therefore, MC-FN-010 was chosen as lead candidate 
for further analysis and optical imaging probe development. 
3.3.1 Dependency of EDB binding on the R-I/V-R-(L) motif and further sequence optimization of 
the selected cystine-knot miniprotein 
The occurrence of the amino acid motif R-I/V-R-(L) in the enriched and specifically binding cystine-
knot miniproteins suggested involvement of this sequence in EDB binding. We performed a systematic 
alanine scanning mutagenesis of MC-FN-010, in which every single amino acid in the variable region 
and the arginine residues in loop 2 and 5 were individually exchanged for alanine (consecutively 
numbered from MC-FN-011 to MC-FN-0114 as shown in supplementary Table 5.4). All constructs were 
tested for binding to single domain FN-B (Figure 3.28 A).  
 
 
 
 
 
 
 
 
 
 
 
 
Results  75 
A 
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Figure 3.28 Dependency of EDB binding on the R-I/V-R-(L) motif. (A) Identification of functionally relevant 
amino acids in the MC-FN-010 sequence by alanine scanning mutagenesis. Trx-cystine-knot miniproteins 
(parental MC-FN-010 and alanine scan variants) were incubated with pre-coated human FN-B. Binding was 
detected with HRP-conjugated anti-s-tag-antibody. Relative binding of each variant was calculated by comparing 
the respective apparent binding constant to parental MC-FN-010. Error bars represent the standard derivation 
of three independent duplicate measurements ± SD. (B) EDB-binding relevant amino acid residues of parental 
MC-FN-010. Disulfide bonds (brackets) between cysteine residues (bold), residues relevant (red) or at best 
marginally relevant (green) for target-binding are indicated. 
Five constructs with exchanges of single amino acids within the common motif positions had lower 
binding as compared to that of the respective original sequence. An additional alanine substitution in 
the fifth loop also led to reduced target interaction. In contrast, target binding was preserved in the 
seven constructs with alanine exchanges in the beginning of the sequence, indicating that those 
positions were not crucial for EDB binding. Together, these results confirm that the four amino acid 
residues in the first loop (RIRL), and the arginine residue in the fifth loop impact binding to EDB either 
directly or indirectly by affecting miniprotein conformation (Figure 3.28 B). 
This analysis also identified mutagenized variants, which were comparable with regard to binding to 
the EDB domain. We leveraged these data for selection of a second development candidate, with 
which we could also address that the lysine residue in loop 1 of MC-FN-010 may interfere with the 
selective linkage to primary amines required for full exploitation as an imaging reagent. MC-FN-016 
had a primary amine only at the N-terminus, and was found to be comparable to MC-FN-010 with 
regard to its specificity for binding to FN-67B89 (Figure 3.29). The affinities of tag-free MC-FN-010 and 
MC-FN-016 towards biotinylated FN-67B89 as tested by SPR analysis were in the single-digit 
micromolar range with fast off-rates (Table 3.3). 
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Figure 3.29 ELISA-based binding of MC-FN-010 and MC-FN-016 to human FN-67B89 and FN-6789. Trx-cystine-
knot miniproteins were applied at different concentrations and binding was detected with HRP-conjugated anti-
S-tag-antibody. Data shown as mean ± SD resulting from duplicates of a single performed ELISA using 1 µg coated 
FN-67B89 or FN-6789 per well. 
Table 3.3 SPR binding analysis of cystine-knot miniproteins to EDB. Kinetic parameters of EDB-specific 
cystine-knot miniprotein variants resulting from SPR analysis. Biotinylated human FN-67B89 was immobilized to 
a SA sensor to determine affinity of MC-FN-010 and MC-FN-016 using two-fold serial dilutions starting from 
4000 nM. Kinetic parameters were calculated using a 1:1 Langmuir fitting model applied to generated 
sensorgrams (supplementary Figure 5.4). 
Name Concentration (nM) Kon (1/Ms) Koff (1/s) KD (µM) 
MC-FN-010 50 – 4000 4.95 x 104 0.07831 1.58 
MC-FN-016 62.5 – 4000 1.33 x 105 0.1873 1.41 
 
3.3.2 Targeting the tumor vasculature on tumor tissue sections and in mice with selected cystine-
knot miniproteins 
Glioblastomas are known to express the fibronectin EDB isoform in their vasculature154 and models 
derived from them are commonly used for in vitro and in vivo characterization of EDB-binding 
ligands136,155. We resorted to a model based on inoculating the human glioblastoma cell line U-87 MG 
subcutaneously into the flanks of Fox n1/nu mice to obtain xenograft tumors. 
First, we tested the capacity of MC-FN-010 to stain tissue sections derived from these xenograft 
tumors. MC-FN-0115 was used as non-binding negative control (alanine substitutions in three 
positions; PMCTQRANRIAACRRDSDCTGACICRGNGYCG) (supplementary Figure 5.3). For IF imaging 
experiments, biotinylated MC-FN-010 and MC-FN-0115 were tetramerized with Cy3-labeled SA to 
increase avidity. Tetramerized MC-FN-010-bio bound almost selectively to areas around tumor 
vessels, as confirmed by co-localization with the vascular marker CD31, a surface protein ubiquitously 
expressed on endothelial cells (Figure 3.30). In addition, tetramerized MC-FN-010-bio was found to 
localize in perivascular areas. In contrast, MC-FN-010-bio did not stain normal mouse brain sections 
and U-87 MG tumor sections stained with the negative control construct MC-FN-0115 showed no 
fluorescent signal at all. 
Next, we assessed the capacity of both MC-FN-010 and MC-FN-016 in the U-87 MG xenografted mouse 
model in vivo with regard to their capacity to visualize tumor vasculature. The cystine-knot 
miniproteins were chemically trimerized by oxime ligation and tagged with a near-infrared fluorescent 
dye, Alexa Fluor 680. All three trimeric constructs showed no critical aberration in size and purity as 
demonstrated by SDS-PAGE and RPC analysis (supplementary Figure 5.5). Oligomerization profoundly 
improved affinity of both EDB binding cystine-knot miniproteins (AF680-(MC-FN-010)3 and AF680-
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(MC-FN-016)3) to a three-digit picomolar binding constant and remarkably slower off-rates (Table 3.4) 
compared to those of the monomeric variants (Table 3.3). 
 
Figure 3.30 Specific binding of MC-FN-010 to tissue sections derived from the human U-87 MG glioblastoma 
cell line grown as mouse xenograft tumor. Representative IF staining of U-87 MG tumor tissues (A) and normal 
mouse brain (B) with EDB ligand MC-FN-010 and negative control MC-FN-0115. Tissue sections (6 µm) were 
stained with tetramerized cystine-knot miniprotein-biotin / SA-Cy3 complex (red) and an anti-CD31 antibody to 
visualize vasculature (green). Scale bars, 100 µm. 
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Table 3.4 SPR binding analysis of trimeric cystine-knot miniprotein variants to EDB. Kinetic parameters of 
AF680-(MC-FN-010)3 and AF680-(MC-FN-016)3 resulting from SPR with single-cycle kinetic analysis. Biotinylated 
human FN-67B89 was immobilized to SA chip to perform binding determination of AF680-(MC-FN-010)3 and 
AF680-(MC-FN-016)3 using two-fold serial dilution starting from 10 nM. Kinetic parameters were calculated 
using a 1:1 Langmuir fitting model applied to generated sensorgrams (supplementary Figure 5.6). 
Name Concentration (nM) Kon (1/Ms) Koff (1/s) KD (pM) 
AF680-(MC-FN-010)
3
 1.25 – 10 8.04 x 106 3.47 x 10-3 431 
AF680-(MC-FN-016)
3
 1.25 – 10 2.56 x 106 2.31 x 10-3 902 
AF680-(MC-FN-0115)
3
 1.25 – 10 No binding to FN-67B89 
 
Whole-body imaging of mice and ex vivo measurement of resected organs was performed after retro-
orbital i.v. injection of 3.34 nmol AF680-(MC-FN-010)3, AF680-(MC-FN-016)3 and the negative control 
AF680-(MC-FN-0115)3. Both AF680-(MC-FN-010)3 and AF680-(MC-FN-016)3, but not the control 
variant strongly accumulated in the tumor within the first hours and remained for the whole recording 
period of 6 h. Signals for all trimeric constructs were detected in liver and kidney 1 h and 2 h post 
injection, but were of transient nature (Figure 3.31 A).  
The kinetics of ex vivo measured fluorescence in the tumor, kidney and liver, normalized to their 
respective weight, were assessed for the two EDB-specific probes as compared to the AF680-(MC-FN-
0115)3 negative control (Figure 3.31 B). The parental AF680-(MC-FN-010)3 as well as AF680-(MC-FN-
016)3 were found to target to the tumor and to remain significantly enriched over the recorded 6 h 
time period as compared to the triple alanine negative control. The results show that the identified 
EDB-specific cystine-knot miniproteins are suitable for use as imaging agents for tumor targeting. 
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A B 
 
 
 
Figure 3.31 Targeting the tumor vasculature in mice with selected cystine-knot miniproteins. (A) In vivo and ex vivo imaging of U-87 MG bearing mice. Tumors derived 
from human U-87 MG cells injected s.c. in flanks of mice were imaged after i.v. application of 3.34 nmol AF680-(MC-FN-010)3, AF680-(MC-FN-016)3 (EDB binder) and control 
AF680-(MC-FN-0115)3. Groups of three mice per group were stratified to each represent a range of tumor sizes. (B) Kinetics of fluorescence signals in different organs 
quantified and normalized to the respective organ / tumor weight. Data are shown as mean ± SD of triplicates from a single experiment. Statistical significance was calculated 
with two-way ANOVA (* p<0.05, ** p<0.01, *** p<0.001, n.s. = not significant). 
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4 Discussion 
This work comprises the process and technology extension of the internal cystine-knot miniprotein 
discovery platform adjusted for the early research and development phase. In addition, another part 
presents the generation of novel tumor imaging probes based on trimeric fibronectin EDB specific 
ligand and a conjugated near-infrared fluorescence dye. In the following sections the single parts of 
the work are summarized and discussed in detail. 
4.1 An efficient cell-based panning approach for cystine-knot miniprotein 
selection 
Phage display represents a powerful technology for the discovery of novel target-specific binding 
ligands. A very common and widely applied method is to use target proteins in their soluble form, 
which can e.g. be presented on immunotubes or captured on beads for panning32. This requires a 
recombinant production of target protein in suitable expression systems. In addition, the protein 
purification is also crucial to obtain pure products with ideally high yields156,157. The protein quality 
such as purity, solubility and natural conformation plays a critical role for a successful ligand 
identification using e.g. phage display140,158. Nonetheless, this methodology is not necessarily 
accessible for all proteins due to structural complexity, expression and purification difficulties or 
solubility issues. The flexibility of the phage display approach however allows not only panning 
against soluble targets, but also the usage of whole cells to provide proteins in their native 
conformational environment18. 
Many cell-based panning strategies have been described with differences in the detailed protocol and 
alteration of the panning conditions18. These include incubation conditions, the type of applied 
phages, cells as well as washing and elution conditions as briefly summarized in Table 4.1. The variety 
of available cell-based panning protocols and the possible modifications of single parameters 
basically demonstrates the high diversity of implementing this approach. Consequently, a universally 
applicable protocol for any phage library cannot be directly defined, but nevertheless the overall goal 
of effective ligand selection remains the same. However, most publications describe the ligand 
selection against whole cells from large antibody or peptide libraries, whereby primary cells, tumor 
cells or stably transfected cell lines were applied159–162. 
Table 4.1 Overview of cell-based panning parameters and its potential modifications.  
Panning parameter Alteration opportunity 
Incubation conditions Blocking agent, incubation buffer, duration, temperature 
Phages Library (type, presented POI), applied phage particles 
Negative depletion Cell line, duration, repetition 
Target cells Primary or immortalized cells, adherent or in suspension 
Washing conditions Buffer, duration, temperature, repetitions 
Elution conditions Buffer, duration, temperature, repetitions 
 
Cain and colleagues screened a mutated C5a phage library against human C5aR-expressing CHO cell 
line and selected interacting ligands163. Another study described a similar panning strategy of a 
peptide phage library against human CCR5-expressing CHO cells, but the authors included an 
additional subtraction of phages towards non-transfected CHO cells159. An implementation of a 
counter-selection step should decrease the number of unspecific ligands from the phage population 
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and enable a target panning with a roughly pre-selected library141. In close relation to the published 
panning procedure from Wang and colleagues159, the proof of concept experiment in this work 
demonstrates the feasibility to specifically enrich MC-FA-010 presenting phages by screening against 
CHO-K1-FAP-α cells (Figure 3.3 B). Based on the initial dilution factor of MC-FA-010 presenting phages 
to MCopt 1.0 library, the respective clones were detected after one, two or three successive panning 
rounds. But even more convincing was the successful identification of FAP-α binding MC-FA-010 out 
of the complete naïve MCopt 1.0 phage library by applying the protocol (Figure 3.10 B), which 
simulated real panning conditions. This outcome highlights the efficiency of the established cell-
based panning protocol to select target interacting cystine-knot miniprotein from a combinatorial 
phage library. 
Stable transfected cell lines represent a good basis to establish a cell-based protocol suitable for our 
cystine-knot miniprotein phage library, as the target protein is overexpressed on the cell surface and 
an ideal negative counterpart (non-transfected cell line) is easily accessible141. Thereby, the target 
amount plays a crucial role during phage panning, which depends on the protein density on the cell 
surface and the applied cell number. The protein surface density of stable cell lines relies on the 
transgene integration efficiency into the host genome mediated by PiggyBac transposon system and 
its consistent gene expression164. A bulk cell population consists of single clones with different target 
density, which consequently hampers a full control of antigen availability during cell-based panning. 
The CHO-K1-FAP-α cell line represents a heterogeneous FAP-α expressing pool, but nonetheless 
allowed specific cystine-knot miniprotein selection (chapter 3.1.1). Alternatively, a homogeneous 
CHO-K1-FAP-α cell population can be obtained by isolation and expansion of monoclonal cells based 
on the same strategy that was applied to generate the CHO-K1-dsRed-Mock cell line in this work 
(Figure 3.11). A further possibility to generate desired stable target expression cell line represents the 
Flp-FRT system, a yeast-derived Flp recombinase-mediated site-specific transgene integration. Zhou 
and colleagues constructed an engineered CHO cell line that harbors a single site-specific 
recombinase-recognition sequence, which allowed directed target gene integration and yielded cells 
with homologous protein expression165. However, the negative selection on the corresponding non-
transfected cell line is also important to deplete ligands from the library that interact with 
endogenous receptors. A stringent depletion of irrelevant ligands can thus positively influence target 
selection outcome. 
Specific gene silencing or knockdown using e.g. RNA interference or CRISPR/Cas system166 is another 
approach to obtain matching target expressing and off-target cell line counterparts. Thereby, tumor 
cells with suppressed target gene expression could serve for negative depletion, whereas the naïve 
tumor cells are applied for positive selection that provides an unmodified presentation of the target 
protein in its natural frequency and environment. 
The implementation of a cellular phage screening pipeline increases the power of the cystine-knot 
miniprotein discovery platform enormously. So far, the cell-based panning technology was adjusted 
to target overexpressing cell lines, but a direct usage of primary cells or above-mentioned tumor cell 
lines is also conceivable. The flexible application of various cell types provides on the one hand further 
selection opportunities and on the other hand requires the adaption panning procedures.  
4.2 A robust cell-based hit identification approach in a high-throughput manner 
The purpose of the hit identification process is to select individual clones with respect to target 
binding ability and specificity. A fast, robust and high-throughput approach is favorable in order to 
cover an analysis of all selected clones from previous phage panning. ELISA for example represents a 
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traditional methodology for assay protein interaction of putative candidates in a 96-well format167. 
This involves a specific antibody for binding detection via HRP or alkaline phosphatase, while the 
analyte can either be directly applied exposed on the phage surface after selection or on protein level 
itself. Moreover, the target can be provided in soluble form or expressed on the cell surface168–171. An 
ELISA-based assay is also applied within our platform for hit screening against soluble target proteins. 
We used Trx-cystine-knot miniprotein fusions directly after cloning, expression and purification via 
heat-incubation in a 96-well format for binding analysis. The cloning of selected cystine-knot 
miniprotein sequences from the enriched phage pool into the expression vector is a critical step, as 
the sequence distribution can be altered and sequences with lower frequencies might be lost during 
amplification. However, this approach was initially implemented to be able to screen cystine-knot 
miniproteins outside from the phage background in order to avoid potential avidity effects resulting 
from the pVIII display and probable stickiness of the phages. Although we showed the general 
feasibility to perform whole-cell ELISA with phages displaying cystine-knot miniproteins (Figure 3.1 C), 
the low sensitivity required high amounts of phages. As these high amounts could not be generated 
in a 96-well format the whole-cell ELISA system was not considered for further method development. 
We preferred an adaption of flow cytometry based analysis for cell-based hit screening in relation 
with the pre-existing high-throughput protein expression system. Flow cytometric analysis is 
advantageous for hit identification purposes, since a measurement generates multiparametric data 
of a single cell172, while covering a large number of cells for a statistically relevant amount. This work 
presents a robust flow cytometry-based system for the analysis of enriched cystine-knot 
miniproteins. For assay development the phage pool of the second panning round against CHO-K1-
FAP-α was used (the initial dilution ratio of 1:109), which contains a moderate number of MC-FA-010 
displaying phages (Figure 3.3 B). The cystine-knot miniprotein sequences from the screen pool were 
cloned into the expression vector and subsequently underwent routinely performed 96-well 
production procedure. For binding analysis of Trx-cystine-knot miniprotein fusion containing bacterial 
supernatant, CHO-K1-FAP-α and CHO-K1-Mock cells were assessed in two separate plates. Increased 
fluorescence signals in CHO-K1-FAP-α cell population was observed and resulted from Trx-MC-FA-010 
miniprotein fusion (Figure 3.7). For data processing, interaction of each clone was evaluated as a 
cellular binding value by dividing the CHO-K1-FAP-α signal with the corresponding CHO-K1-Mock 
signal. At the end, the three major components of our downstream hit identification process were 
collected in a ranking list consisting of the cellular binding value, the protein expression rate and the 
sequence (Figure 3.5). This resulted in a generation of a ranking value for every clone as a measure 
for specific target interaction. Table 5.1 represents the ranking list of the performed hit identification 
procedure with middle to high ranking values from all Trx-MC-FA-010 variants as well as from two 
additional cystine-knot miniproteins and peptide clones. Consequently, our ranking system enables 
a differentiation of clones with target binding ability from those with no interaction. In addition, the 
developed downstream process was verified with the successful identification of Trx-MC-FA-010 and 
target interacting peptides resulting from the naïve MCopt 1.0 library panning against CHO-K1-FAP-
α cells (Figure 3.10). Overall, these results demonstrate the applicability of the flow cytometry-based 
hit identification system for the efficient screening of target binding cystine-knot miniproteins in a 
96-well scale format. The data evaluation scheme allows a correlation of obtained values for reliable 
identification of promising candidates. However, this system also harbors limitations, including the 
lack of a suitable threshold to be able to distinguish hit candidates from unspecific binders or the 
arising of false positive clones due to single sample measurements. Hit screening is thus supposed to 
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give first insights of putative candidates, while a more detailed analysis of single clones afterwards is 
imperative in any case. 
The high-throughput nature of the system was further optimized by the generation of a red 
fluorescent mock cell line for applying simultaneous detection of target and off-target binding 
(Figure 4.1 A). The second negative cell line (CHO-K1-dsRed-Mock) was generated to endogenously 
express a red fluorescent dye allowing discrimination from the target expressing cell lines that carried 
the GFP reporter gene. Figure 3.12 shows the feasibility study with the mixed cell populations and 
the crucial FAP-α binding of Trx-MC-FA-010 miniprotein fusion to CHO-K1-FAP-α cells, in which no 
interaction towards CHO-K1-dsRed-Mock cells was observed. In particular, adequate functional assay 
sensitivity can be concluded, while the doubling of hit screening throughput additionally leads to an 
improved cost- and time-efficient analysis. 
Furthermore, a 96-well expression system for the in vivo biotinylation of Trx-cystine-knot 
miniproteins in E. coli was implemented to improve the potential sensitivity of detection. The 
biotinylated protein can be tetramerized for target binding in order to increase putative binding 
strength by exploiting potential avidity effects. Figure 4.1 illustrates the binding detection principle 
of monomeric Trx-cystine-knot miniprotein fusion and tetramerized Trx-cystine-knot miniprotein 
fusion. This procedure increases the assay sensitivity extremely by means of signal enhancement, 
which was generated by tetramerized Trx-MC-FA-012 miniprotein fusion in comparison to 
monomeric version in a flow cytometric setup (Figure 3.13 B). 
A B 
  
 
Figure 4.1 Schematic illustration of monomeric and tetramerized Trx-cystine-knot miniprotein fusion for 
cellular binding analysis via flow cytometry. (A) Target binding analysis of monomeric applied Trx-cystine-knot 
miniprotein via fluorescence-dye labeled anti-His-tag antibody. (B) Tetramerization of biotinylated Trx-cystine-
knot miniprotein fusion using fluorescence-dye conjugated SA for target binding detection. 
In sum, the presented approach allows the downstream hit screening of individual clones in a high-
throughput manner. It consists of two 96-well production systems yielding ligand candidate as Trx-
cystine-knot miniproteins either unmodified or in site-specifically biotinylated format. Both versions 
can be used for flow cytometry-based target interaction assessment using on the one hand 
monomeric Trx-cystine-knot miniprotein fusion and on the other hand tetramerized variants of 
biotinylated Trx-cystine-knot miniprotein fusions. Cellular data outcome can be easily correlated with 
the protein expression values for the generation of a ranking list that enables the identification of 
promising hit candidates. Our system is advantageous, as already a small volume of roughly purified 
proteins in the bacterial lysate can be directly assessed with sufficient sensitivity outcome in a primary 
hit screen. However, putative hits generally undergo secondary or further functional characterization, 
for which the developed high-throughput cellular binding assay would be suitable to analyze e.g. 
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different concentration range of fully purified candidates. For this purpose, 96-well His-tag 
purification system can be easily introduced to achieve purified Trx-cystine-knot miniprotein fusions. 
Yang and Nolan presented a high-throughput approach for screening and characterization of selected 
phage clones. The authors set up a multiplexed binding assay based on optically-encoded 
microsphere and flow cytometry. To assess target binding ability, the phages were captured on anti-
M13 antibody-bearing microspheres, while the target protein was fluorescence labeled for the 
measurement173. A similar strategy could be considered for our platform as well. Binding of cystine-
knot miniprotein presenting phage to target expressing cell could be directly assessed within panning 
using flow cytometry. In any case, a reliable screening protocol has to be developed and validated. 
4.3 Improved cystine-knot miniprotein phage libraries 
In this work the design, construction and characterization of three cystine-knot miniprotein phage 
libraries is reported that are based on previous obtained findings from the literature combined with 
sophisticated rational design strategies. These represent fundamental and crucial steps for efficient 
ligand selections within the internal drug discovery platform. As described in detail in chapter 3.2.1, 
the oMCoTI-II protein scaffold was the basis for the new libraries. The MCopt 2.0 library consists of 
ten randomized amino acids in the functional amino-terminal loop of the oMCoTI-II protein, while 
MCopt 2.1 library harbors ten amino acid sequence randomization in loop 5. A third library 
(MCopt 3.0) was constructed with ten randomized amino acids in both adjacent loop 1 and loop 5. 
Crucial requisites of combinatorial libraries are high clonal diversity, properly folded and displayed 
proteins as well as correct amino acid sequence compositions161,174. In this work, three phage libraries 
were generated with reasonable primary transformation numbers of at least 1.06 x 109 clones 
(Figure 3.17 A). Sequencing was done to analyze library quality on a molecular level of all three 
libraries (Figure 3.17 B). In the MCopt 2.0 library a proportion of 72.9 % represented the expected 
cystine-knot miniprotein sequences. On the contrary, the frequency of correct sequences in 
MCopt 2.1 and MCopt 3.0 library was much lower, while a similar proportion of non-assignable 
sequences in the loop regions emerged. Those clones were shown to be most probably cells with 
double or multiple transformed phagemids (chapter 3.2.2), which consequently negatively affects the 
essential characteristic of a genotype and phenotype coupling within the phage display system32. We 
present an E. coli infection approach to overcome this problem according to a procedure described 
by Sblattero et al., who established a scFv library with high clonal diversity using a Cre recombinase 
system151. We assumed that an infection of E. coli with the primary library phages (resulting from the 
multiple transformed cells) would restore the genotype-phenotype linkage when a low MOI is used. 
As a prerequisite each phage must contain only a single DNA species and the MOI must be sufficiently 
low to ensure that a single phage only infects an individual cell. The hypothesis was confirmed, as the 
occurrence of non-assignable sequences in the loop position in all libraries decreased enormously 
with a proportion of below 3.1 % (Figure 3.18 B). However, the reinfection procedure of primary 
phage particles hampers a reliable calculation of library diversity. Although an absolute number could 
not be calculated, the theoretical clonal diversity of all libraries is supposed to be below the 
determined number of infected cells (Figure 3.18 A). A further quality requisite of functional cystine-
knot miniprotein presentation on phage particles was indirectly proven with an antibody directed 
against the assembled Fos-molecule (Figure 3.19 A, Figure 3.19 B). Therefore, the MCopt 2.0, 
MCopt 2.1 and MCopt 3.0 libraries accomplished quality requirements on molecular and phage level.  
For downstream hit identification procedure, the accessibility of Trx-cystine-knot miniproteins 
derived from MCopt 2.0, MCopt 2.1 and MCopt 3.0 libraries for recombinant expression in a mini-
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scale setting was shown. The majority of MCopt 2.1 and MCopt 3.0 library clones yielded protein 
concentrations below 1 mg/mL, while the product yield of MCopt 2.0 library clones was equally 
distributed in the range of < 1 mg/mL and 1.49 mg/mL (Figure 3.20). Furthermore, an influence of the 
sequence exchanges and extension in specific loop positions on correct oMCoTI-II protein folding and 
functionality was assessed. Individual clones of MCopt 2.0, MCopt 2.1 and MCopt 3.0 libraries were 
recombinantly produced for mass determination. The formation of three characteristic disulfide 
bonds of oMCoTI-II framework was taken as a measure of tolerance to sequence and length 
modification. Most of the cystine-knot miniproteins had the expected mass, while MCopt 2.0 proteins 
revealed the highest frequency (Table 3.2). A general tolerance of loop 1 to substitutions can be 
concluded, while retaining constrained structural motif. In contrast, amino acid exchanges and length 
alteration in loop 5 or in dual-loop positions seemed only to be bear in a moderate manner. 
The feasibility of modifying the inhibitory loop position in the oMCoTI-II sequence for randomized 
combinatory library construction has been previously demonstrated92,175. But also the in-house 
experience based on the MCopt 1.0 phage library emphasized these observations. Furthermore, 
Kimura and co-workers presented a loop-grafting approach in the related acyclic MCoTI-II sequence 
to a pharmacokinetically stabilized knottin with αvβ6 integrin binding ability91. However, loop 5 or 
dual-loop randomization of oMCoTI-II scaffolds has not been systemically investigated so far. In a 
previous report from Glotzbach and colleagues, sequence composition in loop 5 of oMCoTI-II protein 
has been substituted in a very moderate variation manner as a part of combinatorial library design. 
Yeast display screening resulted in selection of engineered knottin directed against human 
matriptase-1 with binding and inhibitory function92. 
The MCopt 3.0 library design with loop-selective randomization scheme was based on a conceptual 
strategy to increase the potential binding area, which might result in a higher target affinity. 
Moreover, cystine-knot miniproteins with dual-loop functionalities are a very interesting option to 
gain bispecific targeting. Successful ligand selection of MCopt 2.0 and MCopt 2.1 phage libraries 
against independent target molecules offers the opportunity to combine loop 1 and loop 5 
subsequently via loop grafting for achieving dual-binding functionalities. Recently, Chan and co-
workers grafted two anti-angiogenic epitopes in loop 1 and loop 5 or loop 5 and loop 6 of the cyclic 
MCoTI-II framework with inhibitory effects on HUVEC and tumor cell proliferation176. Based on their 
experimental results, the general concept of dual-targeting seems to be feasible and encouraged our 
rational designed approach. 
In recent years, various combinatorial cystine-knot miniprotein-based libraries were constructed for 
tumor-associated antigen identifications. This mostly involved engineered knottin presentation via 
yeast display and high-throughput screening in combination with flow-cytometry. The evolution-
directed strategy resulted in selection of several knottin ligands against target proteins90,92,93,175. But 
also functional displaying of EETI-II and kalata B1 derived knottin libraries on bacterial surface has 
been reported177,178. However, we present the functional phage surface presentation of cystine-knot 
miniprotein using the pJuFo phagemid system42. A low valency display through the recombinant pIII´ 
protein was intended to provide the possibility of high target affinity cystine-knot miniproteins 
selection, based on the hypothesis of avoiding strong avidity effects on phage level. The control of 
protein copy numbers alone might however not be sufficient enough, an inclusion of panning 
stringency might support the route to this purpose179. 
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4.4 Challenges and hurdles of novel MCopt 2.0 phage library 
The successful ligand selection from a combinatorial phage library relies on different parameters, 
including library quality, panning stringency or binding affinity53. After panning completion of 
MCopt 2.0 library against CHO-K1-DSG-3 cells a strong enrichment of deletion mutants lacking the 
whole Fos-cystine-knot miniprotein and Jun-pIII´ sequence part was observed (Figure 3.22). The 
deletion mutants showed growth advantages over MCopt 2.0 library pool (Figure 3.23) and therefore 
developed to be a critical issue that needed to be overcome. Their general incidence became 
challenging, since a lack of sufficient target specific phage population enrichment resulted in no novel 
cystine-knot miniprotein selection and furthermore deteriorated the library quality. Mueller reported 
about a similar observation of deletion in the Fos/Jun region, which predominantly occurred under 
low selection pressure. The author solved this problem by introduction of an additional antibiotic 
resistance marker gene145. Another report describes a genetic instability of repetitive gene segments, 
which eventually can cause insertion or deletion of DNA sequences153. We could show that the 
deletion mutants in our case most likely developed based on repetitive DNA sequences in the 
promotor and pelB leader segments. The construction of a pPDIII-1 phagemid vector, in which all 
tandem repeats were removed clearly prevents the occurrence of deletion mutants during panning 
procedure (Figure 3.27 B). This effect could have been achieved due to suppression of putative 
recombination processes of genetic elements. Or secondly, a deletion mutant outgrowth or 
enrichment was prevented, as pPDIII-1-MCopt 2.0 library clones revealed equal growth behavior 
(Figure 3.26 B). Although the pelB as well as the ompA leader sequence follow the sec pathway for 
translocation of proteins to the cell membrane and are routinely used for antibody phage display180, 
the usage of ompA in pPDIII-1-MCopt 2.0 sub-library resulted in a weaker frequency of molecule 
presentation on the phage surface than pJuFoIII-MCopt 2.0 library (Figure 3.26 A). However, the 
monocistronic gene structure of expression cassettes within the pPDIII-1 vector might also contribute 
to that incidence (Figure 3.24 B). So far, however an interfering impact on library quality was not 
observed, as a display of Fos-cystine-knot miniprotein was clearly detected. 
In addition to the observed genetic instability of the phagemid, other factors concerning the DSG-3 
target protein structure or the target density on the cell surface could have negatively affected the 
selection. The single-pass transmembrane protein is composed of an intracellular domain and four 
extracellular cadherin (EC) domains181, which results in a rather linear structure. The structural 
feature of the expressed DSG-3 ectodomains on CHO-K1 cells might thus not be presented ideally for 
tight cystine-knot miniprotein binding and selection using our applied cell-based phage screening 
approach. Moreover, the protein cell surface density could have an additional impact on accessibility 
during panning. Both hypotheses are possible, but however not explicitly proven. In contrast to the 
described cell-based selection against DSG-3, a soluble protein-based selection against single domain 
FN-B protein was successful, although FN also forms to a linear array108 and shares overall structural 
similarity with DSG-3 (chapter 3.3). Consequently, a phage panning against a single EC domain of DSG-
3 in a soluble form might lead to successful cystine-knot miniprotein identification as well. In our case 
it can be concluded that likewise multiple parameters influence the selection outcome enormously, 
as known in advance. Not only the library quality and panning strategy plays a critical role, but most 
probably also the target protein of choice and the target protein presentation. 
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4.5 EDB specific cystine-knot miniproteins as tumor imaging agents 
Targeted tumor imaging with peptide or protein-based molecular probes may improve cancer 
diagnosis, staging and treatment monitoring182. The selective expression of the extra domain B 
containing isoform of FN in tumor-associated neovasculature121,122, makes it an ideal target for ligand-
based delivery of drug molecules. Derivatives of the EDB binding human L19 antibody have been 
widely used as molecular system to deliver radioisotopes or cytokines in cancer imaging and 
therapy183–185. Several L19-based approaches are currently under clinical investigation with promising 
early results186,187. This together with the fact that cystine-knot miniproteins entail a broad range of 
favorable characteristics encouraged us to generate EDB-binders based on this scaffold. 
In this study, we present the development of novel cystine-knot miniprotein-based ligands with high 
specificity for fibronectin EDB and its preclinical evaluation as an in vivo imaging probe in a 
glioblastoma mouse model. The screening of two combinatorial libraries against an EDB-containing 
protein fragment resulted in strong enrichment of six clones, five of which shared the distinctive R-
I/V-R-(L) motif. We characterized the identified hits and selected MC-FN-010 based on the robust 
affinity and specificity of its binding to EDB for further development. Mapping of the MC-FN-010 
binding site through alanine scanning mutagenesis revealed that the amino acid residues R-I-R-L in 
the first loop and an arginine residue in the fifth loop are required for EDB binding activity of the 
peptide (Figure 3.28). One may speculate that the consensus sequence together with amino acids 
located in loop 2 (R-R-D-S-D) and loop 5 (R-G-N-G-Y) forms a patch of positively charged residues that 
mediate binding to EDB mainly via electrostatic interactions. This hypothesis is supported by the 
dominance of negative charges with only two positively charged residues being represented within 
the 91 amino acids of EDB188. 
The measured binding affinities of the parental MC-FN-010 and its derivative MC-FN-016 to FN-67B89 
were in the single-digit micromolar range (Table 3.3). As a higher binding strength is may be favorable 
for efficient tumor uptake and retention in vivo, in particular for small peptides that are excreted 
rapidly via the kidneys189,190, we oligomerized these ligands and conjugated the resulting trimers with 
a fluorescent dye. This resulted in apparent affinities in the picomolar range (~1500- to 3600-fold 
stronger as compared to the monomeric versions) (Table 3.4), comparable with the reported binding 
constants for the single-chain Fv L19 fragment127. 
The ability of the trimerized and labelled formats of MC-FN-010 and MC-FN-016 to bind to EDB-
expressing tumors in vivo was investigated in an U-87 MG xenograft mouse model. Both molecules 
were selectively taken up and maintained within the tumor over the entire recorded period of 6 h in 
contrast to a triple alanine mutant that served as a negative control (Figure 3.31). Signals observed in 
liver and kidney decreased over time. The uptake and retention of oMCoTI-II-based peptides in the 
kidneys was reported in other studies and attributed to a high content of arginine residues91. 
Taken together, the strong tumor uptake of these trimeric constructs and their favorable 
biodistribution indicate the suitability for diagnostic imaging applications. These EDB ligands may 
provide a platform, which can support a diversity of in vivo cancer imaging and targeting approaches 
including conjugation of radioactive tracers, use for PET or SPECT nuclear imaging techniques and 
targeting of bioactive payloads. 
4.6 Concluding remarks and future perspectives 
Cystine-knot miniproteins emerged as a promising non-immunoglobulin class with high potential as 
molecular scaffold for a variety of different clinically relevant applications84. In particular, the ability 
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of various cystine-knot miniprotein derived formats for tumor imaging approaches has been 
extensively evaluated in preclinical studies96,98,191,192. One of the most advanced imaging agents is 
based on the CTX peptide, which has been conjugated to the radioisotope iodine-131 for clinical 
phase I dose study in human glioblastoma patients. The patients tolerated the single-dose 
administration, while the imaging compound specifically accumulated in the tumor100. Moreover, a 
modified version of CTX was conjugated to indocyanine green (BLZ-100) for intraoperative and 
diagnostic application in a preclinical setting101,193. Beside the strong advancement for tumor imaging 
technologies, therapeutic applications can also be taken into account. These include the exploitation 
of inhibiting functionalities or antagonistic activity after target binding92,176,194,195 or by conjugation of 
bioactive payloads that are specifically delivered to the tumor site. The versatility of the cystine-knot 
miniprotein scaffold for targeted delivery have been successfully demonstrated by conjugated 
radioisotope or toxins and as antibody surrogates via fusion to IgG Fc portion196–200. 
So far, the internal phage screening pipeline enabled a reasonable de novo discovery of target 
interacting cystine-knot miniproteins by using soluble target proteins. This thesis reports about the 
establishment of an efficient phage panning procedure for cystine-knot miniprotein selection against 
target protein overexpressing mammalian cells. In addition, a robust hit identification process was 
developed for high-throughput screening of single clones towards target interaction ability. The flow 
cytometry-based measurement allows the analysis of monomeric or tetramerized Trx-cystine-knot 
miniprotein fusions by using two different detection systems. The implementation of a cell-based 
screening pipeline could potentially augment the power of our discovery platform and may offer 
novel opportunities to additionally address surface receptors in their native conformation, especially 
to overcome limited accessibility of target proteins for recombinant production. The second part of 
this work describes the extension of the cystine-knot miniprotein phage library repertoire. Novel 
phage libraries were constructed based on an improved rational design strategy and resulted in ten 
randomized amino acids in loop 1, loop 5 or dual loop positions of the oMCoTI-II protein scaffold. All 
phage libraries were successfully generated with reasonable quality. The last part of this thesis 
reported for the first time about the development of an engineered cystine-knot miniprotein for 
targeting of EDB expressing tumors, which was initially selected from a combinatorial phage library. 
This molecule underwent each step of our cystine-knot miniprotein technology platform and entered 
together with a second candidate a preclinical in vivo imaging testing. Their usage as imaging probes 
was evaluated in a U-87 MG based xenograft glioblastoma mouse model. All in all, the whole work 
demonstrates the availability of a powerful platform for the preclinical discovery and the 
development of cystine-knot miniprotein candidates, which were further engineered as protein 
scaffolds for tumor imaging technologies as presented in Figure 4.2. In addition, the results further 
emphasize the relevance of cystine-knot miniprotein framework as tumor diagnostic tool. 
 
Figure 4.2 Overview of internal cystine-knot miniprotein discovery platform. 
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Figure 5.1 Purity of Trx-cystine-knot miniprotein fusion after heat-purification step. Representative E-
PAGE™ analysis of expressed Trx-cystine-knot miniprotein fusions from MCopt 1.0 library in a 96-well scale. 
Analysis was performed with 10 µL of bacterial supernatant that contained roughly purified Trx-cystine-knot 
miniprotein. Purified Trx-MC-Myc-010 was applied as protein reference at 3 µg (a), 10 µg (b) and 20 µg (c). 
Percentage of protein purity was determined via densitometric analysis and shown in numbers above each 
band. 
Table 5.1 Ranking list of hit identification procedure for spike-in screening against CHO-K1-FAP-α. Phage 
pool after second panning round of initial dilution ratio of 1:109 was used. Cellular binding value [signal (CHO-
K1-FAP-α)/signal (CHO-K1-Mock)], protein expression value and sequence are shown for each variant. Ranking 
value was generated by dividing cellular binding value with the corresponding expression value. Variants were 
sorted according to the highest ranking value. MC-FA-010 sequences are highlighted in bold letters. 
Variant 
Cellular 
binding 
value 
Expression 
value 
Ranking 
value 
Sequence 
H01 6.61 0.31 21.32 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
A01 38.40 4.90 7.84 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
A07 26.08 4.37 5.97 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
C01 33.71 5.90 5.71 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
E01 35.28 7.12 4.96 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
G01 23.86 4.97 4.80 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
C11 16.71 5.12 3.26 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
F01 24.22 7.72 3.14 NRCKENHMDTYQHQQVVPSRLRLPDGMHLPW 
C04 18.84 6.68 2.82 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
G05 13.52 5.40 2.50 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
B09 18.34 7.46 2.46 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
H05 2.12 0.89 2.38 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
D08 15.67 6.95 2.26 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
B01 17.79 7.90 2.25 KYCTDESHGCRRDSDCIAACICRGNGYCG 
E05 15.16 6.82 2.22 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
D10 12.74 5.96 2.14 HQVPSRLRLSDGMHLPW 
D12 13.94 7.18 1.94 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
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D01 15.14 7.96 1.90 DECTNLEKYKRPCRRDSDCNLACICRGNGYCG 
F02 15.04 7.99 1.88 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
E11 12.29 6.56 1.87 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
G03 8.19 4.45 1.84 GKCPYSNWTPGRGPNCRRDSDCPGRCICRGNGYCG 
E10 12.36 6.91 1.79 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
H11 5.50 3.52 1.56 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
G02 8.57 5.68 1.51 NRCKENHMDTYQHQQVVPSRLRLPDGMHLPW 
H08 2.04 1.40 1.46 NQCSRNTDSLSSRLRLPGSLYLPW 
F08 11.30 7.94 1.42 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
G11 6.86 5.11 1.34 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
D02 8.63 6.56 1.32 NRCKENHMDTYQHQQVVPSRLRLPDGMHLPW 
G10 6.02 5.37 1.12 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
H09 1.47 1.52 0.96 frameshift 
G06 4.47 5.38 0.83 NRCKENHMDTYQHQQVVPSRLRLPDGMHLPW 
F04 8.98 10.98 0.82 frameshift 
C02 4.79 8.16 0.59 GECGANNDTKRTCRRDSDCPGGCICRGNGYCG 
E02 4.13 7.18 0.58 DRCNQHQMSCRRDSDCPMACIRRGNGYCG 
B02 3.03 6.34 0.48 GTCRKRIRSCRRDSDCQGACICRGNGYCG 
C10 2.15 4.87 0.44 NRCKENHMDTYQHQQVVPSRLRLPDGMHLPW 
H07 0.98 2.23 0.44 sequence failure 
H06 1.10 2.59 0.42 GGCKSQSPRKTDKWGCRRDSDCPLACICRGNGYCG 
H02 1.25 2.97 0.42 RDCTEQADRRYNCRRDSDCPGACICRGNGYCG 
A02 2.78 6.93 0.40 TDCEKEPGTDKERTPCRRDSDCEGACICRGNGYCG 
G04 1.58 4.23 0.37 YKCKNPGRYCRRDSDCDMACICRGNGYCG 
A03 2.50 7.16 0.35 PHCKPQGWPCRRDSDCPIACICRGNGYCG 
C03 2.29 7.38 0.31 STCTSEPSPCRRDSDCPGSCICRGNGYCG 
F03 2.54 8.49 0.30 HTCPREKENCRRDSDCERACICRGNGYCG 
A09 1.02 3.51 0.29 PWCNSIYHWCRRDSDCPGACICRGNGYCG 
H04 1.06 3.68 0.29 EYCKISSKNPGYCRRDSDCTRACICRGNGYCG 
B11 2.17 7.57 0.29 NRCKENHMDTYQHQQVVPSRLRLPDGMHLPW 
A11 1.03 3.72 0.28 QRCRGYTPSDHTCRRDSDCKMACICRGNGYCG 
H10 1.02 3.77 0.27 HTCKGRYHYCRRDSDCPGACICRGNGYCG 
C09 1.12 4.30 0.26 RPCNKWPSNYHYTKGCRRDSDCHWACICRGNGYCG 
F05 2.02 7.97 0.25 IDCSTYPQQPGQQSGCRRDSDCPGDCICRGNGYCG 
A12 1.00 4.68 0.21 QYCLDRGPHGSSPSHCRRDSDCNGACICRGNGYCG 
D04 1.58 7.42 0.21 HWCTRYPHNCRRDSDCPVACICRGNGYCG 
G08 1.00 5.03 0.20 VNCPSGRRGHRIGIWMPSRLRLPGSMHLPW 
A06 1.20 6.13 0.20 QGCTRTHSPDHQCRRDSDCGYRCICRGNGYCG 
B06 1.03 5.30 0.19 sequence failure 
A08 1.06 5.46 0.19 DTCKSYGYYYDECRRDSDCSGACICRGNGYCG 
B04 1.09 6.22 0.17 frameshift 
E08 1.36 8.00 0.17 TDCPTNKSECRRDSDCPKACICRGNGYCG 
C06 1.03 6.16 0.17 TKCYHKEQQDYTPPKCRRDSDCPWRCICRGNGYCG 
C12 1.01 6.14 0.16 NSCIQSRNPCRRDSDCPGACICRGNGYCG 
A04 1.10 6.83 0.16 EHCPQPYSRCRRDSDCPRACICRGNGYCG 
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A10 0.99 6.24 0.16 QYCLDRGPHGSSPSHCRRDSDCNGACICRGNGYCG 
D09 1.04 6.64 0.16 TYCKRQHETCRRDSDCDMRCICRGNGYCG 
B12 1.00 6.44 0.16 HKCEQPLDRCRRDSDCNGACICRGNGYCG 
G09 1.00 6.41 0.16 vector re-ligand 
D07 1.02 6.58 0.15 QPCASQRAYRNVCRRDSDCPIACICRGNGYCG 
E12 0.96 6.35 0.15 KSCSTDEPKNEYCRRDSDCYGRCICRGNGYCG 
C08 1.05 7.01 0.15 STCTNFRGGCRRDSDCPKQCICRGNGYCG 
G12 1.02 6.86 0.15 PRCQTRNPYQQSESPCRRDSDCPGACICRGNGYCG 
D03 1.14 7.63 0.15 TGCYSSNHYCRRDSDCPTNCICRGNGYCG 
D05 1.03 6.91 0.15 YKCKPGEEQCRRDSDCPGACICRGNGYCG 
B07 1.21 8.30 0.15 frameshift 
C07 1.00 6.89 0.15 SYCTGNQLECRRDSDCPKHCICRGNGYCG 
G07 1.03 7.12 0.14 TDCYRTKEQCRRDSDCQMACICRGNGYCG 
B08 1.06 7.32 0.14 RPCKPNMSQCRRDSDCPGACICRGNGYCG 
A05 0.97 6.74 0.14 GKCDKPSDYCRRDSDCPGECICRGNGYCG 
D06 1.06 7.81 0.14 HYCPHQEDDCRRDSDCPGACICRGNGYCG 
E06 1.05 7.76 0.14 TGCLQYYTEGPECRRDSDCPGACICRGNGYCG 
E04 1.03 7.70 0.13 PPCGMSEPSCRRDSDCPVACICRGNGYCG 
B10 1.02 7.63 0.13 QPCISYGTTCRRDSDCPHNCICRGNGYCG 
E07 1.00 7.92 0.13 SYCGPAYYYCRRDSDCPGSCICRGNGYCG 
B05 0.98 8.21 0.12 GECSTDESEHSDHYGCSRDSDCKMNCICRGNGYCG 
F07 1.02 8.56 0.12 GHCIRRSSNCRRDSDCPKECICRGNGYCG 
C05 1.12 9.39 0.12 RTLPGNPVEVPSRLRLPWSMHLPW 
F10 1.04 8.87 0.12 PGCRTHMPYEHTRPECRRDSDCSRACICRGNGYCG 
E09 1.03 8.88 0.12 QSCKNKSEQCRRDSDCGMACICRGNGYCG 
F06 1.04 9.24 0.11 frameshift 
F12 1.00 9.11 0.11 QYCKMSHRKERKCRRDSDCPGACICRGNGYCG 
F09 1.01 9.51 0.11 PECNRKYTTCRRDSDCPIACICRGNGYCG 
F11 1.01 9.86 0.10 GQCRIRGEDCRRDSDCQGACICRGNGYCG 
D11 1.00 9.93 0.10 vector re-ligand 
 
Table 5.2 Ranking list of hit identification procedure for MCopt 1.0 library screening against CHO-K1-FAP-
α after third panning round. Cellular binding value [signal (CHO-K1-FAP-α)/signal (CHO-K1-Mock)], protein 
expression value and sequence are shown for each variant. Ranking value was generated by dividing cellular 
binding value with the corresponding expression value. Variants were sorted according to the highest ranking 
value. X represents sequencing error. 
Variant 
Cellular 
binding 
value 
Expression 
value 
Ranking 
value 
Sequence 
D06 9.93 0.69 14.39 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
A11 1.40 0.39 3.60 GKCGKVPSMDRTNQLPSRLRLPXXMYLPW 
D09 4.89 1.42 3.44 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
D08 5.61 2.14 2.62 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
B07 5.86 2.77 2.12 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
E04 11.78 7.05 1.67 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
D12 3.18 2.57 1.24 GKCPYSNWTPGRGPDCRRDSDCPGRCICRGNGYCG 
A10 4.45 3.69 1.21 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
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A12 1.73 2.05 0.84 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
E06 6.08 8.62 0.70 GKCGKVPSMDRTNQLPSRLRLPGNLYLPW 
D10 1.15 2.46 0.47 TNCWEQPSKHRSGCRRDSDCNGACICRGNGYCG 
C11 1.02 2.27 0.45 GQCRXXDQXXLGXCRRDSDCPVTCICRGNGYCG 
C06 3.01 6.98 0.43 LTCMDGREQCRRDSDCSGACICRGNGYCG 
A03 1.26 3.3 0.38 TNCWEQPSKHRSGCRRDSDCNGACICRGNGYCG 
D01 1.56 4.15 0.38 KECYPPRQHGHECRRDSDCRGACICRGNGYCG 
D05 2.31 6.68 0.35 KDCRNDYDGCRRDSDCQGACICRGNGYCG 
B02 1.15 3.41 0.34 SGCHNKISYDYGCRRDSDCSYRCICRGNGYCG 
B08 1.03 3.12 0.33 DKCNLQHEYGHNGGPCRRDSDCQWACICRGNGYCG 
C07 1.04 3.27 0.32 KPCPTKMYGCRRDSDCPGACICRGNGYCG 
E02 1.11 3.66 0.30 HPCNSKLNHCRRDSDCTWACICRGNGYCG 
C05 1.12 3.97 0.28 STCYHPHYESHYAYPCRRDSDCDRACICRGNGYCG 
C10 1.05 4.18 0.25 TGCQMEHSRHPENRSCRRDSDCTGGCICRGNGYCG 
D04 1.15 4.86 0.24 TKCTGSTKNCRRDSDCPGACICRGNGYCG 
B04 1.23 5.28 0.23 QQCPYNSTHGDYCRRDSDCPTACICRGNGYCG 
A08 1.17 5.47 0.21 PECRYDPEYKPQCRRDSDCHGACICRGNGYCG 
D03 1.29 6.25 0.21 QRCGKETEQCRRDSDCNTACICRGNGYCG 
A09 0.99 4.96 0.20 PLCQHPKYQCRRDSDCPTACICRGNGYCG 
B05 1.35 6.96 0.19 TNCSETPNLCRRDSDCYAECICRGNGYCG 
C04 1.19 6.35 0.19 QHCNEDCRRDSDCPVKCICRGNGYCG 
B10 1.08 5.86 0.18 HTCQPGRNQGYRCRRDSDCEGQCICRGNGYCG 
D07 1.05 5.75 0.18 SHCTTATSPCRRDSDCTGQCICRGNGYCG 
C03 1.13 6.25 0.18 SKCQQPPHQIQPCRRDSDCPMECICRGNGYCG 
E08 1.13 6.24 0.18 TRCNTYPRSYTPNQICRRDSDCPMDCICRGNGYCG 
A02 1.10 6.33 0.17 ERCPDKKSECRRDSDCPWACICRGNGYCG 
B09 1.03 6.3 0.16 TSCTSYKAHCRRDSDCPGRCICRGNGYCG 
B11 1.07 6.68 0.16 PGCGSLGPDCRRDSDCDKACICRGNGYCG 
D11 1.02 6.43 0.16 GECQNNRTQEEGGRQCRRDSDCQGSCICRGNGYCG 
E09 1.04 6.7 0.16 GHCNKTTRQCRRDSDCPIECICRGNGYCG 
E05 1.12 7.35 0.15 IRCKYGSQQCRRDSDCPGHCICRGNGYCG 
A05 1.28 8.79 0.15 TQCSDPRYWSQQCRRDSDCGGACICRGNGYCG 
C12 1.02 7.09 0.14 HECSRSQPKCRRDSDCPLACICRGNGYCG 
D02 1.29 9.29 0.14 EQCEHKRPERASDGDCRRDSDCPVACICRGNGYCG 
E01 1.03 7.5 0.14 TGCTQKDSHPPNCRRDSDCPLACICRGNGYCG 
A07 1.13 8.97 0.13 KSYNSNEYNCRRDSDCPAACICRGNGYCG 
C01 0.99 7.98 0.12 SQCLDMPNQSETLPPCRRDSDCPRACICRGNGYCG 
B01 1.02 8.49 0.12 HKCPEYGLTTRTCRRDSDCPAECICRGNGYCG 
B12 1.05 8.97 0.12 MHCDDEPTTTKACRRDSDCEKNCICRGNGYCG 
C02 1.08 11.28 0.10 EHCTMPEHQCRRDSDCGGQCICRGNGYCG 
A01 0.93 0 0 KRCNRNDRWYYPCRRDSDCPGRCICRGNGYCG 
A04 1.01 0 0 sequence failure 
A06 0.97 0 0 GKCGKVPSMDRTNQLPSRLRLPWRLYLPW 
B06 1.00 0 0 KYCGPPEYHCRRDSDCYRSCICRGNGYCG 
C08 0.98 0 0 sequence failure 
C09 0.99 0 0 RTCRERVEYTLQCRRDSDCTIDCICRGNGYCG 
E07 1.09 0 0 KQCQKNGPQQSDYHQCRRDSDCDWACICRGNGYCG 
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Figure 5.2 Analysis of high-throughput production of Trx-cystine-knot miniprotein fusions. E-PAGE™ 
analysis of produced Trx-cystine-knot miniprotein fusions from MCopt 1.0 library (A), MCopt 2.0 library (B), 
MCopt 2.1 library (C) and MCopt 3.0 library (D) in a 96-well format. Bacterial supernatant containing roughly 
purified Trx-cystine-knot miniprotein fusions were applied in a volume of 10 µL for E-PAGE™ analysis. Trx-MC-
Myc-010 was used as protein reference at 3 µg, 10 µg and 20 µg (black borders). 
Table 5.3 Amino acid sequences of MCopt 1.0, MCopt 2.0, MCopt 2.1 and MCopt 3.0 library clones of 
protein production and mass analysis.  
Library clone Amino acid sequence 
MCopt 1.0 clone 1 GSAHDCPGDSPNCRRDSDCSVACICRGNGYCG 
MCopt 1.0 clone 2 GSAMNCNTDPSRYGLCRRDSDCRGDCICRGNGYCG 
MCopt 1.0 clone 3 GSAQVCYYGPEDSNYYPYCRRDSDCNLACICRGNGYCG 
MCopt 2.0 clone 1 GSGSVCMSWAIDQETMCRRDSDCPGACICRGNGYCG 
MCopt 2.0 clone 2 GSGSVCQWVSQKQYNLCRRDSDCPGACICRGNGYCG 
MCopt 2.0 clone 3 GSGSVCTVWSWMGAEKCRRDSDCPGACICRGNGYCG 
MCopt 2.0 clone 4 GSGSVCAQEVQTYPWQCRRDSDCPGACICRGNGYCG 
MCopt 2.0 clone 5 GSGSVCTPRVALGQGDCRRDSDCPGACICRGNGYCG 
MCopt 2.1 clone 1 GSGSVCPAILIRCRRDSDCPGACICGWKQKRPSLPCG 
MCopt 2.1 clone 2 GSGSVCPAILIRCRRDSDCPGACICGRWSLDRRVECG 
MCopt 2.1 clone 3 GSGSVCPAILIRCRRDSDCPGACICDIGWNSNLFMCG 
MCopt 2.1 clone 4 GSGSVCPAILIRCRRDSDCPGACICHYDSEWRDVICG 
MCopt 3.0 clone 1 GSGSVCHHPLIWSMPTCRRDSDCPGACICHNGPWFGEMECG 
MCopt 3.0 clone 2 GSGSVCTPLAEFEQIRCRRDSDCPGACICDSSVDMMMPWCG 
MCopt 3.0 clone 3 GSGSVCHPDIQQLYWMCRRDSDCPGACICWHAQEVVSFQCG 
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Table 5.4 Amino acid sequence of EDB ligand MC-FN-010 and its alanine scanning variants. Respective 
amino acids in the first, second or fifth loop of parental MC-FN-010 sequence were exchanged with alanine. 
Alanine substitutions are highlighted in bold letter. 
Construct name Amino acid sequence 
MC-FN-010 (parental sequence) PMCTQRKNRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-011 AMCTQRKNRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-012 PACTQRKNRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-013 PMCAQRKNRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-014 PMCTARKNRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-015 PMCTQAKNRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-016 PMCTQRANRIRLCRRDSDCTGACICRGNGYCG 
MC-FN-017 PMCTQRKARIRLCRRDSDCTGACICRGNGYCG 
MC-FN-018 PMCTQRKNAIRLCRRDSDCTGACICRGNGYCG 
MC-FN-019 PMCTQRKNRARLCRRDSDCTGACICRGNGYCG 
MC-FN-0110 PMCTQRKNRIALCRRDSDCTGACICRGNGYCG 
MC-FN-0111 PMCTQRKNRIRACRRDSDCTGACICRGNGYCG 
MC-FN-0112 PMCTQRKNRIRLCARDSDCTGACICRGNGYCG 
MC-FN-0113 PMCTQRKNRIRLCRADSDCTGACICRGNGYCG 
MC-FN-0114 PMCTQRKNRIRLCRRDSDCTGACICAGNGYCG 
 
 
Figure 5.3 Binding analysis of MC-FN-010 and negative control MC-FN-0115. ELISA-based binding analysis of 
Trx-cystine-knot miniproteins with applied concentration at 200 nM to coated FN-B and FN-67B89 target 
proteins and to the control protein FN-6789 (coated at 1 μg/well). Binding was detected with 10 ng of HRP-
conjugated anti-S-tag antibody. ELISA was performed in duplicates (± SD). 
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Figure 5.4 SPR analysis of MC-FN-010 and and MC-FN-016. Sensorgrams resulting from multi-cycle kinetic 
analysis of monomeric MC-FN-010 (A) and MC-FN-016 (B) binding to biotinylated FN-67B89 captured on SA 
sensor chip. Concentrations ranging from 50 nM to 4000 nM for MC-FN-010 and 62.5 nM to 4000 nM for MC-
FN-016 (curves from bottom down to top) were applied. The curves were corrected to a blank SA control flow 
cell. Kinetic parameters obtained by applying a 1:1 Langmuir fitting model are shown in Table 3.3. 
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Figure 5.5 Quality control of AF680-(MC-FN-010)3, AF680-(MC-FN-016)3 and AF680-(MC-FN-0115)3. 
(A) Analytical SDS-PAGE of AF680-(MC-FN-010)3, AF680-(MC-FN-016)3 and AF680-(MC-FN-0115)3. Proteins 
were applied at 1 µg to SDS-PAGE under reducing (with β-mercaptoethanol) and non-reducing (without β-
mercaptoethanol) conditions. AF680-(MC-FN-010)3 has a molecular weight of 13681.9 Da, AF680-(MC-FN-016)3 
of 13510.6 Da and AF680-(MC-FN-0115)3 of 13129 Da. Contrast and brightness has been altered in this image 
for better visualization. (B) RPC chromatograms of AF680-(MC-FN-010)3, AF680-(MC-FN-016)3 and AF680-(MC-
FN-0115)3. A total of 2 µg was applied to a HPLC column Poroshell 120 (EC-C18) in acetonitrile 2 % and 0.05 % 
TFA buffer at a flow rate of 2 mL/min. Proteins were analyzed spectroscopically via absorbance measurement 
at 280 nm. 
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Figure 5.6 SPR analysis of AF680-(MC-FN-010)
3
 and AF680-(MC-FN-016)
3
. Sensorgrams arises from a single-
cycle kinetic analysis of AF680-(MC-FN-010)
3
 (A) and AF680-(MC-FN-016)
3
 (B) binding to biotinylated FN-67B89 
captured on SA sensor chip. Different concentrations of trimeric constructs from 1.25 – 10 nM were 
subsequently analyzed. The sensorgrams were referenced to a blank SA control flow cell. Kinetic parameters 
obtained by applying a 1:1 Langmuir fitting model are depicted in Table 3.4. 
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